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ABSTRACT 
Background 
Iya neerizhivu is one of the types of the Madhumega Noikal. It’s maybe 
correlated with Chronic Obstructive Pulmonary Disease in Diabetes Mellitus.  
Chronic Obstructive Pulmonary Disease (COPD) is the leading cause of morbidity 
and mor-tality worldwide. There is evidence to support a connection between COPD 
and Diabetes mellitus (DM), another common medical disorder. However, additional 
research is required to improve our knowledge of these relationships and their 
possible implications. In this study, we investigated the impact of DM on patient 
outcomes through the clinical course of COPD treated with SEENTHIL Sarkkarai. 
 
Methods 
We conducted a prospective open labelled randomized clinical study in 
patients from the OPD and IPD of Pothu Maruthuvam Department, GSMCH, 
Palayamkottai Database between April 2016 and June 2018. 40 Patients with Iya 
neerizhivu were recruited for evaluated the role of Seenthil Sarkkarai in COPD in 
type II diabetes. The treatments chedule was 30mg/kg body weight for two times per 
day with ghee for 90 days. Assessed the FBS, PFT changes, MMRC score, and Lipid 
Profile before and after treatment. 
 
Results 
In clinical study 60% of out patients and 55% of In patients showed good 
improvement 30% of out patients and in 40% of In patients showed Moderate 
improvement 10% of out patients and 5% of the In patients showed Poor 
improvement. No adverse reaction was found in this clinical study. The Statistical 
analysis was done by SPSS statistical package version 20.0. Paired 2 tailed test 
revealed that the fasting (P<0.001) and postprandial blood glucose (<0.001) and 
HbA1c (P<0.001), PFT (p<0.001), showed significant reduction after Seenthil 
Sarkkarai intervention. The trial drug subjected to biochemical and pharmacological 
studies and gave significant results also. The results suggest Seenthil Sarkkarai to be 
beneficial for the treatment of Iya neerizhivu (chronic obstructive pulmonary disease 
in type II diabetes). Further follow-up studies are warranted to confirm the safety 
aspects of Seenthil Sarkkarai use. 
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CHAPTER-I 
INTRODUCTION 
1.1 BACKGROUND 
Diabetes mellitus is a chronic debilitating and devastating disease. The 
incidence and prevalence of diabetes mellitus and its complications are increasing day 
by day. Its complications gives rise to micro and macro vascular diseases which affect 
eyes, kidneys, heart, blood vessels, nerves and also lungs. Chronic conditions are 
large in number, the prevalence of each one is high and so does the annual cost of 
their care. More over, clinicians alert about the impact of one disease on the 
development and severity of others. Among chronic morbidities the most prevalent 
are cardiovascular disease (CVD), cancer, diabetes mellitus (DM) and Chronic 
Obstructive Pulmonary Disease (COPD) (Chillón et al., 2009).  
Chronic Obstructive Pulmonary Disease (COPD) and Diabetes Mellitus (DM) 
are common medical conditions in India. COPD is a progressive, partially reversible 
airflow obstructive condition and it over burden in developing counties life. In 2020 
more predicted that COPD and DM are a third leading cause of death in Asian 
countries having three times the number of patients than the rest of the world. The 
mortality and co-morbid conditions like DM associated with COPD is greater impact 
on health outcomes. 
Diabetes mellitus (DM) is Co Morbidity of chronic pulmonary air way 
disease. A series of studies have shown that DM is associated with impaired lung 
functions. The chronic complications of Diabetes mellitus includes a number of 
pathological changes involving different systems and among there, lung represents a 
target organ for diabetes mellitus micro angioapathy in patients with diabetes mellitus. 
The Framingham Heart Study is readed that, the association between glycaemic status 
and reduced lung functions. The diagnosis of DM was associated with lower adjusted 
mean residual force expiratory volume in one second (FEV1) and forced vital 
capacity (FVC). The Copengehan Heart Study, a longitudinal analysis, has reveled 
that an association between a new diagnosis and impaired lung function is more 
prominent in diabetic subjects treated with insulin compared with subjects treated 
with oral hypoglycaemic agents.  
The association between impaired lung function and diabetes thought to be the 
result of biochemical changes in the structures of the lung tissue and air ways that 
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involves various mechanisms like to systemic inflammation, oxidative stress, 
hypoxemia, or ultimately to the direct damage caused by chronic hyperglycaemia. 
The lung function decline in patients with diabetic is a consequence itself and diabetic 
patients seem to have increased risk of several non-neoplastic lung conditions such as 
asthma and COPD and other airway diseases.  
 
COPD classification by symptoms and spirometry analysis 
COPD classification by symptoms/disability 
COPD stage‡ Symptoms Spirometry 
At Risk  
(not yet COPD) 
Asymptomatic smoker or ex-smoker 
or chronic cough/ sputum 
FEV1 ≥ 80% predicted  
FEV1 / FVC ≥ 0.7 
Mild Shortness of breath from COPD with 
strenuous exercise or while hurrying 
on the level or walking up a slight 
hill 
FEV1  60% - 79%  
predicted FEV1 / FVC < 0.7 
Moderate Shortness of breath from COPD 
causing the patient to walk slower 
than most people of the same age on 
the level or stop after walking about 
100 m on the level 
FEV1 40% - 59%  
predicted FEV1 / FVC < 0.7 
Severe Shortness of breath from COPD 
resulting in the patient too breathless 
to leave the house, or breathless after 
dressing or undressing or the 
presence of chronic respiratory 
failure or clinical signs of right heart 
failure 
FEV1 30% - 39%  
predicted FEV1 / FVC < 0.7 
Very Severe  FEV1 < 30%  
predicted FEV1 / FVC < 0.7 
 
Adapted from the Canadian Thoracic Society recommendations for 
management of chronic obstructive pulmonary disease - 2007 update. 
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As per the Siddha perception, according to the classical texts Noinadal and 
Noi Mudhal Nadal Part II and Yugi Vaidhaya Chinthamani 800 are clearly illustrated 
that clinical symptoms of Iya Neerizhivu. 
Our Theraiyar in his “Theran karisal” is classified the diseases of the urinary 
system into two major categories of “Neerinai Perukkal” and “Neerarugal Noigal”. 
Any pathology which gives rise to increased urination in quantity or frequency 
irrespective of the varied causes is included under the heading of Neerinai Perukkal 
noigal or neerizhivu or mega neer or madhumegam. Diabetes mellitus is viewed 
under “Neerinai Perukkal Noigal” which produces the symptom of polyuria in the 
affected individuals. Based on the involvement of the three doshas in the 
pathogenesis, Neerizhivu is categorized as Vali, Azhal and Iyam. 
 
The onset of these general symptoms and signs could be assumed as COPD in 
patients with Non-Insulin Dependent Diabetes Mellitus. While using the literature to 
form the hypothesis, my study attempts to quantifu the direct relationship between 
various levels of insulin resistance and changes in pulmonary function on COPD in a 
clinical setting. 
 
RATIONALE  
Seenthil Sarkkarai is a Siddha herbal formulation taken from the siddha 
literature. Recently, the plant is of great interest to researchers across the world wide, 
because the therapeutic and pharmacologically proven that the medicinal properties, 
like Anti-Diabetic, Bronchodilator, Anti-Periodic, Anti-Spasmodic, Anti-
Inflammatory, Anti-Arthritic, Anti-Oxidant, Anti-Allergic, Anti-Stress, Anti-
Lipidemic, Anti-Malarial, Hepatoprotective, Immunomodulatory and Anti-Neoplastic 
activities.  
The above mentioned references and the pharmacological research works 
undergone on the constituents of the trial medicine Seenthil Sarkkarai is potential 
effect in the clinical study of the management of DM and COPD. So, the trial 
medicine is safe for COPD in Type II Diabetes Mellitus Patients.  
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1.2 AIM AND OBJECTIVE  
 
AIM OF STUDY 
 
To Clinical study about the therapeutic efficacy of Siddha formulation in good 
glycemic control in COPD in Patients  
 
A. PRIMARY OBJECTIVE  
 
To evaluate the therapeutic efficacy of Seenthil Sarkkarai in Iya Neerizhivu 
(COPD in Type II Diabetes Mellitus) 
 
B. SECONDARY OBJECTIVES 
 
a. To evaluate the Anti-microbial, Pharmacological activities of Seenthil 
Sarkkarai  
b. To evaluate the changes of siddha parameters in Iya Neerizhlivu. 
c. To Study about the prevalence of Iya Neerizhivu in Paruva kaalankal 
(seasons) and Thinai (Geographical distribution)  
 
 
1.3 JUSTIFICATION OF RESEARCH 
In clinical practice Iya Neerizhivu (COPD in Patients with Type II Diabetes 
Mellitus) is successfully being treated through the therapeutic application of trial 
medicine Seenthil Sarkkarai. Therefore it was felt essential to undertake a study to 
precisely gauge the therapeutic efficiency of Seenthil Sarkkarai in clinical 
management of Iya Neerizhivu. 
 
The clinical study is carried out in Department of Pothu Maruthuvam (PG), 
GSMC, Palayamkottai. To establish an effective management of Iya Neerizhivu with 
Seenthil Sarkkarai through an open labelled randomized clinical trial, the following 
objectives had been drawn. 
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1. The literatures were collected concerning the aetiology, pathogenesis, 
clinical features, prognosis and the treatment protocol for Iya Neerizhivu 
in both Siddha and Modern perspectives. 
2. 20 in patients and 20 out patients of either sex with Iya Neerizhivu were 
screened and selected for the study. 
3. The distribution percentage of Iya Neerizhivu under sex, age, occupation, 
social economical status, personal habits, diet, paruvakaalam and 
hereditary factors with reference to the clinical study were understood. 
4. The therapeutic efficacy of the trial drug on Iya Neerizhivu with the aid of 
Siddha and modern clinical parameters and the prognosis of the disease 
were assessed. 
5. The potency of the trial drug through evaluation of Biochemical, 
Microbiological and Pharmacological analysis was carried out. 
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CHAPTER-II 
REVIEW OF LITERATURE 
2.1 SIDDHA ASPECT – NEERIZHIVU 
In the Siddha system of medicine all creation and genesis of matter on earth 
are controlled and regulated by the Pancha Bhootas, and it based on Tridoshas and 
Dasa  naadigal  at Microcosm and Macrocosm plane, an  imbalance in the creative 
forces subsequently causes defective function, affecting the existence, qualitatively 
and quantitatively. Our ancestors elaborated the knowledge of the disease Neerizhivu 
in many school of thoughts.  Saint Theraiyar in his “Theran Karisal” has classified 
the diseases of the urinary system into two major categories of “Neerinai Perukkal” 
and “Neerarukal Noigal”. Any pathology which gives rise to increased urination in 
quantity or frequency irrespective of the varied causes is included under Neerinai 
Perukkal Noigal. Diabetes mellitus has also been viewed under “Neerinai Perukkal 
Noigal” which produces the symptoms of polyuria.  
 
The different classifications of Neerizhivu which have been documented based 
on the observations of the complaints of the patients. The classification of Neerizhivu 
has been disclosed by Yugi muni in Yugi Vaithiya Cinthamani 800, Agathiyar in the 
text book of Agathiyar Kanma Kandam, Theraiyar in Theraiyar Vaagadam and 
Thirumoolar in Thirumoolar Vaithiyam 600. 
 
2.1.1 ,ay; (DEFINITION OF NEERIZHIVU) 
Neerizhivu is a disease characterized by frequency of passing urine (polyuria), 
presence of honey odour in urine on heating. It ultimately deteriorates all the seven 
Udal thathus (seven fundamental tissues of the body) 
‘,dpg;ghd ,dpg;gy;y < te;jhLk; 
xU Jsptha; tpl;lhh;ifg; gpzpaha; Njhd;Wk;” 
              - FUehb 
‘mz;ikahabf; fbf;F ePhpwq;F 
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 kbf;fbf;F miuehop jdpNy fhZk; 
ntz;ikahd jbajdpw;whd; gpbf;Fk; 
 kpf;fhd rlk; ntSj;J Nkdp fd;Wk;” 
- A+fp itj;jpa rpe;jhkzp-800 
2.1.2 Neha; tUk; top (ETIOLOGY) 
The etiological factors described by various siddhars are,  
i. Excessive sexual activity.  
ii. High fat food. 
iii. Chronic alcoholism. 
iv. Obesity  
v. Physical inactivity 
vi. Psychosomatic stress 
vii. Genetic factors are lead to neerizhivu. 
‘Nfhijah; fytp Nghij 
 nfhOj;j kPd; ,iwr;rp Nghij 
ghJtha; nea;Ak; ghYk; 
 ghpTld; cz;gP uhfpy; 
Nrhj ghz;LUt kpf;f 
 Rf;fpy gpuNkfe;jhd; 
xJ ePhpopT Nru 
 Tz;nld mwpe;J nfhs;Ns” 
-mfj;jpah;-1200 
The same also discussed in “Yugi Vaidhya Cinthamani”, Yugimuni in his text 
attributes this disease due to injudicious diet containing high fat, sweet.  Too much of 
sedentary habits without exercise also leads to neerizhivu, undue fear, severe 
depression has also emphasized for the development of Neerizhivu noi.  
“cw;gtpf;Fk; ghy; nea;ahy; ,iwr;rp fs;shy; 
 Thpiraha; kPd;jd;dha; mUtpUe;j 
kw;gtpf;Fk; gjhh;j;jj;jhy; kJut];jhy; 
 ke;jq;fs; jidGrpj;jy; Ntfhg; gz;lq; 
Fw;gtpf;Fk; FSj;j td;d kq;if Nfh\;b 
 Fwpj;j epj;jpiu jtph;jy; mf;fpdp ke;jk; 
jw;gtpf;Fe; rhPue;jhd; kpfg;gUj;jw; 
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rQ;rye;jhd; kpfg;gaj;jhy; jhpf;Fk; NehNa” 
                              - A+fp itj;jpa rpe;jhkzp-800 
 
 
2.1.3 Neha; vz; (CLASSIFICATION) 
Basically, Neerizhivu is the disease associated with and increased frequency 
and quantity of urine. The below twenty varieties are described in the works of almost 
all the Siddhars. Out of these twenty different kinds of Neerizhivu, four are caused by 
Vatham, six are caused by Pitham and the remaining ten are due to Kapham.  
 
The following quotations describe, twenty different kinds of urinary disorders 
on the basis of colour, consistency, taste, smell, weight etc.,   
 
‘cl;bz Nuhfj; jhYk; KWk;ngUk; grpapdhYq; 
 fl;ltpo; Nfhijkhjh; fytpkl;byh ikayhY 
 Kl;lwh ehYkhW Kd;%d;W nkhd;W nkd;W 
 jpl;lkha; tUtnjd;W jpUkKdp aUspr; nra;jhh;”  
       - mfj;jpah;-1200 
 
‘my;Y nkd;Nw NkfkJ ,uz;Lgj;J  
 kfpo;e;J eP NfSnkd;W trdpj;jhNu” 
       - a+fp itj;jpa rpe;jhkzp-800 
 
‘trdpj;j NkfkJ ,uz;L gj;J 
 thjj;jpw; gpwe;jryk; ehNyahFk; 
gprdpj;j gpj;jj;jp Yw;g tpj;j 
 Nguhd rye;jhD khW khFk; 
Njrdpj;j Nrl;Lkj;jpy; cw;g tpj;j   
          rPuhd rye;jhD gj;Nj ahFk; 
,rdpj;j ,jDila Fzh Fzq;fs; 
 vopyhd cw;gj;jpap ak;gf; NfNs” 
     - a+fp itj;jpa rpe;jhkzp-800 
Neerizhivu caused due to deranged vatha dosham (tspf; Fw;wj;jhy; 
tUk;  NkfePh; Neha;) are 4 types. Namely with synonyms,  
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i. Achiya megam (nei mana neer) 
ii. Suththa megam (pasu mana neer)  
iii. Pramiya megam ( oon mana neer) 
iv. Mangisaravi megam ( Elamarik kozhuppu mana neer)  
‘jhpj;jpl;l thjj;jpd; rye;jh dhY 
 jdpahd ehYf;Fk; NgNu njd;dpy;   
mhpj;jpl;l Mr;rpanfe;jp Nkfj; NjhL  
 mjd;gpwF Rw;wkh Nkf nkhd;W  
Nguhd khq;fprutp Nkfnkhd;W  
 Fwpj;jpl;l ,Jthj rye;jhdhY 
FzhFzj;jpDl;gnky;yhk; Fwpg;gha; NfNs” 
      - a+fp itj;jpa rpe;jhkzp-800 
 
Neerizhivu caused due to deranged pitha dosham (gpj;jf; Fw;wj;jhy; 
tUk; NkfePh; Neha;) totally six in numbers. They are,  
 
i. Appiya megam (yanai matha neer) 
ii. Apiramiya megam (kattralai mana neer) 
iii. Sampirna megam (chunna mana neer) 
iv. Mathumiya megam (thithippu neer) 
v. Asaththiya (palingu mananeer) 
vi. Arkka megam (muyatkuruthi neer) 
 
‘Kiwahd gpj;jry khW khFk; 
 Kjpu;e;j mg;gpankd;Wk; gpukpa nkd;Wk; 
 Jiwahd rhk;gPu;zk Jk;g nkd;Wk; 
 rhj;jpfNt ahtpUjj; jd;Ndh lhW 
kiwahd tpe;jhW Nkfe; jd;id 
 kfhNjtH; nrhy;yplNt Njtp Nfl;fj; 
Jiwahd FzhFzj;ij tpupj;Jr; nrhy;y 
 Rw;wkh ag;gpaj;jpd; R&gq; NfNs” 
- a+fp itj;jpa rpe;jhkzp-800 
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Neerizhivu caused due to deranged kapha dosham (fgf; Fw;wj;jhy; tUk; 
NkfePh;  Neha;) totally ten in numbers. They are, 
 
i. Vasa megam (vasa neer) 
ii. Uththama megam (theli neer) 
iii. Machcha megam(moolai neer) 
iv. Akiha megam (ela neer) 
v. Surari megam (kal neer) 
vi. Sikkila megam (thavala neer) 
vii. Udhaha megam (kalu neer) 
viii. Pinani megam (then neer) 
ix. Lavana megam (uppu neer) 
x. Thayiththiya megam (eraichchi neer)  
 
‘Mwhd rpNyl;gryk; gj;J jd;id 
 Muz;nrhy; ythj;jhs;jhd; Nfl;Fk; NghJ 
thwhd trhNkfk; cj;jk Nkfk; 
 kr;rpah Nkfj; Njhlh fPf Nkfk; 
J}whd RuhupRf;y Kj;j Nkfk; 
 Rw;wkhk; gpdhdpNahL ytz Nkfk; 
Njwhd njapj;jpakh Nkf nkd;W 
 nrg;gpdhh; rpNyl;gj;jpd; nryj;Jj; jhNd” 
- a+fp itj;jpa rpe;jhkzp-800 
 
2.1.4 Kw; FwpFzq;fs; (PREMONITORY SYMPTOMS OF NEERIZHIVU) 
In Siddha we can find the description of early symptoms of the disease. They 
are voracious appetite, excessive thirst, weight loss, polyuria, insomnia, anxiety, and 
striae of the skin all over the body due to sweating, exertion and fatigue.  
     
‘rhpahf Nkfj;jhy; mghd thA 
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 jhd; Giff;F NkNywpf; fghyr;#lhk; 
nghpjhd Nkfj;jhy; mj;jp nte;J 
 Nghkg;gh jirnte;J uj;jk; tw;wpg; 
ghpthfpj; jrthAthy; ke;jq;nfhz;L 
 ngUe;jPdp kyge;jk; cjhdthA 
thpthfpj; Njfnky;yhk; tplePuhNy 
 nka;aope;j Nkfnkd;w jpUgjhr;Nr” 
       - rpj;j kUj;Jtk; 
 
According to Dhanvanthiri Vaithyam Part-II, which is given some other 
premonitory symptoms like burning sensation in hands and feet, itching, frequency of 
thirst, polyuria etc. 
  
‘kz;lye; jd;dpYs;s khjh;f;Fk; GUlh;f;Fq;  
 nfhz;lNjhh; ryf;fopr;ry; nfhs;SKd; fhZNeha;fs; 
fz;bL Kly; fhy; iffs; fhd;woe; njhpe;J fhe;jp 
 Az;lePh; Rtwpf; fhl;b Aile;JePh; fopAnkd;Nw”  
      - jd;te;jphp itj;jpak; 
 
2.1.5 FwpFzq;fs; (SIGNS AND SYMPTOMS OF NEERIZHIVU) 
Yugimuni has described the common symptoms and signs of 20 types of 
Neerizhivu as followed,   
 Excessive Urination 
 Excessive Thirst 
 Excessive Appetite 
 Cough 
 Dry mouth 
 Tiredness 
 Fatigue 
 Irritability 
 Fluctuation of weight 
 Blurring of vision, nausea, headache 
 Burning and spasmodic pain in urethra and dull ache in testis. 
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 urine may be cold, slimy to touch, brownish yellow in colour and produces 
white sediments 
 Ants and flies are attracted to the site of voided urine 
 When the urine is heated it gives honey odour 
 
‘$whd NkfkJ ,UgJf;Fk; 
 Fze;jid rptd;nrhy;y NjtpNfl;f 
jhwhd jhfnkhL Nrhf Nkfe; 
 jhpahky; ePhpopjy; ,Uky; %r;R 
MwhdmUrp rj;jp rpj;j gpuik 
 mbf;fbf;Fj; jz;zPh; jhdd;dq; Nfl;ly; 
<whd ,Lg;Gfs; fLg;G fhzy; 
 vYk;G ow;wyow;wNyh  nlhpTz;lhFk;”; 
 
‘vhpNthL rhPunky;yh kiwgl;lhw; Nghy; 
 vopOlk;G Nehjy; epj;jpiu apy;yhik 
kdJ rQ;ryg;gLjy; fhw;W Ntz;ly; 
 nkhpNthL  Nky;%r;R kpfTz;lhjy; 
tpf;fnyhL kaf;fe;jhd; nkj;jf; fhzy; 
 njhpNthL Njfnkq;Fk; ntSUz;ljhy; 
Njfnkj;j thNyhgg;gLjy; fhNz” 
 
‘jz;ikaha; rye;jhDk; gRg;G kQ;rs; 
 jhdpwq;Fk; gPrKk; NfhrKq; fLf;Fk; 
mz;ikahabf; fbf;F ePhpwq;Fk; 
 mbf;fbf;F miuehop jdpNy jhZk; 
 
‘ntz;ikaha; abajdpw;whd; gpbf;Fk; 
 kpf;fhd rlk;ntSj;J Nkdpfd;Wk;  
gz;ikaha;g; gQ;thz;ljdpw; nfhy;Yk; 
 gfph;fpd;w kJNkfj;jpd; ghq;F jhNd” 
 
- a+fp itj;jpa rpe;jhkzp-800 
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In Agasthiyar Aayulvagadam signs and symptoms of neerizhivu little vary 
with above and are mentioned like,  
 Burning sensation on hands, legs 
 Dryness of mouth 
 Giddiness 
 General weakness 
 Tiredness 
 Tremors 
 Loss of appetite 
 Sweating 
 Pallor of skin   
‘KfNk fhe;jp neQ;Ryh;e;J KWj;J 
 KlY eLq;fp efNk gupe;J rPh; nefpo;e;J 
eQ;Rz;lth; Nghy; Njfk; Nrhh;e;J gfYkpuT KUf;fpAly; 
 gfWNkdpAk; jsh;e;J kpfNt jhtzKz;lhFk;” 
       - mf];jpaH MAs;thflk; 
 
2.1.6 Common Sign and Symptoms of Vali, Azhal and Iya neerizhivu  
Saint Yugi clearly described the 20 subtypes of Neerizhivu the different 
clinico-pathological conditions produced out of specific doshas and saptha dhathus 
showing gross urinary characteristics and clinical manifestations, and also prognosis 
of the disease if left untreated. 
Table shows clinical features of different subtypes of Neerizhivu 
Doshas Types Specific Signs 
Common Symptoms of 
Doshas 
Vali Neerizhivu 
1.  
Nei Mana 
Neer 
 Urine contains colour of ghee, 
stickiness and ghee smell.  
 Polyuria 
 Weight loss 
 Death occurs 7 days after 
disease appeared.  
 Burning sensation of 
hands, feet and face. 
 Dryness of mouth 
 Black discolouration of 
teeth, tongue and throat. 
 Difficulty in speech  
 Giddiness  2.  Pasu Mana  Urine likes cow’s urine and 
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Neer smell 
 Polyuria 
 Weight loss and fatigue 
 Death occurs 15th day after 
disease appeared.  
 Excessive Thirst 
 Excessive Appetite 
 Ache and pain all over 
the body  
3.  
Oon Mana 
Neer 
 Polyuria 
 Smell like blood  
 Gives honey odour when 
burned  
 Killed in 6 months  
4.  
Elamarik 
Kozhuppu 
Mana Neer 
 Urine contains particles of 
flesh and membrane  
 Give smell of Billy meat 
washed water (pink). 
 Polyuria  
 Death occurs 3-8 days or 5th 
month  
 
Azhal Neerizhivu  
1.  
Yanai Matha 
Neer 
 Simile of such patients is given 
with adult elephant as regards 
passes of urine. 
 Sediment like sea sand if boiled  
 Killed in 6 months 
 Burning sensation in 
all over the body  
 Emaciation  
 Excessive perspiration  
and bad odour  
 Urine passes like pus, 
honey, aloe juice  
 Burning in urethra, 
scrotum, liver and 
stomach  
2.  
 Kattralai 
Mana Neer 
 Polyuria  
 Aloe smell  
 Gives putrid odour when boiled 
 Killed in 3 years  
3.  
Chunna Mana 
Neer 
 Urine is like an alkali (ash) 
solution, in smell, colour and 
touch. 
 Killed in 2 years  
4.  Thithippu  Frequency of micturition 
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Neer  Pain in urethra 
  Honey smell when boiled  
 White colour sticky 
precipitation in bottom 
 Pallor of the body 
 Killed in 5 years 
5.  
Palingu 
Mananeer 
 Dysuria 
 Quality of urine is turbid & 
slimy. It is sticky & threads 
may be demonstrated like gum. 
 Killed in 5 years 
6.  
Muyatkuruthi 
Neer 
 Frequent and excessive 
micturition  
 Urine red in colour like hare’s 
blood and meat smell. 
 Dysuria  
 Killed in 9th month  
Iya neerizhivu  
1.  Vasa Neer 
 Urine contains fat (vasa) and 
smell 
 Pain in penis and scrotum  
 Death occurs within 7 years 
 Obesity  
 Pallor of body  
 Skin rashes like itching, 
ulcers and allergic 
rashes  
 Excessive Thirst 
 Excessive Appetite 
 Cough 
 Sputum collection in 
throat   
2.  Theli Neer 
 Clear urine in larger quantity 
without odour, feels cold 
sensation while passing urine. 
 Killed in 10 years  
3.  Moolai Neer 
 Urine seems to like contains 
bone marrow (majjai). 
 Polyuria 
 Putrid smell  
 Life span-5 years  
 
4.  Ela Neer  Urine like tender coconut water  
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and smell.  
 Gives coconut oil smell when 
boiled  
 Polyuria  
 Weight loss  
 Thirst  
 Anxiety  
 Killed in 7 years  
5.   Kal Neer  Urine-white in colour and frothy 
like toddy and smell.  
 Fatigue 
 Killed in 7th year 
6.  Thavala Neer  Patient passes urine similar to 
quality of semen or semen itself 
may be mixed with urine.  
 Black colour sediment like liver 
after boiled 
 Killed in 3 years   
7.  Kalu Neer  Urine incontinence present  
 Precipitation like lime of conch 
 Body odour present 
 Killed in a year 
8.  Then Neer  Enormous urine output like 
honey and smell 
 Sediment like wax 
 Ants and flies are attracted to the 
site of voided urine 
 Honey odour present in body 
 Killed in 5 months 
9.  Uppu Neer  Urine seems to be salty and 
white and it’s odour. 
 Polyuria  
 Alkali ash precipitation 
 Sediment salt when boiled  
 Weight loss, worries, loss of 
appetite, and indigestion 
 Killed in 15 years   
10.  Eraichchi Neer
  
 Urine red in colour and smell 
like meat washed water. 
 Dysuria 
 Polyuria 
 Killed in 3rd year 
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tspf;Fw;wj;jhy; tUk;  NkfePh;  Neha;: 
‘Mr;nrd;w ehYk;Kq; Fzj;ijf; Nfsh 
 aofhd iffhy;fz; Zly ow;Wk; 
ehr;nrd;w ehtwSk; gy;Y ehf;F  
 eLj;njhz;il fWg;NgW Kjnyl; lhe;jhd;  
Ngr;nrd;w ehtwSk; gy;Y ehf;F  
 eLj;njhz;il fWg;NgW Kjnyl; lhe;jhd;  
Ngr;nrd;w gpyr\akhq; fz;Nky; Nehf;Fk; 
 ngUftd;de; jz;zPU kpfNt thq;Fe; 
jhr;nrd;w rhPue;jhd; fj;jp ntl;Lj;  
 jhd;Nghyf; fLj;JNk joYz;lhNk”  
     - a+fp itj;jpa rpe;jhkzp-800 
 
moy; Fw;wj;jhy; gpwf;Fk; NkfePh; Neha;fs;:  
 
‘mwpaNt gpj;jrykhWNk jhd; 
 mq;fkjpw; nra;fpd;w Fzj;ijf; Nfsha; 
jwpaNt cly;tw;wp vhpTz;lhFk; 
 rlj;jpYe;jhd; ePhpYe;jhd; ftpr;Rz;lhFk; 
njwpaNt rPg;NghYq; fw;whio NghYe; 
 Nry;NghYe; Njd;NghY ehw;wKz;lhk; 
ntwpaNt gPrj;jpw; Nfhrj;jpy; Fj;jy; 
 kpFkPuy; ehgpapYk; Ntf;fhlhNk” 
‘Ntf;fha; tpuzKz;lha; tha;jhdhYk; 
 tpf;fNyhL mUjpaha;r; RuKz;lhFk; 
jPf;fhlha; Njfe;jhd;  fplf;nfhl;lhJ 
 jpaf;fnkhL %h;r;irAz;lh kaf;fkhr;Nr 
rhf;fhlha; ehtwSq; fz;zPh; jhfQ; 
 rhj;jpnahU  rhPunkyhe;  jsh;r;rp ahFe; 
jhf;fhlha; kyrye;jhd; kpfTz;lhFe; 
 jhf;fhlha; kyrye;jhd; kpfTz;lhFQ; 
rkFze;jhd; gpj;jry khWkhr;Nr” 
- a+fp itj;jpa rpe;jhkzp-800 
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Iaf;Fw;wj;jhy; gpwf;Fk; NkfePh;Neha;fs;: 
‘jrkhd gj;Jf;Fq; Fzj;ij Nfsha; 
 rhPue;jhd; gUj;JNk ntSg;Gz;lhFk; 
mrkhd jpdTz;lh kbf;fbf;F 
 frkhd tpUkYld; Nfhio Az;lhq; 
fdthpth ahahr KoiyahFq; 
 Frkhd Fzq;fisnay;yhk; rpNyl;Lke; jd;dpy; 
nfhba ryf;Fznkd;W $wpdhNu” 
- a+fp itj;jpa rpe;jhkzp-800 
 
2.1.7 Kf;Fw;w Kjypa NtWghLfs; (PATHOGENESIS) 
The direct inference from these poems is that all Siddhars attribute diabetes 
mellitus mainly due to excessive indulgence in sex which results in total loss of body 
strength as a whole including the nervous system. Due to the intrinsic, extrinsic and 
other causes tridoshas are affected. Initially the pitha dosham has vitiated and causes 
burning sensation of the body and altered vayus also. According to this Kapham and 
Vatham are deranged and udal kattugal get disturbed to do their normal functions. 
Gradually body become emaciated and essense are excreted through urine. The 
severity of the disease is measured by the functions of three doshas and seven thathus. 
Debilitation and other sequence of disease will be occurring due to loss of appetite 
and loss of body strength. This as follow,  
According to the below references , the nourishment of Saptha Dhathus loosen 
and excessive discharge of the urine containing sweetness accompanied by thirst 
together with loss of strength is an important characteristic feature of the Mega neer.  
‘gfh;gpj;j tpe;ijayhJ Nkfk; tuhJ” 
- Njiuau; 
 
‘FwpAlNd Nkfe;jhd; 
 nfhLik nra;J 
Fiwe;JtUe; jhJnty;yhq; 
 Fd;wpg;NghFk;” 
- gjpnzd; rpj;jh; ehb E}y; 
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PATHOGENESIS OF NEERIZHIVU 
 
EXTRINSIC AND INTRINSIC FACTORS 
 
 
 
 
 
 
 
                             
                   
 
      
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perspiration,  
Muscular cramps 
ALTERED PITHA 
DOSHAM 
Associated With Altered 
Vatham 
Associated With Altered 
Vatham and Pitham 
Associated with 
Altered Iyam 
CHANGES IN UYIR DHATHU AND UDAL 
KATTUKAL 
Affected  
Abanan, Udhanan, 
Viyanan,Samanan and 
Ranjagam. 
Saaram, Senneer 
Affected  
Samanan, Kilethagam, 
Analagam, Saaram 
Affected Prasagam 
& Oon 
Polyuria, Nocturia 
Burning Sensation in 
urethrae, Pruritus of 
vulvae, Balanatitis 
Pallor, Fatigue, Loss of 
complexion of the skin  
Weight loss, Polydipsia. 
Drymouth, Polyphagia, 
Body ache, Dryness of the Skin, 
Tiredness. 
Affected Sadhagam & 
Sukkilam/ Suronitham 
Affected Alosagam & 
Kozhuppu 
Affected Pranan, Enbu 
Silethagam &  Majjai 
Spermaturia,  
Infertility/ Impotence 
Dysuria, Headache, 
Blurring of Vision, 
Dyspnoea 
Low backache, Giddiness 
Irritability, Emaciation  
Exhaustion, Depression   
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2.1.8  kJNkf Nehapy; fhZk; gj;Jtif mtj;ijfs;  
(COMPLICATIONS OF THE DISEASE)  
 
Saint Yugi well elaborated in the text book of yugi vaidhya chinthamani, the 
onset of the following sufferings as avathaigal will be followed gradually if the 
disease is not controlled or left untreated.  
 
Avathai-1: Progressive weight gain and dilatation of urinary meatus 
Avathai-2: Excessive urination, disorder of semen (polyuria, Asthenospermia) 
Avathai-3: Dryness of the tongue and gaseous abdominal distension (polydipsia,  
and diabetic gastro enteropathy) 
Avathai-4: Excessive thirst may leads to excessive fluid loss  
(Encephalopathy, polyphagia,   Diabetic metabolic encephalopathy) 
Avathai-5: Frequency of urination, spermatorrhoea (chronic renal failure)  
Avathai-6: Patient awakening in bed, breathlessness (metabolic syndrome)  
Avathai-7: Recurrent nausea with vomiting, breathlessness (metabolic Syndrome)  
Avathai-8: Chronic ulcer, abscess or carbuncles are present in body (Diabetic  
Ulcer) 
Avathai-9: Immoral behaviours, watery diarrhoea (Superadded opportunistic  
infections) 
Avathai-10: Pulmonary and extra pulmonary tuberculosis   
 
 ‘fhzNt Kjytj;ijr; rhPue; jhDq; 
 fdkhfg; gUj;jpWfp ePh;j;J thuk; 
NtzNt Ntz;lhf;fp afyk; gz;Z 
 kpf;ftuz; lhktj;ij tpsk;gf; Nfsha; 
%zNt %j;jpug;gP ilAkhr; Rf;y 
 KfKOfpj; Nj[Rjhd; kpfNt Fd;Wk; 
ehzNt %d;whF ktj;ijf; Fj;jhd; 
 ehtwSk; thAtJ kPWe; jhNd” 
‘jhdhd ehytj;ij aq;f jhfQ; 
  rd;dpaJ ghjKz;lh ike; tj;ijj; 
Njdhd ePh; ngUFe; jhJe\;lk;  
 epiyahw ktj;ijAlw; fpilnfhs;shJ 
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%dhd %h;r;irtU Nko tj;ij 
 kpf;ftNuh frQ;Rthre; Njf rhl;bak; 
Vdhd vl;lht jtj;ij jhNd 
 vOfpue;jp gpsit Ae;jhd; kpfTz;lhNk 
cz;lhF nkhd;gjh ktj;ijf; Nfsha; 
 cof;fhd tjprhuq; fpUkp Az;lhk; 
gz;lhd gj;jhe;jh itj;ij Nfsha; 
ghukhk; raq;fz;L guj;Jf; NfFk;” 
     - a+fp itj;jpa rpe;jhkzp-800 
According to the different school of thoughts, the above 3 avathaigal will be 
cured with medicines and up to nine avathaigal can treat.   
 
2.1.9 jPUk; jPuhjit (PROGNOSIS OF THE DISEASE)  
Disease is always producing the imbalance between the ratio of Vatham, 
Pitham and Kapham. This imbalance affects the five vayus (abanan, udhanan, 
viyanan, samanan, pranan), seven udalkattukal and slowly affects the appetite. An 
imbalance in Kapham does imply an imbalance in the other two doshas too, and 
contribute in further destruction of the system.   
 
 According to Yugi, the 20 types of megam also could be further divided in 
three categories as prognostic classification as below,  
1. Sadhyam (Manageable) - Kapha megam (10)  
2. Yapyam (Palliative) - Pitha megam (6) 
3. Asadhyam (Unmanageable) - Vatha megam (4) 
 
‘nra;aNt tr;rpukhe; jz;l khd  
 nrakhd KJFj;jz;ilg; gw;wp epw;Fk; 
nga;aNt ngUeuk;gpy; Nkfe; jhDk;  
 gpwf;Fnkd;Nw jhdwpe;J thje; jd;dhy; 
gpa;aNt gpwde;jryk; ehy rhj;jpak;  
 gpj;jj;jpw; gpwe;jrykhWk; ahg;ak;  
ifaNt Nrl;Lkj;jpw; gpwe;j gj;Jk;  
 gukDiuj; jhh;rhj;jpak; guhg hpf;Nf” 
      - a+fp itj;jpa rpe;jhkzp-800 
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Even though some sequence of disease will be occur in madhumega disease, it 
also incurable, if associated with Diarrhoea, Excessive swelling in the Body, 
Tuberculosis, Excess Breathing, Hiccough, Abdominal Pain, Abscess etc.  
‘ePh;Nehapdp yjprhuK 
 dpkph;tPf;f kpisg;G 
khh;%r;Rwy; tpf;fybf; 
 fbNatuy; tapw;wpy;  
Nrh;NehNahL gpsittuy; 
 jPuhf;Fwp nad;Nw 
ehh;nfhz;Liw nra;jhhpij  
 ed;whawp thNa”  
                    - fz;Zrhkpak; 
The patient is sure to die if Neerizhivu associated with Vatha diseases, griping 
of the Stomach, Excessive Accumulation of Gas, Hiccough, Dyspnoea, and Asthma 
stated in the Sathaga Nadi,  
 
‘Jjpg;ghd Nkfj;jpy; ePupopT khfh 
 Njhd;wpaeP hpopTjd;dpy; thjK khfh 
kjpg;ghd thjj;jpy; tapw;Wisr;r yhfh  
 tUKisr;ry; jd;dpy;thA nfhOj;J khfh 
nfjpg;ghd tha;tjpNy tpf;f yhfh  
 $z;ltpf;fy;  jdpypisg;G nfhOj;j yhfh 
Fjpg;ghd ,isg;gjpNy Rthrk; te;J 
 fye;jhYk; kuzk; vd;W fUjyhNk” 
         - rjf ehb 
2.1.10 Neha; fzpg;G (DIAGNOSIS OF THE DISEASE) 
In Siddha System of Medicine Eight different parameters of diagnosis have 
been devised to establish the exact underlying pathology known as envagai thervu 
(Nadi, Sparisam, Na, Niram, Mozhi, Vizhi, Malam and Moothiram) and confirmation 
through interrogation.  
 
‘ehbg;ghprk; ehepwk; nkhoptpop  
kyk; %j;jpukpit kUj;JtuhAjk;” 
- Njiuah; 
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 Nadi Nadai (Reading of Pulse) 
 The most important parameter of diagnosis is Nadi.  
 In Thirumoolar Naadi, it is quoted that when the three Vatha, Pitha and 
Kapha naadi are feeble, the corresponding derangement in the doshas leads 
to Neerizhivu. 
 
‘ghh;j;jpL %d;Wk; gjpe;J nkype;J epw;fpy; 
 Njh;e;jpL Nkfk; te;Njhd;wpNa nghUe;jp nka;apy;” 
- jpU%yh; ehb 
 
In other way Thirumoolar said, the Pitha and vatha variation is indicated 
clinically by excessive hunger, thirst, emaciation and passing of large quantities of 
urine with sweet taste. 
 
“,Ukpa gpj;jKk; thjKk;  $by; 
  kUTy Nkfk; thUjp NghyhLk; 
 cUtk; NtnwhU Kz;lTlw; fha;e;jpLk;  
  cUfNt t+NdhL cwpQ;rp ,dpf;FNk’ 
      - jpU%yh;ehb 
 
Thirumoolar also states that when Vatham combines with Kapham, the 
consistency of the urine becomes like toddy with emaciation of the body and pallor as 
seen in chronic cases. It is also known as “Kudila Nadi” (Like movement of worm). 
 
‘,dpf;fpd;w thjj;jpil Nrhpy; Iae;jhd; 
  gdpf;fpd;w fs;Sg; gjdpNghy; ePNuhLk; 
 fdpf;fpd;W Nkdp fiue;J ntSg;NgWk; 
  fdpf;FkJ Nkfe; jg;NghijaNk”  
- jpU%yh;ehb 
In Thirumoolar nadi and Parioorana nadi are quoted that, in the developed 
stage of the disease the vatha, pitha and kapha nadi will be feeble.  
‘ghh;j;jpL %d;Wk; gjpe;J nkype;J epw;fpy; 
 Njh;e;jpL Nkfk; te;Njhd;wpNa nghUe;jp nka;apy;” 
     - jpU%yh; ehb 
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‘JuzKld; ePh;g;ghL nfh;g;gg; ghlhzhw; 
 nrhy;YfpNwd; ehbnay;yhe;  fod;W fhZk;” 
     - ghpg+uzehb 
 
‘ePh;Nkfkhdth;f;F ehb jhDk; 
 ePh;kakha; ehbnay;yhk; gyNk nfl;Lf; 
fhh;Nkfk; NghNyte; njhpNky; Guz;L  
 tpOk;GOg; NghyNt Guz;L fhl;Lk;” 
     - ghpg+uzehb 
The aggravation of Pitha naadi is seen, it leads to excessive burning sensation 
and indicate mega neer.    
 
‘gw;gpbf;f Nkfk; vd;why; gpj;jkPWk; 
 ghyfNd fhq;if nfhz;L ePuhk; ghNu” 
     - ghpg+uzehb 
 SPARISAM (SENSATION OF PATIENT DURING TOUCH) 
 
Warm, dry, pricking pain all over the body especially palms and sole are the 
features can be found on madhumega disease.   
 
In mega neer due to Vatha, Pitha and Kapha dosham, have burning sensation 
in hands, feet, eyes and face and also fever. 
 
 NA (EXAMINATION OF TONGUE) 
 
In tongue examination following things are should be consider as follows,  
 
 Niram (colour)    - Pale in kapha neer 
Black in vathaneer  
Yellow pitha neer 
 Thanmai (character)   -  Dry and fissured  
 Pulan (sense)    - Saliva tend to taste sweet 
 Umizh neer (salivary secretion) -          Reduced  
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 NIRAM (EXAMINATION OF COLOUR AND COMPLEXION) 
It is different from their original complexion on the skin. In madhumega 
disease pale or dark complexion is common.   
 
 MOZHI (EXAMINATION OF SPEECH) 
Speech due to increase of pitham, the patient is likely to suffer from tiredness 
and giddinees, therefore the bound of speech become low pitched.  
 
 VIZHI ( EXAMINATION OF EYE) 
In neerizhivu visual disturbances (blurring of vision, glaucoma and cataract) 
may be present and following things also should consider,  
 
 Niram (colour)  - red/pale 
 Thanmai (character) - dry 
 Pulan (sense)   - reduced touch sensation impairment in vision 
 
 MALAM (EXAMINATION OF STOOL) 
 Niram (colour)      
 Nurai (froth)      
 Elagal / Erugal (consistency) are should be consider in examination of 
stools. When Vatham is in high proportion there is constipation, with 
increase of Pitham there exists diarrhoea and increase in Kapham results 
in white, milky motion.  
 
 MOOTHIRAM (EXAMINATION OF URINE) 
Urine examination is done under two categories,  
a) Neerkuri (The common nature of urine) 
b) Neikuri  (oil drop method)  
 
a) Neerkuri (The Common Nature of Urine): 
The following points have to be taken into account in the urine examination: 
 Colour  
 Weight and density  
47 
 
 Odour   
 Froth  
 Quantity  
 
‘te;j ePh;f;fhp vil kzk; Eiu vQ;rnyd; 
 iwe;jpaYstit aiwFJ KiwNa”  
 According to many schools of thought well described the nature of urine in 20 
types of madhumega disease.  The common features of neerkuri are following,  
 Niram (colour) - crystal clear urine 
 Weight and density - thickening of the urine 
 Manam (odour) - honey smell  
 Nurai (froth) - increased 
 Enjal (deposits) - small deposits in urine 
If the urine is crystal clear, it indicates the vitiation of kapha in which the 
prognosis is said to be very bad. 
 
‘ntz;ikAw;W kpfj; njspTilj;Njy; 
cz;ikahe; Rj;j rPjsj; Jjfkhh; 
,e;ePh;g; grg;glhjpj;tDila ae;juk; 
Ke;ePh; ngUf;fkopthd; ca;jnthf;FNk” 
- NjiuaH ePHf;Fwp nea;f;Fwp 
b) Neikuri (Oil Drop Method): 
A drop of gingely oil is dropped in to a wide vessel containing the urine to be 
tested and kept it under the sunlight. The variations of three doshas in disease can be 
diagnosed by the shape of gingely oil on the surface of urine. It gives the details of 
prognosis of the disease.  
If the observed pattern like as head structure or human or body and of 
kamandalam, then the patient has the ability to get cure of diabetes. 
‘FwpaJNfSk; ePupy; Fiwj;jiy NghYe; Njhd;wpy; 
 gpwpe;jpLKliyNghYk; ngUq; fkz;lyk;Nghy;jhDk; 
twpe;jplr;rhjpak;kPjhk; typgpy kDNthHf;nfd;W 
 nrwpe;jpLKdpth;jhKQ; nrg;gpaFwpg;gjhNk.” 
-a+fpKdp itj;jpa fhtpak; 
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If the observed pattern like as circle or thoranam i.e hanging decorations 
shape, then it cannot be treated and classified as incurable (mrhj;jpak;). 
 
‘ifapdpnyz;izthq;fp fope;j ePu;jd;dpw;Fj;j 
 nra;jJtl;lkhFQ; NrUe;Njhuzk;Nghy;jhDk; 
IaKkpy;iyfz;lha; rhj;jpaky;yntd;W 
 Ja;aed;Kdpth;jhDQ; nrhy;ypaFwpg;gjhNk” 
-a+fpKdp itj;jpa fhtpak; 
 
According to Thanvanthiri Vaithiyam, which is given elaborately about the 
shapes and their prognosis of the main three types of madhumega disease are follows, 
 
Vatha Neer: 
‘%isAk; epzKk;Nghy Kwpe;j Rf;fpyNk Nghy  
 Mshp NtYq;NfhY kzq;fDk; mk;GNghy 
ePspa euk;GNghy ePh;jdp nyz;nza; fhzpy; 
 thspid ntd;w fz;zha;!thjj;jpd; $WjhNd” 
       - jd;te;jphp itj;jpak; 
 
The above stanza says that if the oil drop is like the brain or lymph or 
fractured sperm or sword or Cupid’s bow or long nerve is indicated features of vatha 
type of neerizhivu.  
 
Pitha Neer: 
‘igauty;Fy; khNj! ghUs; NshHfpope;j ePhpw; 
 ifapNynaz;nz thq;fpf; fope;jNjhh; JUk;ghw;Fj;j 
ikaWNkdpnahj;j tl;lQ; nra;jpUf;Fkhfpy; 
 ma;AW ePujhF ky;yjhw; gpj;jkhNk” 
- jd;te;jphp itj;jpak; 
 
When the oil drop is made dark colour circle it is a symptom of pitha type of 
neerizhivu.  
In the text book of Siddha Maruthuva Noi Thoguthi-I, Megaroga Nithanam 
well defined the prognosis of the types of madhumega disease, 
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 The oil drop doesn’t spread and placed like circle of eye and then adhere to 
the mouth of the dish is indicate the disease curable.  
 When the oil drop sinks into the bottom and given sudden spread then oil 
and urine mixed is known as incurable.  
 If the oil drop has appeared in the surface of the urine it indicates Kapham, 
if it is hide its Pitham and it is going to sink known as Vatham.   
 
‘ghuha; ePh; ghz;lj;jpy; ghq;fhajpd;Nky; ey;nyz;nza; 
 rPuha; xU Jsp tpl;lhf;fhy; rpjwp Xb Nghfhky; 
Neuha; epd;W fz; tl;lk; Nghy; neUq;fp rl;btha; vq;Fk; 
 Nru neUq;fp epHf;fpYNk jPUk; ,jw;F kUe;J nra;Na 
 
nra;Ak; tifaJ Nfsha; rpwe;j ePujpNy vz;nzapl;lhy;  
 iga;a fPNo jho;e;jpbDk; gjwp Xb rpjwpbYk;  
nea;Ak; ePUk; xd;whf kpfNt $b fye;jpbDk;  
 ca;Ak; tifaJ jPuhJ cj;jkk; vy;yhk; kj;jpgNk 
 
ifapdhy; vz;nza; thq;fp fope;j ePh; jd;dpy; Cw;wp 
 xa;Awpy; IakhFk; xope;jpby; gpj;jkhFk;  
nka;AWk; vz;nza; jhspy; kpFe;jNjhH thjkhFk; 
 ngha;ay;y ,k; %d;Wf;Fk; Gj;jpaha; mwpe;J ghNu” 
     - NkfNuhf epjhdk;-rpj;jkUj;Jt njhFjp-I 
 
2.1.11 Neha;f;fzpg;G tpthjk; (DIFFERENTIAL DIAGNOSIS) 
 
 Theli Neer (Diabetes insipidus) 
 Neer Kiricharam (Urinary Tract Infection) 
 
2.1.12 kUj;Jtk;  
In siddha the management of a disease not only depends on the medicine but 
the modification of food, habits, and lifestyle also. There are several medicines said in 
the literatures and practiced successfully by Siddha practitioners. The regulations in 
food, daily habits etc. are the specialty of most of these medicines. 
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2.2 MODERN ASPECT - DIABETES MILLUTUS  
2.2.1 Definition and description of diabetes mellitus 
 
Diabetes is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action or both. The chronic 
hyperglycemia of diabetes is associated with long-term damage, dysfunction, and 
failure of different organs, especially the eyes, kidneys, nerves, heart, and blood 
vessels. Several pathogenic processes are involved in the development of diabetes.  
 
These range from autoimmune destruction of the pancreatic b-cells with 
consequent insulin deﬁciency to abnormalities that result in resistance to insulin 
action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in 
diabetes is deﬁcient action of insulin on target tissues. Deﬁcient insulin action results 
from inadequate insulin secretion and / or diminished tissue responses to insulinatone 
or more points in the complex pathways of hormone action. Impairment of insulin 
secretion and defects ininsulin action frequently coexist in the same patient, and it is 
often unclear which abnormality, if either alone, is the primary cause of the 
hyperglycemia.  
 
Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, 
sometimes with polyphagia, and blurred vision. Impairment of growth and 
susceptibility to certain infections may also accompany chronic hyperglycemia. 
Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with 
ketoacidosis or the nonketotic hyperosmolar syndrome.  
 
Long-term complications of diabetes include retinopathy with potential loss of 
vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot 
ulcers, amputations, and Charcot joints; and autonomic neuropathy causing 
gastrointestinal, genitourinary, and cardiovascular symptoms and sexual dysfunction. 
Patients with diabetes have an increased incidence of atherosclerotic cardiovascular, 
peripheral arterial and cerebrovascular disease. Hypertension and abnormalities of 
lipoprotein metabolism are often found in people with diabetes. 
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2.2.2 Epidemiology 
The mortality rate of diabetes mellitus is high and is ranked in 5th amongst the 
ten major causes of death in southern part of India. The rising prevelance of diabetes 
is associated with industrialization and socioeconomic development. The prevelance 
of diabetes in adults globally is estimated to be 150 million and this figure is expected 
to double by 2025. Although the prevelance of type-I and II diabetes mellitus is 
increasing worldwide. The prevelance of type-II diabetes mellitus is expected increase 
more rapidly in future because of increasing obesity and reduced physical activity. 
The WHO estimates that 75 per cent of the 300 million adults with diabetes in 2025 
will live in devolopig countries.  
 
2.2.3 Classification of diabetes mellitus 
Etiologic classification of diabetes mellitus: 
I. Type-1 diabetes (β-cell destruction, usually leading to absolute insulin 
deficiency) 
A. Immune mediated 
B. Idiopathic 
II. Type-2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly secretory defect with insulin 
resistance) 
III. Other specific types 
A. Genetic defects of β-cell function 
1. Chromosome 12, HNF-1α (MODY3) 
2. Chromosome 7, glucokinase (MODY2) 
3. Chromosome 20, HNF-4α (MODY1) 
4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) 
5. Chromosome 17, HNF-1β (MODY5) 
6. Chromosome 2, NeuroD1 (MODY6) 
7. Mitochondrial DNA 
8. Others 
B. Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
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3. Rabson-Mendenhall syndrome 
4. Lipoatrophic diabetes 
5. Others 
C. Diseases of the exocrine pancreas 
1. Pancreatitis 
2. Trauma/pancreatectomy 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalculous pancreatopathy 
7. Others 
D. Endocrinopathies 
1. Acromegaly 
2. Cushing's syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
8. Others 
E. Drug or chemical induced 
1. Vacor 
2. Pentamidine 
3. Nicotinic acid 
4. Glucocorticoids 
5. Thyroid hormone 
6. Diazoxide 
7. β-adrenergic agonists 
8. Thiazides 
9. Dilantin 
10. γ-Interferon 
11. Others 
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F. Infections 
1. Congenital rubella 
2. Cytomegalovirus 
3. Others 
G. Uncommon forms of immune-mediated diabetes 
1. “Stiff-man” syndrome 
2. Anti-insulin receptor antibodies 
3. Others 
H. Other genetic syndromes sometimes associated with diabetes 
1. Down syndrome 
2. Klinefelter syndrome 
3. Turner syndrome 
4. Wolfram syndrome 
5. Friedreich ataxia 
6. Huntington chorea 
7. Laurence-Moon-Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
11. Others 
IV. Gestational diabetes mellitus 
Patients with any form of diabetes may require insulin treatment at some stage 
of their disease. Such use of insulin does not, of itself, classify the patient. 
2.2.3.1 Type-I diabetes mellitus 
Type-I diabetes characterized by deficiency of insulin due to destructive 
lesions of pancreatic b-cells; usually progresses to the stage of absolute insulin 
deficiency. Typically, it occurs in young people with acute-onset with typical 
symptoms of diabetes together with weight loss and tendency to ketosis, but type 
1diabetes may occur at any age, sometimes with slow progression.  People, who have 
antibodies to pancreatic b-cells such as glutamic-acid-decarboxylase (GAD), are 
likely to develop either typical acute-onset or slow-progressive insulin dependent 
diabetes. Today antibodies to pancreatic b-cells are considered as a marker of type-I 
diabetes, although such antibodies are not detectable in all patients.   
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2.2.3.2 Type-II diabetes mellitus 
Type-II diabetes is caused by a combination of decreased insulin secretion and 
decreased insulin sensitivity. Typically, the early stage of type-II diabetes is 
characterized by insulin resistance and decreased ability for insulin secretion causing 
excessive post-prandial hyperglycaemia. This is followed by a gradually deteriorating 
first-phase insulin response to increased blood glucose concentrations. Type-II 
diabetes, comprising over 90% of adults with diabetes, typically develops after middle 
age. The patients are often obese or have been obese in the past and have typically 
been physically inactive. Ketoacidosis is uncommon, but may occur in the presence of 
severe infection or severe stress.  
 
2.2.3.3 Gestational diabetes mellitus 
Gestational diabetes constitutes any glucose perturbation that develops during 
pregnancy and disappears after delivery. Long-term follow-up studies, recently 
reviewed by Kim et al., reveal that most, but not all, women with gestational diabetes 
do progress to diabetes after pregnancy. In some cases, type-I diabetes may be 
detected during pregnancy.  However women who had diagnosed diabetes before 
pregnancy cannot be said to have gestational diabetes. The definition applies 
regardless of the type of treatment needed during the course of the pregnancy and 
whether the patient remains diabetic after delivery. 
 
2.2.3.4 Other Types  
Other types include:  
i. Diabetes related to specific single genetic mutations that may lead to rare 
forms of diabetes, as for instance Maturity Onset Diabetes of the Young 
(MODY) 
ii. Diabetes secondary to other pathological conditions or diseases (as a 
result of pancreatitis, trauma, or surgery of pancreas) 
iii. Drug or chemically induced diabetes.  
 
The clinical classification also comprises different stages of hyperglycaemia, 
reflecting the natural history of absolute or relative insulin deficiency progressing 
from normoglycaemia to diabetes. It is not uncommon that a non-diabetic individual 
may move from one category to another in either direction. Usually, a progression 
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towards a more severe glucose abnormality takes place with increasing age. This is 
reflected by the increase in the 2-hPG level with age. The currently valid clinical 
classification criteria have been issued by WHO and ADA. The WHO 
recommendations for glucometabolic classification are based on measuring both 
fasting and 2 hour post prandial glucose (2-hPG) concentrations and recommend that 
a standardized 75 g OGTT should be performed in the absence of overt 
hyperglycaemia. The thresholds for diabetes on fasting and 2-hPG values were 
primarily determined by the values where the prevalence of diabetic retinopathy, 
which is a specific complication of hyperglycaemia, starts to increase. Even though 
macrovascular diseases such as CHD and stroke are major causes of death in type-II 
diabetic patients and people with IGT, macrovascular disease has not been considered 
in the classification. This sounds illogical and may give an impression that 
macrovascular diseases are less important than microvascular consequences of 
diabetes.  Classification according to the ADA criteria strongly encourages the single 
use of fasting glycaemia only without an OGTT.  
 
CRITERIA FOR DIABETIC DIAGNOSIS 
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2.2.4 Complications of diabetes mellitus  
2.2.4.1 Acute Complications   
The usual clinical symptoms of DM include polyuria, polydipsia, weight loss, 
fatigue, weakness, blurred vision, frequent superficial infections, and poor wound 
healing. However, patients can occasionally present with acute complications, such as 
hypoglycaemia, diabetic ketoacidosis, hyperosmolar non-ketotic coma.  
 
2.2.4.2 Chronic Complications   
The major chronic complications of DM are usually microvascular, 
neuropathic and macrovascular in nature. The microvascular and neuropathic 
complications present as retinopathy, nephropathy, peripheral neuropathy, autonomic 
neuropathy and foot disease. The macrovascular complications present as myocardial 
infarction/ ischaemia, transient ischaemic attack, stroke and claudication have also 
indicated that other chronic complications of diabetes may be non-vascular, e.g. 
gastroparesis, infections and skin changes.  
 
2.2.4.3 Macrovascular Complications   
Boyle (2007) stated that in patients with type-II diabetes, there is an increased 
risk of macrovascular disease. Factors that may play a linkage role in the development 
of  macrovascular disease in type-II diabetes include low concentration of the 
adipocyte  specific protein (adiponectin) , increased production of the vascular cell 
adhesion molecule-1 and the subsequent adhesion of T-lymphocytes to the endothelial 
walls of the coronary arteries, higher procoagulation with increased expression of  
Plasminogen Activator Inhibitor-1 (PAI), and an increased production of Matrix 
Metalloproteinases (MMPs) by macrophages which ultimately leads to an instability 
of atherosclerotic plaques. Almdal et al (2004) also indicated that type-II diabetes 
typically occurs in the setting of the metabolic syndrome, which also includes 
abdominal obesity, hypertension, hyperlipidaemia, and increased coagulability. These 
other factors can also act to promote cardiovascular disease. In this setting of multiple 
risk factors, type-II diabetes itself acts as an independent risk factor for the 
development of ischemic disease, stroke, and death.   
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2.2.4.4 Retinopathy   
Diabetic retinopathy which occurs in all forms of diabetes is the commonest 
cause of blindness in adults in most developed countries. The development of 
retinopathy, as with all diabetic complications, depends on the duration of the disease. 
The natural history of diabetic retinopathy according to Nathan (1993) has been best 
defined in IDDM, where it is possible to predict the date of onset of the disease. 
Course of progression of retinopathy in NIDDM is more difficult to ascertain, since 
the diabetes may be progressing silently for many years before it is diagnosed. As a 
result, patients with NIDDM may present with retinopathy and even, rarely, advanced 
retinopathy at the time of diagnosis. However, the development of retinopathy is still 
dependent on how long the patient has had NIDDM, as it is in IDDM.   
  
The clinical features of diabetic retinopathy are; ‘microaneurysms, retinal 
haemorrhages, exudates, cotton wool spots, neovascularisation, fibrosis, pre-retinal 
and vitreous haemorrhages’. These features occur in various combinations in different 
patients and are used to classify the severity of the disease.  
 
2.2.4.5 Neuropathy   
This is a relatively early and common complication affecting approximately 
half of all patients diagnosed with both types-I and II diabetes. Fauci (2008) asserts 
that the condition may manifest as polyneuropathy, mononeuropathy, and/or 
autonomic neuropathy. As with other complications of DM, the development of 
neuropathy largely depends on duration of diabetes and how well or otherwise 
glucose levels are controlled. Also increased body mass index and smoking are 
considered risk factors for developing the complication. 
 
2.2.5 COPD and Diabetes 
The term COPD encompasses two other lung diseases, chronic bronchitis and 
emphysema. COPD is progressive and currently incurable, and without proper 
diagnosis and treatment, health will continue to deteriorate. With COPD, pulmonary 
inflammation prevents the proper exchange of air. Diabetes or diabetes mellitus is a 
term used to describe a group of diseases that affect blood sugar, also known as blood 
glucose, throughout the body. People with diabetes suffer from high amounts of 
glucose in the blood, which can lead to numerous health complications and adverse 
symptoms. The hormone insulin regulates glucose levels. 
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Two top factors cause COPD to develop–smoking and environmental or 
occupational pollution. For the most part, diabetes occurs because of genetic and 
environmental factors. The end result for COPD is that the blood is not properly 
oxygenated, and for diabetes, low levels of insulin result in skyrocketing glucose in 
the blood which cannot reach the body’s cells to provide energy. 
 
2.2.5.1 The Connection between COPD and Diabetes 
Diabetes mellitus (DM) is a common comorbidity of chronic obstructive 
pulmonary disease (COPD). A series of studies have shown that DM is associated 
with impaired lung function. The chronic complications of diabetes include a number 
of pathological changes involving different districts and, among these, lung represents 
a target organ for diabetic microangiopathy in patients with diabetes. The 
Framingham Heart Study has reported an association between glycemic status and 
reduced lung function. The diagnosis of DM was associated with lower adjusted mean 
residual forced expiratory volume in one second (FEV1) and Forced vital capacity 
(FVC). The Copenhagen City Heart Study, a longitudinal analysis, has shown an 
association between a new diagnosis of diabetes and impaired lung function that was 
more prominent in diabetic subjects treated with insulin compared with subjects 
treated with oral hypoglycemic agents. In a prospective Australian study, the 
Fremantle Diabetes Study, 125 patients with type 2 diabetes mellitus (T2D) and no 
history of lung disease was assessed by spirometry at baseline and revaluated seven 
years later. The key finding was that the average rate of decline in lung function, as 
measured by FEV1 was 71 ml/year compared to an expected decline in healthy non-
smokers of 25–30 ml/year, suggesting that the exposure to blood glucose may be a 
strong and consistent negative predictor of lung function follow-up after adjustment 
for baseline and potential confounders. The association between impaired lung 
function and diabetes is thought to be the result of biochemical changes in the 
structures of the lung tissue and airways that involves a series of mechanisms likely 
due to systemic inflammation, oxidative stress, and hypoxemia or ultimately to the 
direct damage caused by chronic hyperglycemia. The lung function decline in patients 
with diabetes may be a consequence of diabetes itself and diabetic patients seem to 
have an increased risk of several non-neoplastic lung conditions such as asthma and 
COPD. 
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2.2.5.2 Epidemiology  
Diabetes occurs more often in people with COPD than in the general 
population, although the exact prevalence varies between studies 
. 
A retrospective analysis examined the relationship between COPD and 
comorbidities using Health Search Database information obtained from Italian 
College of General Practitioners that stores information of nearly 1.5 % of the 
national population. Compared to the non-COPD individuals, COPD patients were at 
increased risk of DM, 10.5 % in the general population vs. 18.7 % in COPD patients. 
Unexpectedly, in this study COPD patients had an increased prevalence of both 
cardiovascular diseases and T2D and a very low prevalence of the metabolic 
syndrome, suggesting that COPD is a real risk factor for cardiovascular diseases and 
diabetes,  
  It has been consistently reported (Table 1) an impaired pulmonary function 
and glucose intolerance in several cross-sectional and perspective studies. A 
prospective study conducted in a five years observation period reported that the 
development of DM was associated with greater rates of decline of pulmonary 
function suggesting that diabetes may be, in particular at its onset, is associated with a 
significantly accelerated decline of respiratory function, Lazarus et al within the 
Normative Aging Study in their perspective analysis reported that FVC was 
negatively associated with the risk to have higher levels of insulin resistance and a 
similar associations were found for FEV1 and maximal mid-expiratory flow rate 
(MMEF), suggesting the possibility that insulin resistance could be the factor 
correlated with the impairment of pulmonary function. In another prospective study 
with a median follow up of 13 years, the authors concluded that the risk of developing 
diabetes is inversely associated with pulmonary function and the longitudinal 
associations between vital capacity (VC) and diabetes (P = 0.001) and log glucose 
(P = 0.036) were significant after adjustments for confounders. 
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Summary of epidemiological study 
COPD risk of 
T2D 
Population studied Findings 
Prospective cohort 
study with a mean 
follow up of 20.9 
years 
n:1,050 men (with no 
self-reported DM) 
included in the final 
analysis mean age: 41.4 
years mean BMI: 25.6 
kg/m2 
Reduced FVC, FEV1 and MMEF 
were associated with greater fasting 
insulin and fasting insulin resistance 
after logistic regression analysis. 
Prospective cohort 
study with a mean 
follow up of 13 
years 
n: 382 non-diabetic men 
BMI: 24.4–24.7 years 
(depends on the 
pulmonary VC subgroup) 
15 new cases of DM 2 were 
diagnosed during the follow up. DM 
and glucose were inversely 
associated with baseline VC. 
Prospective cohort 
study with a 
follow up of 5 
years 
n: 9,220 men non-
diabetic at baseline mean 
age: 41.4 years mean 
baseline BMI: 24.4 
kg/m2for patients without 
type 2 DM at follow up 
and 26.7 kg/m2 for 
patients with type 2 DM 
at follow up 
207 patients developed T2D with the 
incidence of 2.2 %. FEV1 and FVC 
were negatively associated with 
T2D. In patients with BMI < 25 
kg/m2 the lowest quartile of FVC 
and FEV1 had OR of 2.15 (95 % CI 
1.02–4.57) and 2.19 (95 % CI 1.09–
4.42) for incident T2D. 
Prospective cohort 
study. From 1988 
to 1996 
data from the Nurses’ 
Health Study from 1988 
to 1996 which enrolled 
103,614 females 
COPD was found to have a 
multivariate RR of 1.8 (95 % CI 1.1-
2.8) for new onset T2D. 
Prospective study 
of middle-aged 
and older US 
women followed 
over 12 years 
38,570 women who were 
aged ≥ 45 years, free of 
cardiovascular disease 
and cancer at baselineand 
free of diabetes at 
baseline 
The presence of COPD was 
associated with an approximately 
1.50-fold increased risk of T2D 
independently of traditional diabetes 
risk factors including cigarette 
smoking 
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COPD risk of 
T2D 
Population studied Findings 
Cohort from the 
Genetic 
Epidemiology of 
COPD Study 
(COPDGene) 
smokers with and without 
COPD at 21 clinical 
centers throughout the 
United States Between 
2007– 2011 
Non-emphysematous COPD, defined 
by airflow obstruction with a paucity 
of emphysema on chest CT scan, is 
associated with an increased risk of 
diabetes. 
 
The Nurses' Health Study, a prospective cohort study, during the 8 years 
follow-up found that the risk to have T2D was significantly higher in patients with 
COPD than those without COPD (multivariate relative risk 1.8, 95 % CI 1.1–2.8) nor 
those with asthma. These data suggest that COPD could be a risk factor for 
developing T2D, perhaps sharing common inflammatory and cytokine profile. In 
another Korean study, planned to assess the relationship between lung function and 
incident T2D, 9,220 men without T2D were prospectively followed for five years. 
The authors found that impaired lung function is independently associated with the 
incidence of T2D. FVC and FEV1 were negatively associated with T2D (P < 0.05) 
independently by confounding factors. It is therefore proposed on the basis of these 
results, the possibility that the reduced lung function, as measured by FEV1 and FVC, 
may precede the development of T2D. 
 
Differently, in a prospective study conducted in a cohort of 38,570 women 
with median follow-up of 12.2 years, the hypothesis that asthma or COPD could be 
involved in the pathogenesis of T2D was tested. Both asthma and COPD were 
individually and independently associated with an increased risk of T2D in women; 
this association was independent of cigarette smoking and other diabetes risk factors 
and also persisted after excluding all COPD cases with asthmatic symptoms. The 
multivariate RRs were 1.38 (95 % CI, 1.14–1.67) for COPD without asthmatic 
symptoms. Recently, an increased prevalence of diabetes in non-emphysematous 
COPD patients (diabetes OR 2.13, p < 0.0001) has been reported in the COPD Gene 
Study, where patients were classified in emphysema-predominant and non-
emphysematous COPD based on CT scan features. Although comorbidities were self-
reported, previous studies have shown that it is a reliable source of information. This 
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association persisted also after performing stratified analyses considering obese and 
non-obese individuals, smoking habit, obstruction severity divided in GOLD 1– 2 and 
GOLD 3– 4, ethnicity and age. These results were also confirmed by the ECLIPSE 
study, where diabetes was reported in 10.6 % of non-emphysema and in 8.2 % of 
emphysema-predominant COPD. The authors suggested to evaluate for diabetes 
patients with COPD, especially those defined non-emphysema.  
 
In a study conducted in UK using the wide primary care data to quantify the 
burden of comorbidity among individuals with COPD, it has been shown that COPD 
is associated with an increased odds of DM. Intriguingly the effect of COPD having 
DM is higher in current smokers for the younger patients, but after the age of 45 
becomes greater in non-smokers, suggesting that this association was independent of 
smoking status.  
 
2.2.5.3 Mechanisms 
DM is a common comorbidity of COPD. What are the mechanisms underlying 
the increased prevalence of diabetes in COPD still remains unclear, although a 
number of potential pathways including inflammation, oxidative stress, hypoxia and 
chronic hyperglycemia may provide some explanation. 
 
Systemic inflammation is a common feature to both COPD and to T2D, which 
drives insulin resistance, atherosclerosis and many systemic expressions of COPD 
itself. The presence of systemic inflammation is poorly defined in patients with 
COPD. Most of the studies were cross-sectional and show that not all patients with 
COPD have a systemic inflammatory response. However systemic inflammation is a 
risk factor for the development of many chronic diseases, which are COPD co-
morbidity. However, we should consider that the persistent systemic inflammation in 
COPD patients is associated with significantly worse outcomes in terms of mortality 
and exacerbation rate as demonstrated by the ECLIPSE study. It appears to be mostly 
independent from the pulmonary component of the disease, raising the possibility that 
systemic inflammation could be a possible therapeutic target in these patients. The 
possible development of COPD and T2D could have evidence in the context of a 
chronic systemic inflammation with the presence of cardiovascular disease or 
metabolic disorders, known to be related to systemic inflammation, increasing the 
63 
 
association between COPD and DM. In any case, systemic inflammation might be 
increased by the coexistence of these two conditions, COPD and diabetes, worsening 
both in their clinical manifestations. 
 
There are many evidences that the levels of inflammatory proteins (Table 2), 
such as cytokines and among these TNF- α, IL-6, or C reactive protein (CRP), are 
increased in patients with COPD. Systemic inflammation is associated with various 
complications in COPD, including cardiovascular and metabolic diseases such as 
diabetes. 
 
Potential mediators involved in the higher prevalence of T2D in COPD 
  COPD DM 
CRP COPD is independently associated 
with increased levels of CRP. 
Moreover, CRP may predict the future 
onset of COPD. 
Elevated CRP levels may predict 
the development of onset of T2D. 
TNF-α COPD is independently associated 
with increased levels of TNF-α. 
activates NF-kB leading to cytokine 
production, upregulation of adhesion 
molecules and increasing oxidative 
stress 
May be a risk factor for the 
development of new onset T2D. 
May interfere with glucose 
metabolism and insulin 
sensitivity, and can be 
antagonized by adiponectin which 
reduces NfkB activation. 
IL-1 IL-1 is implicated in the pathogenesis 
of COPD related inflammation. 
An increase in IL-1β may predict 
the development of new onset 
T2D. 
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  COPD DM 
IL-6 COPD is independently associated 
with increased levels of IL-6. This 
cytokine is a potent stimulator of CRP 
production by the liver and may 
account for the increase in circulating 
CRP found in patients with COPD. 
IL-6 was shown to increase the 
risk for the new onset T2D. 
Leptin Leptin levels are increased in patients 
with COPD. May contribute to COPD 
related weight loss, PFT decline and 
prolonged hospital stay. Leptin 
induced IR and hyperglycemia 
Leptin may increase the risk of 
T2D. Leptin may participate in 
the development of DM related 
complications via its 
proinflammatory actions. 
Adipone
ctin 
Adiponectin levels are increased in 
patients with COPD and low BMI, 
Increased adiponectin was related to a 
decrease in cardiovascular mortality, 
but was associated with an increase in 
mortality due to respiratory causes. 
Adiponectin may prevent the 
development of T2D via its anti-
inflammatory and proinsulin 
actions. 
Resistin Resistin levels may be increased in 
COPD and mediate IR. 
Resistin may directly participate 
in the development of IR 
Catecho
lamine 
Patients with COPD had higher 
catecholamine levels which were 
independently related to a decrease in 
FEV1. 
Insulin antagonists and contribute 
to the occurrence of 
hyperglycemia. Abnormalities in 
the renin angiotensin aldosterone 
system (RAAS) are implicated in 
the development and pathogenesis 
of cardiovascular diseases, 
Metabolic Syndrome and T2D 
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  COPD DM 
NF-kB NF-kB activation is implicated in 
systemic inflammation and could be 
involved in skeletal muscle 
dysfunction in COPD patients 
NF-kB activation has also been 
associated with Diabetes 
 
TNF-α is a marker of systemic inflammation that appears to be associated with 
the severity of COPD, increased levels are seen in severe and very severe COPD. On 
the other hand, high levels of TNF- α may be a risk factor for the development of 
new-onset T2D, interfering with glucose metabolism and insulin sensitivity, 
suggesting a possible link between COPD and T2D. 
Oxidative stress is generated by an imbalance between oxidants and 
antioxidants. In COPD patients, either in stable or during acute exacerbations, 
oxidative stress is increased mainly by inhalation of oxidants such as those generated 
by cigarette smoke or pollution, or as a result of inflammatory leukocytes that are 
activated to release reactive oxygen species. This condition can cause direct damage 
to the lung targeting lipids and proteins, triggering specific pathways, which could 
generate increased gene expression, production pro-inflammatory cytokines and 
ultimately increased inflammation. Finally adiponectin, an adipokin with intrinsic 
anti-inflammatory property, correlates with COPD; data obtained in case-control 
studies demonstrated a higher systemic and airway adiponectin concentrations in 
COPD patients mainly men than controls. Moreover serum adiponectin has a positive 
correlation with lung function in healthy adults, whereas an inverse correlation has 
been found in studies conducted in male individuals with COPD. 
 
In T2D oxidative stress is present through the activation of specific 
biochemical pathways, increased production of reactive oxygen species, and reduction 
of antioxidants and furthermore increase lipid peroxidation. Oxidative stress, mainly 
smoke-induced in COPD patients, could cause in T2D the continuation of the insulin 
resistance by altering the production of energy. Conversely oxidative stress produced 
by T2D might worsen COPD activating inflammation and even compromising the 
response to glucocorticoids. 
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Smoking induces oxidative stress that can trigger local and systemic 
inflammation, though cigarette smoking is not a link between DM and COPD. This is 
especially interesting given that exposure to cigarette smoking is crucial for the 
development of COPD and, at the same time, an independent and modifiable factor 
for the development of DM. Since cigarette smoking does not appear to be the 
connection, it is likely that other mechanisms besides systemic inflammation or 
oxidative stress could define the link between DM and COPD. 
 
Current evidence suggests that COPD, in which hypoxia is one of the typical 
features, is associated with increased levels of oxidative stress, but likewise an 
excessive oxidative stress may be a risk factor for new-onset T2D it can be also a 
result of new onset DM. Moreover, the induction of increased levels of reactive 
oxygen species (ROS), NF-kB and intracellular mediators of inflammation could also 
lead to chronic hyperglycemia and to an increased synthesis of collagen mediated by 
higher levels of advanced glycation end products that ultimately would affect 
negatively lung function. 
 
Hypoxia causes significant changes in metabolism, studies conducted in 
healthy subjects at high altitude showed increased insulin resistance and glucose 
production in the liver with greater insulin sensitivity at peripheral level and increased 
uptake of glucose in skeletal. It seems that pancreatic β cells are sensitive to hypoxia-
induced damage, regardless of the condition of intermittent hypoxia as that observed 
in sleep apnea, or chronic hypoxia seen in COPD. Indeed, chronic hypoxia has been 
observed in association with impaired glucose tolerance, reduced insulin sensitivity 
accompanied by greater lipolysis. In COPD patients, in which the normalization of 
saturation values has been obtained, it can be observed an improvements of glucose 
tolerance and insulin sensitivity. It is possible that both of these diseases, COPD and 
DM, might share common pathophysiological pathways which can be mediated by 
hypoxia inducible factor (HIF).  
 
Inflammation, oxidative stress and hyperglycemia in particular, have been 
shown to induce muscle dysfunction. Lower lung function has also been suggested to 
be associated with increased serum osmolarity, where blood sugar contributes to the 
67 
 
total serum osmolarity. A number of prospective studies have shown that reduced 
lung function is an independent predictor of T2D. In particular, in a prospective study 
on lung function in adults with T2D, it has been suggested the idea that alterations in 
lung function may precede diabetes and then will progress after the onset of diabetes 
itself.  
 
The data suggested that the glucose-induced enhancement of bronchial 
responsiveness is likely to be due to increased activation of a particular intracellular 
pathway: the Rho-kinase pathway. It seems that the Rho/ROCK pathway plays a role 
in regulating several biological pathways, including some that affect the level of 
airway smooth muscle (ASM) tone. The activation of this pathway mediates multiple 
biological functions involving contractility based on actin-myosin. Moreover, our 
results suggested that the Rho/ROCK pathway, together with the mobilization of the 
intracellular calcium and the phosphorylation of MYPT-1, might play a crucial role in 
the reduced lung function observed in patients with diabetes. It is widely accepted that 
airway hyper responsiveness is a risk factor for an accelerated decline in FEV1 and 
the development of obstructive pulmonary disease such as COPD. As well as 
pulmonary function impairment that is greater in patients with poorly controlled 
diabetes, a finding that, however, is not explained by obesity or increasing age. 
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2.2.5.4 Targeting Mechanisms Linking COPD to Type II Diabetes Mellitus 
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2.2.6 Glycated Haemoglobin (HbA1C)   
HbA1c was introduced into clinical use in the 1980s and subsequently has 
become a cornerstone of clinical practice. HbA1C reflects average plasma glucose 
over the previous eight to 12 weeks.It can be performed at any time of the day and 
does not require any special preparation such as fasting. These properties have made it 
the preferred test for assessing glycaemic control in people with diabetes. More 
recently, there has been substantial interest in using it as a diagnostic test for diabetes 
and as a screening test for persons at high risk of diabetes. 
 
In 2009, The International Expert Committee recommended the use of HbA1C 
to diagnose diabetes mellitus with a threshold > 6.5%. However, the diagnosis should 
be confirmed by a repeat test unless symptoms of hyperglycaemia and blood glucose 
level of >11.1 mmol/l (>200mg/dl) are available.In addition, those with an HbA1C 
level between 6 and 6.5% have been identified as being at very high risk of 
developing diabetes, and the risk increases substantially as the values increase.  
  
The ADA's recommended goal for HbA1C is <7% in all patients with diabetes 
mellitus. The same level is recommended for primary prevention of cardiovascular 
disease in people with diabetes. The ideal HbA1C goal for individual diabetic patients 
is as low as <6% without causing significant hypoglycaemia. The recommendations 
are the same for T1DM and T2DM. The ADA recommends checking HbA1C levels 
at least twice a year in patients with relatively stable glycaemic control and quarterly 
among those whose HbA1C targets are not achieved, particularly if drugs are 
changed, to determine the effect of such changes.  
  
HbA1C and CHD in Patients with Diabetes 
Diabetes patients face an 11% increased risk of mortality from ischaemic heart 
disease. While those with HbA1C >8% face a 150% increased risk of death from 
heart disease. Cardiovascular complications are usually present at the diagnosis of 
T2DM, because diabetes is preceded by long period of asymptomatic hyperglycaemia, 
called impaired glucose tolerance. Classical CV risk factors such as smoking, 
hypertension, and hypercholesterolemia do not account for the excess risk of CV 
morbidity and mortality in patients with elevated HbA1C levels. This association is 
equally important in both T1DM and T2DM, and exists across ethnic and 
geographical boundaries. 
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    Materials and Methods 
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CHAPTER-III 
MATERIALS AND METHODS 
3.1 STUDY AREA AND SETTING   
 
The study covered the period of April 2016 to July 2018 at the Govt. Siddha 
Medical College and Hospital, Palayamkottai- 627 002, Tirunelveli, Tamil Nadu. All 
procedures were approved by the IEC, DR MGR Medical University, Chennai.  
 
3.2 STUDY DESIGN 
An open labelled randomized clinical trial of 40 type-II diabetic patients. The 
participants were newly diagnosed and already diagnosed as type-II diabetics and 
undergoing treatment.  A written informed consent form was completed by all the 
participants who were recruited into the study. The purpose of the study was 
explained to the participants in local language they understand. Proformas were used 
to record information of the participants. Information on demography, life style, 
anthropometric measurements and Siddha parameters were taken.   
 
40 patients of both sexes of 40 to 75 age groups were recruited for study and 
treated with the trail drug till the end of the study period of 90 days. Of the 40 
patients, 20 were treated as in patients. After discharge, the IP cases were followed in 
OP until the completion of the study. 
 
Study type      : A Prospective Open labelled Randomized Clinical trial. 
Study Place    : Govt. Siddha Medical College and Hospital, Palayamkottai - 627002 
Study Period : 24 months. 
Sample size : 40 patients  
3.3 SELECTION OF PATIENTS 
The inclusion of cases in the study was based on the screening of patients with 
Iya Neerizhivu. The criteria for screening were increased fasting, post prandial sugar 
levels along with high level of HbA1C, Spirometry test & Dyspnea Scale Score. 
Detailed personal history, family history, occupation, habits, clinical 
symptoms, medical history, and the duration of illness were recorded for each and 
every patient (Proforma annexed). 
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3.3.1 INCLUSION CRITERIA 
1. Age between  ≥ 40 and ≤ 75 years 
2. Type II diabetes mellitus, previously diagnosed diabetic patients which are 
uncontrolled or poorly controlled for more than 5 years duration of the illness.  
3. If yes in any of three  
a. FBS - > 126 mg/dl and ≤250mg/dl or 
b. PPBS - > 200mg/dl and ≤350mg /dl or  
c. HbA1c > 6.5 and<12 
4. Patient with respiratory complaints such as, Coughing, sputum  and  Dyspnea 
a. FEV1/ FVC <0.70 and FEV1 <80% 
b. MMRC Dyspnea score ≥2 
5. Willing to give blood sample for the investigations 
6. Patients who are mono therapy alone  
 
3.3.2 EXCLUSION CRITERIA 
1. Age below <40 years and >75 years  
2. History of occupational exposure 
3. Participation of pulmonary rehabilitation program with 12 months  
4. Systemic hypertension, angina, heart failure 
5. Any physical disability that may affect lung function as kyphoscoliosis, pectus 
excavatum and pectus carinatum.  
6. Resting O2 saturation < 90%  
7. Type 1 diabetes mellitus 
8. Pregnancy  
9. Lactating mother  
10. Chronic kidney disease / Renal failure 
11.  Prolonged Corticosteroid therapy 
12.  Chronic active viral hepatitis/cirrhosis/ascites 
13. Auto Immune disorder 
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WITHDRAWAL CRITERIA: The investigator shall withdraw the patients from 
the study if,  
1. FBS rises to >200mg/dl or PPBS level increases to >350mg/dl  or respiratory 
complaints are not controllable within fifteen days  
2. Shortness of breath from COPD resulting in the patient too breathless to leave 
the house, or breathless after dressing or undressing or the presence of chronic 
respiratory failure or clinical signs of right heart failure and FEV1 30% - 39% 
predicted FEV1 / FVC < 0.7 
3. Any serious complication develops, which required urgent treatment with any 
other Drug/ therapy  
4. Patients turned unwilling to continue in the course of clinical trial 
 
The investigator will mention the probable course of withdrawal and provide 
possible medical treatment to manage the illness. 
 
3.3.3 DIAGNOSIS 
 
The Siddha parameters of diagnosis of diseases were implemented in the 
inclusion of cases for the study which are,                  
 
 Poriyal Arithal 
 Pulanal Arithal 
 Vinathal 
 Mukkutra nilaigal 
 Envagai thervugal 
 Nilam 
 Kaalam & Udal kattugal 
 
3.3.4 INVESTIGATIONS 
1. Blood: 
a. HBA1C, FBS, RBS, PPBS  
b. Lipid profile 
c. CRP  
 
74 
 
2. Sputum Examination  
a. AFB 
b. Culture suitable in selected cases 
3. Pulmonary function tests (computerized Spirometric tests) 
a. FVC - forced vital capacity  
b. FEV1- forced expiratory volume in one second   
c. MMEF – Maximum mid expiratory flow 
d. PEFR- Peak expiratory flow rate (By peak flow meter) 
4. Chest X-ray 
a. PA View 
5. BMI 
 
2. Urine: 
 
 Albumin, Sugar, Deposits 
 
The Biochemical Analysis was carried out before and after treatment at the 
time of discharge, along with regular blood sugar monitoring once in twenty days.  
 
3.4 TREATMENT 
 
The trial medicine choosen for the clinical study was Seenthil Sarkkarai     
30 mg/Kg/BW/daily three times a day it was titrated considering the BMI of the 
patient and dose adjusted accordingly. 
 
Trial Medicine             : Seenthil Sarkkarai  
Reference                     : Gunapadam (Mooligai Vaguppu) C.S.Murugesu Mudaliyar 
Dosage    : 30 mg/ Kg/BW/daily three times a day 
Adjuvant    : Ghee   
Duration    : 90 days 
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3.4.1 Preparation of Trial Medicine  
 
Purification and Preparation of Seenthil Sarkkarai  
All the ingredients of these herbal formulations will purify according to the 
suitable procedure methods described in Siddha classical literature.   Cut and remove 
the outer covering of aged stem of Tinospora cordifolia will be shade dried and make 
into powder. Add 1400 ml water and knead well, then mix 5600ml water and allow 
precipitating. The flour of Tinospora Cordifolia will be precipitated in the latter. After 
filter the water and again add 5600 ml water into it and allow to precipitating. It will 
be done for 10 times. Then add kaadi neer mixed with lemon juice (16:1) allow to 
precipitating for one day. Like another day buttermilk and lemon juice (16:1) allow to 
precipitating. The ratio should be maintained to flour and solution is 1:4. Finally flour 
will be collected and dried.  
 
Drug Storage 
The trial drug is stored in clean dry air tight container and it is dispensed to the 
patients in packets    
 
3.4.2 Collection and authentication of Trial Medicine  
  The stems of Tinospora cordifolia (climber) will be freshly collected from in 
and around the areas of Palayamkottai and Thirunrlveli, Tamilnadu. The plant will be 
identified and authenticated by the Medicinal Botanist and Gunapadam experts at 
Government Siddha Medical College and Hospital, Palayamkottai - 627002. The 
specimen sample of all the herbs will be preserved in PG Gunapadam department 
individually for future reference 
 
3.4.3 Preclinical Analysis of Trial Medicine 
All the preclinical studies of the drugs which had included Bio chemical and 
pharmacological studies had done and cross checked before beginning the trial. The 
Biochemical analysis had done in Dept. of Biochemistry, GSMCH, Palyamkottai.  
All the preclinical studies of the drugs which include Physical, Biochemical 
and Pharmacological studies will be done and will be cross checked before beginning 
the trial. 
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3.4.4 Ethical Review 
The trial was conducted in accordance with the ethical principles that are 
consistent with Good Clinical Practice guidelines and obtained prior approvals before 
start of the trial from the Institutional Ethics Committee of GSMCH, Palayamkottai 
(No: GSMC/3-IEC/2016-I-6/20.07.2016 Dated 20.07.2016) and Institutional animal 
ethical committee (IEAC) of K.M. College of Pharmacy, Madurai 
(TNMGRMU/KMCP/IEAC/312).  The trial was applied and approved in Clinical 
Trial Registry of India. 
 
3.4.5 Study Enrolment   
Participants were informed in Tamil language, regarding the trial, the expected 
benefits and their right to opt-out of trial at any time without prejudice.  Informed 
written consent was obtained from each participant, prior to his/her inclusion into the 
trial.  
Type II Diabetes Patient reporting at the OPD with the clinical features 
sustained with dyspnea, coughing and sputum are chosen for enrolment based on the 
inclusion criteria. The patients who are enrolled are informed about the study trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them and the informed consent would be obtained in writing from 
them in the consent form 
Before commencing the trial all the subjects were advised diet based on their 
body mass index, but no recommendations on diet were given during trial period. All 
subjects of age range between 40-70 years with Fasting Plasma Glucose (FPG) 
>110mg/dl and two-hour Postprandial Plasma Glucose (PPPG) between >160mg/dl 
and with a. FEV1/ FVC <0.70 and FEV1 <80%, MMRC Dyspnea score ≥2 were 
included in the study.  
The subjects with history of serious adverse effects or hypersensitivity 
reactions to the medication such as rashes, diarrhoea, vomiting etc., and history of 
treatment with other anti-hyperglycaemic drugs, active liver disease or hepatic 
dysfunctions, higher serum creatinine (> 2.5 mg/dl) and serious or unstable medical or 
psychological condition are excluded from the study.   
 
During each visit, body weight, blood pressure, respiratory system and 
cardiovascular were examined clinically. During each visit adverse effects present if 
any were documented. 
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At the end of the study period, all the patients were instructed to follow diet 
control, regular exercise, Pranayamam, yoga, meditation and to monitor their blood 
sugar levels, HbA1C, and lipid levels periodically. They were also advised to pursue 
the further treatment in the PG, Pothu Maruthuvam OP for the follow up study. 
 
3.4.6 Statistical Analysis  
 
All data were analysed using the SPSS 25.0 (IBM). Data were expressed as 
means and standard deviation. The significance of the difference between the means 
of the baseline and the final examinations was tested using the paired “t” test. A 
probability value of <0.05 was considered to be statistically significant. 
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   Result  and Observation  
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CHAPTER-IV 
RESULTS AND OBSERVATIONS 
 
PREFACE   
This study was a hospital based an A Prospective Open Labelled Randomized 
Phase II Clinical Trial of “SEENTHIL SARKKARAI” for IYA NEERIZHIVU 
(Chronic Obstructive Pulmonary Disease in Type II Diabetes Mellitus) and evaluates 
blood glucose level and pulmonary function in type-II diabetic subjects. In addition to 
assessed healthcare standards, patient’s knowledge and Siddha parameters were 
among diabetic patients. To perform this, analysis was done to see if there is any 
difference in patients. An attempt was done to correlate between all parameters. The 
results of this study covered 40 known diabetic type-II patients. All patients were 
under the treatment for COPD in diabetes type-II. Plasma glucose level (FBS and 
PPBS) and Pulmanoray Function Test, MMIR score, Serum lipid profile (total 
cholesterol (TC), triglyceride (TG), Low-density lipoprotein cholesterol (LDL-C), 
High-density lipoprotein cholesterol (HDL-C) and Very low-density lipoprotein 
cholesterol (VLDL-C) were measured.  
 
The results were observed with respect to the following criteria by clinical 
study on 20 out patients and 20 In patients of both sexes. The criteria were. 
1. Distribution of Gender  
2. Distribution of Age  
3. Distribution of Educational  
4. Distribution of Occupation  
5. Distribution of Religion  
6. Distribution of Marital Status 
7. Distribution of Clinical Manifestation  
8. Distribution of Mode of Onset  
9. Distribution of Duration of Illness  
10. Distribution of Family History 
11. Distribution of History of Previous Treatment of Madhumegam 
12. Distribution of Personal History 
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13. Distribution of Socio-Economical Status 
14. Distribution of Other System Involvement 
15. Distribution of Body Mass Index 
16. Distribution of Constitution of Body 
17. Distribution of Gunam 
18. Distribution of Kaalam 
19. Distribution of Paruva Kaalam 
20. Distribution of Thinai 
21. Distribution of Mukkutram 
a). Derangement of Vatham 
b). Derangement of Pitham 
c). Derangement of Kapham 
22. Distribution of Involvement of Udal Thathukkal 
23. Distribution of Kanmenthiriyam 
24. Distribution of Imporigal (Gnanendrium) 
25. Distribution of Kosam 
26. Distribution of Conditions of Envagai Thervugal 
27. Distribution of Neer Kuri 
28. Distribution of Nei Kuri 
29. Distribution of Laboratory Analysis  
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1.DISTRIBUTION OF GENDER 
Table-1 illustrates the distribution of sex and its percentage. 
TABLE-1 
DISTRIBUTION OF GENDER 
 
Sl. 
No. 
Sex 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Male 10 50% 14 70% 
2. Female 10 50% 6 30% 
Total 20 100% 20 100% 
 
 
FIGURE-1 
 
 
 
 
In 40 patients included in the study Iya Neerizhivu is distributed in both sexes. 
Table shows among 20 OP patients 50% were female and 50% were male, among 20 
IP patients 70% were male 30% were female. 
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2.DISTRIBUTION OF AGE  
Table-2 illustrates the distribution of age and its percentage. 
TABLE-2 
DISTRIBUTION OF AGE 
 
Sl. 
No. 
Age group 
(In years) 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. 40-49 4 20% 1 5% 
2. 50-59 6 30% 2 10% 
3. 60-69 9 45% 10 50% 
4. 70-75 1 5% 7 35% 
Total 20 100% 20 100% 
 
FIGURE-2 
 
The highest incidence was in Iya Neerizhivu. Among the 20 OP and 20 IP 
patients observed 45% and 50% were affected in age group of 60-69 years, age group 
of 70-75 closely followed and given among 20 patients in OP 5% were affected and 
among 20 patients in IP 35% were affected. 
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3.DISTRIBUTION OF EDUCATIONAL  STATUS  
Table-3 illustrates the distribution of Educational and its percentage. 
TABLE-3 
DISTRIBUTION OF EDUCATIONAL STATUS 
Sl. 
No. 
Educational 
Status 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Illiterate  3 15% 6 30% 
2. Read & Write 2 10% 2 10% 
3. Primary 2 10% 3 15% 
4. Middle School 6 30% 2 10% 
5. High School 3 15% 4 20% 
6. College 4 20% 3 15% 
Total 20 100% 20 100% 
 
FIGURE-3 
 
 From the above table, it is observed that highest incidence of Iya Neerizhivu 
among 20 out patients was attended High School with 15% and among 20 in patients 
was attended College school with 20%. 
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4.DISTRIBUTION OF OCCUPATION 
Table-4 illustrates the occupation and its percentage. 
TABLE-4 
DISTRIBUTION OF OCCUPATION 
Sl. 
No. 
Occupation 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Business 1 5% 1 5% 
2. Agricultural Labours 1 5% 1 5% 
3. House wife 5 25% 1 5% 
4. Cook 3 15% 4 20% 
5. Painter 1 5% 1 5% 
6. Policeman/Army 1 5% - - 
7. Office worker 4 20% - - 
8. Coolie Worker 2 10% 11 55% 
9. Driver 1 5% 1 5 
10. Welding worker 1 5% - - 
Total 20 100% 20 100% 
 
FIGURE-4 
 
 
 
 
 
 
 
 
 
 
 
Population employed in various occupations have observed the highest 
incidence of IyaNeerizhivu. 25% OP patients were house wives 55% IP patients were 
Coolie Worker.  
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5.DISTRIBUTION OF RELIGION 
Table-5 illustrates the distribution of religion and its percentage. 
TABLE-5 
DISTRIBUTION OF RELIGION 
 
Sl. 
No. 
Religion 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Hindu 15 75% 12 60% 
2. Christian 4 20% 7 35% 
3. Muslim 1 5% 1 5% 
Total 20 100% 20 100% 
 
FIGURE-5 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that among 20 out patients 75% were Hindus, 
20% were Christians and 5% were Muslims, among 20 in patients 60% were Hindus 
and 5% were Muslims. 
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6.DISTRIBUTION OF MARITAL STATUS 
Table-6 illustrates the distribution of religion and its percentage. 
TABLE-6 
DISTRIBUTION OF MARITAL STATUS 
Sl. 
No. 
Marital Status 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Married 16 80% 17 85% 
2. Widowed 4 20% 3 15% 
3. Bachelor - - - - 
Total 20 100% 20 100% 
FIGURE-6 
 
 
 
 
 
 
 
 
 
 
 
 
The highest incidence among the OP and IP patients were married 80% and 
85%.  Widowed among both OP and IP were 20% and 15%.  
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7. DISTRIBUTION OF CLINICAL MANIFESTATION 
 Table-7 illustrates the clinical manifestation and its percentage.   
TABLE-7 
DISTRIBUTION OF CLINICAL MANIFESTATION 
Sl. 
No. 
Clinical Manifestation 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percenta
ge (%) 
No. of 
cases 
Percentage 
(%) 
1. Polyuria 15 75% 16 80% 
2. Polyphagia  12 60% 10 50% 
3. Polydipsia 15 75% 16 80% 
4. Nocturia 16 80% 14 70% 
5. Coughing  17 85% 16 80% 
6. Sputum 14 60% 15 75% 
7. Dyspnea 15 75% 13 65% 
8. Wheezing 10 50% 8 40% 
9. Expectoration of sputum   4 20% 3 15% 
10. ChestPain  3 15% 2 10% 
11. Tiredness of chest 10 50% 10 50% 
12. 
Peripheral diabetic 
neuropathy 
10 50% 5 25% 
13. Vascular claudication 2 10% 4 20% 
14 Ulcer/ Skin rashes 5 25% 2 10% 
 
From the above table, it is observed that among 20 out patients 75% of cases 
had polyuria and polydipsia and 50% had tiredness.  75%  dyspnea, 80% nocturia, 
60% had polyphagia, 50% had peripheral diabetic neuropathy, Coughing 85% had 
skin rashes, 25% had visual impairment, and 60% had Sputum .Among 20 In patients 
80% of cases had polyuria polydipsia and 50% had tiredness. 90% had pain, 70% 
nocturia, 50% had polyphagia, 25% had peripheral diabetic neuropathy, 65% had 
dyspnea, 15% had Expectoration of sputum visual impairment. 
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FIGURE-7 
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8. DISTRIBUTION OF MODE OF ONSET 
Table-8 illustrates the distribution of religion and its percentage. 
TABLE-8 
DISTRIBUTION OF MODE OF ONSET 
Sl. 
No. 
Mode of Onset 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Newly Detectable  - - - - 
2. Sub-Acute 7 35% 3 15% 
3. Chronic 13 65% 17 85% 
Total 20 100% 20 100% 
 
FIGURE-8 
 
 
 
 
 
 
 
 
 
 
 
 
The onset of Iya Neerizhivu ensues a chronic mode of onset with a 
relative percentage of 65%in OP and 85% in IP patients.  
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9. DISTRIBUTION OF DURATION OF ILLNESS 
 Table-9 illustrates the duration of illness and its percentage.   
TABLE-9 
DISTRIBUTION OF DURATION OF ILLNESS 
Sl. 
No. 
Duration of illness 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Newly Detectable - - - - 
2. Up to 6 months - - - - 
3. 6 months -2 Years - - - - 
4. 3 Years - 6 Years 16 80% 14 70% 
5. 7 Years - 10 Years 3 15% 5 25% 
6. 11 Years - 15 Years  1 5% 1 5% 
Total 20 100% 20 100% 
FIGURE-9 
 
 
 
 
 
 
 
 
 
 
 
 
Iya Neerizhivu greatly noticed in the 40 patients suffering with Iya Neerizhivu 
for about more than 3 years to 6 years. The percentage of 80% in OP and 70% in IP. 
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10. DISTRIBUTION OF FAMILY HISTORY 
 Table-10 illustrates the family history and its percentage.   
TABLE-10 
DISTRIBUTION OF FAMILY HISTORY 
Sl. 
No. 
Family History 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Paternal 5 25% 3 15% 
2. Maternal 5 25% 2 10% 
3.  Both 2 10% 4 20% 
4.  No family history 8 40% 11 55% 
Total 20 100% 20 100% 
 
  
 
 
 
 
 
 
 
 
 
 
 
The table links a family history with the incidence of Iya Neerizhivu with 
relative percentage among OP 30% had paternal history, 20% had maternal 
history, 15% had both and 35% had no family history.  Among IP 20% had 
paternal history, 15% had maternal history, 5% had both and 60% had no family 
history. 
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11. DISTRIBUTION OF HISTORY OF PREVIOUS TREATMENT OF 
NEERIZHIVU 
Table-11illustrates the previous treatment of Neerizhivu and its percentage. 
TABLE-11 
DISTRIBUTION OF PREVIOUS TREATMENT 
Sl. 
No. 
Previous 
Treatment 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Yes 20 100% 20 100% 
2. No - - - - 
Total 20 100% 20 100% 
 
FIGURE-11 
 
The table shows that 100% of OP and 100% of IP patients had a history of 
previous treatment for Neerizhivu.  
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12. DISTRIBUTION OF PERSONAL HISTORY 
Table-12 illustrates the personal history and its percentage.   
TABLE-12 
DISTRIBUTION OF PERSONAL HISTORY 
 
Sl. 
No. 
Personal History 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
DIET   
1. 
Vegetarian 4 20% 3 15% 
Non Veg - - - - 
Mixed Diet 16 80% 17 85% 
PERSONAL HABITS   
2. 
Smoking  10 50% 14 70% 
Tobacco chewing  1 5% 2 10% 
Betel Chewing 3 15% 2 10% 
Alcohol 4 20% 5 25% 
 
 
IyaNeerizhivu is reported greatly among 80% of OP and 85% of IP patients 
with habit of mixed diet.  
 
In Personal Habits 50% of OP and 70%of IP patients had smoking habit, 10% 
of IP patients had tobacco chewing, 15% of OP and 10% of IP patients had betel 
chewing   and 20% of OP and 25% of IP patients had alcohol consumption.   
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13. DISTRIBUTION OF SOCIO-ECONOMICAL STATUS 
 Table-13 illustrates the distribution of socio-economic status and its 
percentage. 
TABLE-13  
DISTRIBUTION OF SOCIO-ECONOMICAL STATUS 
Sl. 
No. 
Socio-Economical 
Status 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Upper High - - - - 
2. High 6 30% 1 5% 
3. Upper Middle 5 25% 4 20% 
4. Lower Middle 3 15% 5 25% 
5. Poor 5 25% 7 35% 
6. 
Very Poor or Below 
Poverty Line                               
1 5% 3 15% 
Total 20 100% 20 100% 
 
FIGURE-13  
Among the 40 patients of the study group there is a marked percentage of the 
disease of the population of lower middle socio economic status in relative 
percentages of 15% were in OP and 25% were in IP.  
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14. DISTRIBUTION OF OTHER SYSTEM INVOLVEMENT 
 Table-14 illustrates the duration of illness and its percentage.   
TABLE-14 
DISTRIBUTION OF OTHER SYSTEM INVOLVEMENT  
Sl. 
No. 
System Involvement 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Cardiovascular System 1 5% - - 
2. Gastro Intestinal System 1 5% - - 
3. 
Musculo Skeletal 
System 
2 10% 1 5% 
4. Central Nervous System 1 5% 2 10% 
5. Respiratory System 20 100% 20 100% 
6. Endocrine system 1 5% 1 5% 
 
FIGURE-14 
 
 
 
 
 
 
 
 
 
 
 
 
The table shows that the symptoms involving Respiratory System are greatly 
associated along with complaints of IyaNeerizhivu. 
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15. DISTRIBUTION OF BODY MASS INDEX 
Table-15 illustrates the BMI and its relative percentage. 
TABLE-15 
BODY MASS INDEX 
Sl. 
No. 
 
Body Mass Index 
(Kg/m2) 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Under weight (<18.5) - - - - 
2. Normal  (18.5-24.9) 3 15% 2 10% 
3. Over weight (25.0-29.9) 12 60% 12 60% 
4. Obesity (30.0-39.9) 5 25% 6 30% 
5. Morbid  obesity (>40.0) - - - - 
Total 20 100% 20 100% 
 
FIGURE-15 
 
The table shows that the body mass index among the 40 patients of the study 
group patients had normal BMI 15% in OP and 10% in IP. 60% in OP and 60% in IP 
patients had over weight (Class-I &II). 25% in OP and 30% in IP patients showed 
obesity in Iya Neerizhivu.  
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16. DISTRIBUTION OF CONSTITUTION OF BODY 
 Table-16 illustrates the constitution of the body and its percentage. 
TABLE-16 
DISTRIBUTION OF CONSTITUTION OF BODY 
Sl. 
No. Constitution of body 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Vatham 1 5% - - 
2. Vatha Pitham - - - - 
3. Vatha Kapham 2 10% 2 10% 
4. Pitham - - - - 
5. Pitha Vatham 1 5% 2 10% 
6. Pitha Kapham 3 15% 3 15% 
7. Kapham - - - - 
8. KaphaVatham 5 25% 6 30% 
9. Kapha Pitham 8 40% 7 35% 
Total 20 100% 20 100% 
 
FIGURE-16 
 
 
From the above table, it is observed that highest incidence of Iya Neerizhivu 
among 20 Out patients were Vatha PithaThegi with 25%, Pitha VathaThegi with 30%, 
Kapha Pitham with 25 % and Kapha Vatham 10%.  Among 20% In patients Pitha 
Vatha Thegi with 50%, Vatha Pitha Thegi with 30%, Kapha Pitham with 15 % and 
Kapha Vatham 10%. 
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17. DISTRIBUTION OF GUNAM 
 Table-17 illustrates the gunam and its percentage. 
TABLE-17 
DISTRIBUTION OF GUNAM 
Sl. 
No. 
Gunam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Sathuvam Gunam - - - - 
2. Rajo Gunam 20 100% 20 100% 
3. Thamasam Gunam - - - - 
Total 20 100% 20 100% 
 
FIGURE-17 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that highest incidence of Iya Neerizhivu 
among Out patients and In patients with cent percent belongs to Rajo Gunam. 
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18. DISTRIBUTION OF KAALAM 
 Table-18 illustrates the distribution of kaalam and its percentage. 
TABLE-18 
DISTRIBUTION OF KAALAM 
Sl. 
No. 
Kaalam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Vatham (1-33 Years) - - - - 
2. Pitham (34-66 Years) 19 95% 11 55% 
3. Kapham (67- 100 Years) 1 5% 9 45% 
Total 20 100% 20 100% 
 
FIGURE-18 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that the highest incidence of 
IyaNeerizhivu among 20 Out patients is in Pitha Kaalam with 95%, Kapha Kaalam 
with 5%. Among 20In patients, is also Pitha Kaalam with 55%, Kapha Kaalam with 
45%.  
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19. DISTRIBUTION OF PARUVA KAALAM 
 Table-19 illustrates the paruva kaalam and its percentage. 
TABLE-19 
DISTRIBUTION OF PARUVA KAALAM 
Sl. 
No. 
ParuvaKaalam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Elavenil Kaalam 4 20% 2 10% 
2. Muthuvenil Kaalam 6 30% 4 20% 
3. Kaar Kaalam 10 50% 3 15% 
4. Koothir Kaalam - - 1 5% 
5. Munpani Kaalam - - 7 35% 
6. Pinpani Kaalam - - 3 15% 
 Total 20 100% 20 100% 
 
FIGURE-19 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that highest incidence of Iya Neerizhivu 
among 20 Out patients high incidence of the disease is in Kaar Kaalam50% and 
among 20 In patient were in Munpani Kaalam 35%. 
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20. DISTRIBUTION OF THINAI 
 Table-20 illustrates the thinai and its percentage. 
TABLE-20 
DISTRIBUTION OF THINAI 
Sl. 
No. 
Thinai 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Kurinji 1 5% 1 5% 
2. Mullai - - - - 
3. Marutham 18 90% 19 95% 
4. Neithal 1 5% - - 
5. Paalai - - - - 
 Total 20 100% 20 100% 
 
 
 
 
 
 
 
 
 
 
 
 
F 
From the above table, it is observed that highest incidence of Iya 
Neerizhivu among 20 Out patients were in the Marutham land with 90% and 
among In Patients also in Marutham land with 95%. 
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21. DISTRIBUTION OF MUKKUTRAM 
 (a). DERANGEMENT OF VATHAM 
 Table-21(a) illustrates the Derangement of Vatham and its percentage.   
TABLE-21 (a) 
DERANGEMENT OF VATHAM 
Sl. 
No. 
Derangement of 
Vatham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Piraanan 20 100% 20 100% 
2. Abaanan 6 30% 6 30% 
3. Viyaanan 20 100% 20 100% 
4. Uthaanan 20 100% 20 100% 
5. Samaanan 20 100% 20 100% 
6. Naagan - - - - 
7. Koorman 2 10% 4 20% 
8. Kirukaran 20 100% 20 100% 
9. Devathathan 20 100% 20 100% 
10. Dhananjayan - - - - 
 
  
From the above table, it is observed that among 20 out patients 100% were 
affected in Piraanan, Viyaanan, Uthaanan, Samaanan, Kirukaran and Devathathan.  
Among 20 in patients 100% were affected in Piraanan, Viyaanan, Uthaanan, 
Samaanan, Kirukaran and Devathathan. 
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FIGURE-21 (a) 
CONDITION OF VATHAM 
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21 (b) DERANGEMENT OF PITHAM 
 Table-21 (b) illustrates thederangement of pitham and its percentage.   
TABLE-21 (b) 
DERANGEMENT OF PITHAM 
Sl. 
No. 
Derangement of 
Pitham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Analagam 20 100% 20 100% 
2. Ranjagam 20 100% 20 100% 
3. Sathagam 20 100% 20 100% 
4. Prasagam 6 30% 7 35% 
5. Aalosagam 1 5% 5 25% 
 
FIGURE-21 (b) 
CONDITION OF PITHAM 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that among 20 out patients 100% were affected in 
Analagam, Ranjagam and Sathagam; 30% were affected in Prasagam; 5% were affected in 
Aalosagam Among 20 In patients 100% were affected in Analagam, Ranjagam and Sathagam 
35% were affected in Prasagam 25% were affected in Aalosagam. 
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21 (c) DERANGEMENT OF KAPHAM 
 Table-21 (c) illustrates the kapham and its percentage.   
TABLE-21 (c) 
DERANGEMENT OF KAPHAM 
Sl. 
No. 
Derangement of 
Kapham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Avalambagam 20 100% 20 100% 
2. Kilethagam 20 100% 20 100% 
3. Pothagam - - - - 
4. Tharpagam - - - - 
5. Santhigam 13 65% 15 75% 
 
FIGURE-21 (c) 
CONDITION OF KAPHAM 
 
From the above table, it is observed that among 20 out patients 100% were affected in 
Avalambagam and Kilethagam; 65% were affected in Santhigam. Among 20 in patients100% 
were affected in Avalambagam and Kilethagam 75% were affected in Santhigam. 
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22. DISTRIBUTION OF INVOLVEMENT OF UDAL THATHUKKAL 
 Table-22 illustrates the involvement of udalthathukkal and its percentage.   
TABLE-22 
INVOLVEMENT OF UDAL THATHUKKAL 
Sl. 
No. 
Involvement of 
UdalThathukkal 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Saaram 20 100% 20 100% 
2. Senneer 20 100% 20 100% 
3. Oon 13 65% 15 75% 
4. Kozhuppu 16 80% 17 85% 
5. Enbu 13 75% 15 75% 
6. Moolai - - - - 
7. Sukkilam / Suronitham 1 5% - - 
 
FIGURE-22 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that among 20 out patients 100% were affected in 
Saaram and Senneer, 80% were affected in Kozhuppu and 65% were affected in Enbu.  
Among 20 in patients 100% were affected in Saaram and Senneer, 85% were affected in 
Kozhuppu and 75% were affected in Enbu.  
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23. DISTRIBUTION OF KANMENTHIRIYAM 
 Table-23 illustrates the kanmenthiriyam and its percentage.  
TABLE-23 
DISTRIBUTION OF KANMENTHIRIYAM 
Sl. 
No. 
Kanmenthiriyam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Kai 2 10% 1 5% 
2. Kaal 13 65% 15 75% 
3. Vai 1 5% 2 10% 
4. Eruvai 5 25% 4 20% 
5. Karuvai - - - - 
 
FIGURE-23 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that among 20 Out patients, 65% were affected in 
Kaal and 25% inEruvai.  Among 20 in patients 75% were affected in Kaal and 20% in 
Eruvai. 
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24. DISTRIBUTION OF IMPORIGAL(GNANENDRIUM)  
 Table-24 illustrates the gnanenthirium and its percentage.   
TABLE-24 
DISTRIBUTION OF IMPORIGAL (GNANENTHIRIUM) 
 
Sl. 
No. 
Gnanenthirium 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Mei 10 50% 5 25% 
2. Vaai 1 5% 1 5% 
3. Kan 2 10% 4 20% 
4. Mooku 12 60% 10 50% 
5. Sevi - - 1 5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that among 20 out patients and 20 in patients 50% 
and 25% were affected in Mei.  Among 20 out patients 10% and 20 in patients 20% were 
affected in Kan. 
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25. DISTRIBUTION OF KOSAM 
 Table-25 illustrates the kosam and its percentage.   
TABLE-25 
DISTRIBUTION OF KOSAM 
Sl. 
No. Kosam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Annamya Kosam 20 100% 20 100% 
2. Pranamaya Kosam 20 100% 20 100% 
3. Manomaya Kosam 4 20% 6 30% 
4. Vinganamaya Kosam 3 15% 4 20% 
5. Anandamaya Kosam 1 5% - - 
 
FIGURE-25 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that among 20 Out patients 100% were affected 
in Annamaya Kosam, 40% were affected in Manomaya Kosam and 30% affected in 
Vinganamaya kosam.  Among 20 in patients, 100% were affected in Annamaya Kosam, 35% 
were affected in Manomaya Kosam and 30% were affected in Vinganamaya Kosam 
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26. DISTRIBUTION OF CONDITIONS OF ENVAGAI THERVUGAL 
 Table-26 illustrates the envagaithervugal and its percentage.   
TABLE-26 
DISTRIBUTION OF CONDITIONS OF ENVAGAI THERVUGAL 
 
Sl. 
No. 
Conditions of 
EnvagaiThervugal 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. 
Naadi (Thontha Naadi) 
1). Vatha Pitham 1 5% - - 
2). Vatha Kapham 2 10% 2 10% 
3). Pitha Vatham 1 5% 2 10% 
4). Pitha Kapham 3 15% 3 15% 
5). Kapha Vatham 5 25% 6 30% 
6). Kapha Pitham 8 40% 7 35% 
2. Sparisam 10 50% 5 25% 
3. Naa 12 60% 15 75% 
4. Niram 6 30% 7 35% 
5. Mozhi - - 2 10% 
6. Vizhi 2 10% 4 20% 
7. Malam 6 30% 6 30% 
8. Moothiram 15 75% 14 70% 
 
From the above table it is observed that among 20 out patients 40% had Kapha Pitha Naadi, 
25% had Kapha Vatha Naadi, 10% had Vatha Kapha Naadi and 15% had Pitha Kapha Vatha 
Naadi; 100% were affected in Naa and Moothiram; 50% were affected in Sparisam; 30% 
were affected in Niram and Malam; 10% were affected in Vizhi. Among 20 In patients 50% 
had Pitha Vatha Naadi, 20% had Vatha Pitha Naadi and 30% had Kapha Vatha Naadi; 100% 
were affected in Naa and Moothiram; 25% were affected in Sparisam; 35% were affected in 
Niram; 30% were affected in Malam; 20% were affected in Vizhi.   
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27. DISTRIBUTION OF NEER KURI 
 Table-27 illustrates the neerkuri and its percentage.   
TABLE-27 
DISTRIBUTION OF NEER KURI 
Sl. 
No. 
NeerKuri 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Niram (crystal clear)  11 55% 9 45% 
2. Manam (honey odour) 6 30% 4 20% 
3. Edai - - - - 
4. Nurai (present) 7 35% 5 25% 
5. Enjal - - - - 
 
FIGURE-27 
 
From the above table, it is observed in Neerkuri that, among 20 Out patients 
55% were affected in Niram; 30% were affected in manam; 35% were affected in 
Nurai.Among 20 In patients 45% were affected in Niram; 20% were affected in 
Manam and Nurai. 
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28. DISTRIBUTION OF NEI KURI 
 Table-28 illustrates the neikuri and its percentage.   
TABLE-28 
DISTRIBUTION OF NEI KURI 
Sl. 
No. 
NeiKuri 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Vatha Neer / Spreading 
like snake 2 10% 3 15% 
2. Pitha Neer / Spreading 
like ring 7 35% 6 30% 
3. Kapha Neer / Spreading 
like pearl 8 40% 9 45% 
4. Thontha Neer / 
AsathiyaNeiKurigal 3 15% 2 10% 
Total 20 100% 20 100% 
FIGURE-28 
 
 
Among 20 OP patients showed 15% of Thontha Neer; 40% of Kapha Neer; 35% 
of Pitha Neer; 10% of Vatha Neer. Among 20 IP patients showed 10% of Thontha 
Neer; 45% of Kapha Neer; 30% of Pitha Neer; 15% of Vatha Neer features in Neikuri 
observation in Iya Neerizhivu.  
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SOME SHAPES FOUND ON NEIKURI EXAMINATION OF  
IYA NEERIZHIVU AMONG OP & IP PATIENTS 
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29. DISTRIBUTION OF LABORATORY ANALYSIS  
 Table-29 (a) illustrates the reference of HbA1C and its percentage.  
TABLE-29 
HbA1C 
Sl. 
No. 
HbA1C 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Good Control (4-6%) - - - - 
2. Moderate Control (7-8%) 7 35% 6 30% 
3. Poor Control (>8) 13 65% 14 70% 
Total 20 100% 20 100% 
 
FIGURE-29 
 
The table shows among 20 out patients 65% had poor control and 35% had 
fair control, among 20 In patients 70% had poor control and 30% had moderate 
control of HbA1C in recruitment of study. 
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30. DISTRIBUTION OF SUB TYPES OF NEERIZHIVU 
Table-30 illustrates the distribution of subtype of Neerizhivu and its percentage. 
TABLE-30 
DISTRIBUTION OF SUB TYPES OF NEERIZHIVU 
Sl. 
No. 
Sub Types of 
Madhumegam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Vatha Neer 1 5% 1 5% 
2. Pitha Neer 5 25% 4 20% 
3. Kapha Neer 14 70% 15 75% 
Total 20 100% 20 100% 
 
FIGURE-30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The table shows that high prevalence of the 40 patients recruited in the study 
different sub types of Neerizhivu diagnosed by signs and symptoms, Nadi& Urine, 
examination in cases of Iya Neerizhivu. 70% of OP and 75% of IP were Kapha type 
of Neerizhivu. 25% of OP and 20% of IP were Pitha type of Neerizhivu. 
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31. GRADATION OF RESPONSE 
Table-32illustrates the Gradation of Results and its percentage 
TABLE-31 
GRADATION OF RESPONSE 
Sl. 
No. 
Gradation of 
Response 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Good response  12 60% 11 55% 
2. Moderate response 6 30% 8 40% 
3. Poor response 2 10% 1 5% 
Total 20 100% 20 100% 
FIGURE-31 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among the 40 patients included in the study 85% of Outpatients and 55% of in 
patients had good results. 15% of out patients and 40% of in patients had moderate 
response and 5% in patients showed poor response 
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OUT-PATIENT CASE SHEET: 20 PATIENTS TREATED IN OP FOR IYA NEERIZHIVU 
Sl. 
No. OP No. Name 
Age / 
Sex Occupation 
Duration of 
Illness 
Date of 
Onset of 
Treatment 
Date of 
Treminatio
n of 
Treatment 
Total 
Days Results 
1. 32101 Shangar 65/M Cook 8 Years 06.04.2017 16.08.2017 95 Moderate 
2. 37549 Muththu 63/M Retd. Postmaster  5 Years 26.04.2017 21.08.2017 91 Good 
3. 40810 Ramapandiyan  65/M Land broker  4 Years 08.05,2017 30.08.2017 91 Good  
4. 40847 Balasunthari 55/F Nurse  5 Years 08.05.2017 14.09.2017 92 Good 
5. 52651 Kanthavel 48/M Driver 3 Years 19.06.2017 30.10.2017 98 Poor 
6. 58024 Perumal 73/M Retd. Police 10 Years 07.07.2017 17.11.2017 96 Moderate 
7. 59223 Ganthimathy 61/F Housewife 4 Years 11.07.2017 16.12.2017 90 Good 
8. 59746 Suriyakala 48/F Cook 3 Years 13.07.2017 02.12.2017 94 Moderate  
9. 61703 Suppammal 61/F Beedi maker  7 Years 19.07.2017 16.11.2017 99 Poor 
10. 63884 Thagira 40/F Housewife  3 Years 26.07.2017 16.11.2017 90 Good 
11. 66783 Muththulaxmi 48/F Housewife 2 Years 05.08.2017 02.12.2017 91 Good 
12. 71009 Rajinidevi 56/F Tailar  3 Years 19.08.2017 09.11.2017 92 Good 
13. 71838 Pazanisamy  64/M Cooley 5 Years    22.08.2017 06.12.2017 96 Moderate  
14. 71949 Peshimuththu 60/M Welding worker           6 Years   22.08.2018 06.12.2017 97 Moderate  
15. 74507 Mani 61/F Painter  7 Years 30.08.2017 19.12.2017 98 Moderate  
16. 75203 Vasantha 55/F Housewife  5 Years 01.09.2017 20.12.2017 90 Good 
17.  76426 Seenivashan 51/M Clark           3 Years 05.09.2017 28.12.2017 91 Good 
18. 76581 Manommani 60/F Cook           4 Years 06.09.2017 13.12.2017 92 Good 
19. 82948 Chanthanakumar 52/M Clark           4 Years 25.09.2017 16.12.2017 83 Good 
20. 85387 Sangarammal  56/F Housewife 3 Years 26.09.2017 18.12.2017 84 Good 
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IN-PATIENT CASE SHEET: 20 PATIENTS TREATED IN IP FOR IYA NEERIZHIVU  
Sl. 
No. 
IP 
No. 
Name 
Age / 
Sex 
Occupation 
Duration of 
Illness 
Date of 
Admission 
Date of 
Discharge 
No. of Days Total 
Days 
Results 
IP OP 
1. 1135 Rajam 60/F Cooley 5 years 18/04/2017 02/06/2017 55 35 90 Good 
2. 1737 Sangaran 70/M Cooley 4 years  14/06/2017 04/07/2017 20 72 92 Moderate 
3. 1779 Thangaraj 65/M Cook  5 years  17/06/2017 21/07/2017 35 64 99 Poor 
4. 1871 Pisshumani  59/M Cooley  4 years 28/06/2017 17/07/2017 19 71 90 Good 
5. 1957 Thaivakambar 71/M Tailar 7 years 05/07/2017 14/07/2017 10 85 95 Moderate 
6. 2234 Shangar 70/M Milk man  6 years  09/08/2017 29/08/2017 20 72 92 Good 
7. 2441 Thurairaj  65/M Cook  7 years  30/08/2017 20/09/2017 21 70 91 Moderate  
8. 2612 Akpar 70/M Busness  5 years 22/09/2017 31/10/2017 38 52 90 Good 
9. 2959 Suppiramaniyan 69/M Cooley 10 years 02/11/2017 25/11/2017 23 72 95 Moderate  
10. 3167 Eswaran 65/M Painter 5 years  03/12/2017 26/12/2017 23 71 94 Moderate  
11. 3174 Thangasamy  60/M Cooley  6 years  04/12/2017 24/12/2017 20 72 92 Good 
 12. 106 Thiruneelakandar   70/M                Cooley 5 years   19/01/2018 05/02/2018 17 73 90 Moderate 
13. 115 Rajakopal 70/M Cooley  6 years 19/01/2018 26/01/2018 37 53 90 Good 
14. 112 Vellammal 66/F Housewife 3 years  19/01/2018 04/02/2018 15 76 91 Moderate 
15. 122 Serthu  67/M Milk man  4 years  20/01/2018 05/02/2018 15 78 93 Good 
16. 130 Muththaiya 70/M Carepentar  10 years  21/01/2018 05/02/2018 14 76 90 Good 
17. 271 Ranjitham 47/F Cooley 3 years 02/02/2018 16/03/2018 42 50 92 Good 
18. 308 Vellaiyammal 63/F Housewife 5 years 06/02/2018 23/02/2018 17 75 92 Good 
19. 426 Saraswathy 60/F Housewife  3 years  17/02/2018 20/03/2013 33 60 93 Good 
20. 1157 Rathasubbulaxmi 54/F Beedi maker 6 years 28/04/2018 15/05/2018 17 53 70 Moderate 
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INVESTIGATION CHART FOR OUT-PATIENT: BLOOD INVESTIGATIONS & MMRC DYSPNEA SCALE SCORE 
Sl. 
No
. 
OP No. 
BEFORE TREATMENT MMRC  
Dyspnea 
Scale 
Score 
AFTER TREATMENT MMRC  
Dyspnea 
Scale 
Score 
Hb TC 
DC 
Hb TC 
DC 
P L E P L E 
1. 32101 13 9300 62 33 05 4 13.1 9000 64 32 04 3 
2. 37549 12.6 9000 64 34 02 2 12.4 8300 64 34 02 0 
3. 40810 12 8000 62 36 02 3 12.5 8100 63 35 02 1 
4. 40847 11.5 6400 60 36 03 4 13 7300 61 26 03 1 
5. 52651 12.9 6400 64 32 04 4 13 7200 65 32 03 3 
6. 58024 15.2 10100 70 25 05 3 11.8 8000 65 33 02 2 
7. 59223 11.3 8000 50 47 03 3 10.3 8600 68 28 04 1 
8. 59746 12.8 7600 65 31 04 3 12.9 7700 66 33 01 2 
9. 61703 12.8 8000 65 29 06 2 12 8000 64 30 06 2 
10. 63884 10.0 6500 54 40 06 3 10.1 6800 63 36 03 0 
11. 66783 9.3 6800 67 29 04 2 10 7100 63 35 02 0 
12. 71009 11 8700 51 40 09 3 12 8000 65 31 04 1 
13. 71838 10.5 5500 50 45 05 3 11.6 7200 66 32 02 2 
14. 71949 9.6 8100 55 40 05 3 10 8300 68 30 02 2 
15. 74507 9.5 9800 59 30 11 4 9.7 9600 62 33 05 3 
16. 75203 11 7500 57 40 03 2 10.8 8000 59 37 04 0 
17. 76426 12.5 7000 62 34 04 3 13 7000 63 33 04 1 
18. 76581 12 8800 68 29 05 2 12.3 8500 66 30 04 0 
19. 82948 12 9800 62 30 08 3 11.8 8900 64 31 05 1 
20. 85387 11.2 8000 55 40 05 2 11.5 8400 65 28 07 1 
Hb-Hameoglobin, TC- Total White Cell Count, DC- Differential Count White Cell Count, P-Polymorph, L-Lymphocyte, E-Eusinophil 
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INVESTIGATION CHART FOR IN-PATIENT: BLOOD INVESTIGATIONS & MMRC DYSPNEA SCALE SCORE 
Sl. 
No. IP No. 
BEFORE TREATMENT MMRC 
Dyspnea 
Scale 
Score 
AFTER TREATMENT MMRC 
Dyspnea 
Scale 
Score 
Hb TC 
DC 
Hb TC 
DC 
P L E P L E 
1. 1135 10.8 8000 66 28 06 3 11.1 6500 60 34 06 1 
2. 1737 14.7 7000 55 40 04 3 14 7200 60 38 02 2 
3. 1779 10.3 6800 58 38 04 3 10.6 7000 60 38 02 3 
4. 1871 13.9 9600 55.3 31.6 03 2 11.7 7000 62 38 00 0 
5. 1957 10.1 8000 58 36 06 3 10.5 7800 60 37 03 1 
6. 2234 10.5 8800 64 34 06 2 9.9 7800 64 32 04 0 
7. 2441 14.7 7000 55 40 04 4 14.0 7200 60 38 02 3 
8. 2612 11 9100 54 44 04 2 12.0 9500 60 33 07 1 
9. 2959 12 8600 60 24 16 4 12.4 8100 60 36 04 3 
10. 3167 11.5 8100 60 35 05 2 12.2 8100 60 38 02 0 
11. 3174 10.9 8200 60 35 05 3 10 8000 62 36 02 1 
12. 106 10.8 9200 69 16 15 4 11.6 7500 70 20 10 3 
13. 115 12.1 9800 70 26 04 3 12.0 8900 68 28 04 1 
14. 112 11 9100 54 44 02 4 12.0 9500 60 33 07 3 
15. 122 10.4 9900 80 15 05 2 12.5 9000 70 26 04 1 
16. 130 11.1 6000 62 34 04 3 12 7000 60 34 06 1 
17. 271 12 8000 62 36 02 3 12.5 8000 62 36 02 1 
18. 308 12.8 6500 61 35 04 3 13.8 6500 60 36 04 0 
19. 426 12 8600 60 24 16 3 12.4 8100 60 36 04 1 
20. 1157 15 9000 58 38 04 3 13.2 7200 65 33 02 2 
Hb-Hameoglobin, TC- Total White Cell Count, DC- Differential Count White Cell Count, P-Polymorph, L-Lymphocyte, E-Eusinophil 
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INVESTIGATION CHART FOR OUT-PATIENT: PATIENTS BLOOD SUGAR & URINE SUGAR 
Sl. 
No. OP No. 
BLOOD TEST URINE TEST 
BEFORE 
TREATMENT AFTER TREATMENT BEFORE TREATMENT AFTER TREATMENT 
FBS PPBS S.U FBS PPBS S.U ALB SUGAR DEPOSITS ALB SUGAR DEPOSITS 
1. 32101 180 255 35 150 225 31 Nil +++ NAD Nil ++ NAD 
2. 37549 165 242 33 110 153 30 Nil ++ NAD Nil + NAD 
3. 40810 145 220 26 100 143 26 Nil Nil NAD Nil Nil NAD 
4. 40847 160 235 19 121 202 20 Nil + NAD Nil Nil NAD 
5. 52651 291 315 30 280 300 29 Nil +++ NAD Nil +++ NAD 
6. 58024 150 225 25 140 223 25 Nil Nil NAD Nil Nil NAD 
7. 59223 170 248 23 105 148 23 Nil Nil NAD Nil Nil NAD 
8. 59746 240 290 28 200 270 27 Nil ++ Pus cells ++ Nil ++ NAD 
9. 61703 260 308 28 240 290 28 Nil ++ Pus cells ++ Nil Nil NAD 
10. 63884 185 260 33 152 165 30 Nil ++ NAD Nil Nil NAD 
11 66783 168 243 28 120 201 27 Nil ++ Pus cells ++ Nil Nil NAD 
12. 71009 148 225 22 110 138 21 Nil Nil NAD Nil Nil NAD 
13. 71838 160 235 33 150 215 31 Nil Nill Pus cells +++ Nil Nill Pus cells + 
14. 71949 162 238 34 132 208 32 Nil Nill Pus cells +++ Nil Nil Pus cells +  
15. 74507 189 268 21 140 220 20 Nil +++ NAD Nil ++ NAD 
16. 75203 160 235 29 112 143 28 Nil ++ NAD Nil + NAD 
17. 76426 172 253 30 124 151 29 Nil + NAD Nil Nil NAD 
18. 76581 136 220 29 110 134 28 Nil Nill NAD Nil Nil NAD 
19. 82948 160 240 31 115 145 30 Nil Nil NAD Nil Nil NAD 
20. 85387 143 223 30 98 139 29 Nil Nil NAD Nil Nil NAD 
FBS-Fasting Blood Sugar, PPBS-Post Parandial Blood Sugar, S.U-Serum Urea, ALB-Albumin 
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INVESTIGATION CHART FOR IN-PATIENT: PATIENTS BLOOD SUGAR & URINE SUGAR 
Sl. 
No. IP No. 
BLOOD TEST URINE TEST 
BEFORE 
TREATMENT AFTER TREATMENT BEFORE TREATMENT AFTER TREATMENT 
FBS PPBS S.U FBS PPBS S.U ALB SUGAR DEPOSITS ALB SUGAR DEPOSITS 
1. 1135 165 238 26 115 148 26 Nil + Pus cells ++ Nil Nil Nil 
2. 1737 152 226 25 142 221 25 Nil Nil Nil Nil Nil Nil 
3. 1779 227 301 35 180 165 34 Nil +++ Nil Nil Nil Nil 
4. 1871 136 214 28 95 135 27 Nil Nil Nil Nil Nil Nil 
5. 1957 175 250 27 150 224 26 Nil + Pus cells ++ Nil Nil Nil 
6. 2234 160 235 26 122 203 25 Nil + Nil Nil + Nil 
7. 2441 178 252 30 135 205 29 Nil + Nil Nil Nil Nil 
8. 2612 162 242 34 117 147 33 Nil ++ Pus cells ++ Nil ++ Nil 
9. 2959 159 236 24 149 224 23 Nil + Nil Nil Nil Nil 
10. 3167 175 254 22 145 220 21 Nil ++ Pus cells ++ Nil + Pus cells ++ 
11. 3174 167 242 30 121 203 29 Nil ++ Pus cells ++ Nil + Nil 
 12. 106 160 235 23 152 227 23 Nil + Nil Nil Nil Nil 
13. 115 159 232 26 121 202 26 Nil + Pus cells ++ Nil + Pus cells ++ 
14. 112 225 298 28 176 256 28 Nil ++ Pus cells ++ Nil Nil Nil 
15. 122 175 254 28 125 152 27 Nil + Nil Nil Nil Nil 
16. 130 145 224 27 110 139 27 + + 5-7 pus cells Nil Nil Nil 
17. 271 136 210 22 85 123 21 Nil Nil Nil Nil Nil Nil 
18. 308 140 220 28 110 139 28 Nil + Nil Nil Nil Nil 
19. 426 155 230 26 120 148 25 Nil + Pus cells ++ Nil Nil Nil 
20. 1157 170 245 27 143 224 27 Nil + Nil Nil + Nil 
 
FBS-Fasting Blood Sugar, PPBS-Post Parandial Blood Sugar, S.U-Serum Urea, ALB-Albumin 
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INVESTIGATION CHART FOR OUT-PATIENT: PATIENTS HbA1C & LIPID PROFILE  
Sl. 
No. OP No. 
BEFORE TREATMENT AFTER TREATMENT 
HbA1C 
LIPID PROFILE 
HbA1C LIPID PROFILE  
TC HDL LDL VLDL TGL TC HDL LDL VLDL TGL 
1. 32101 7.9 240 58 158 46 232 6.9 223 36 140 47 236 
2. 37549 7.4 234 34 148 49 246 6.4 187 46 140 50 260 
3. 40810 6.7 191 37 130 23 118 6.1 180 32 135 20 80 
4. 40847 7.3 175 48 103 24 170 5.9 181 52 96 26 120 
5. 52651 11.9 213 30 68 95 475 11.3 223 57 91 80 398 
6. 58024 6.9 119 53 37 29 143 6.5 155 67 50 21 105 
7. 59223 7.6 208 42 130 36 180 6.4 192 51 95 46 228 
8. 59746 10 236 60 144 32 161 8.7 211 65 121 25 127 
9. 61703 10.6 206 31 186 12 190 10 185 31 136 12 60 
10. 63884 8.1 239 67 138 34 168 6.2 213 66 120 25 140 
11. 66783 7.5 247 57 170 20 98 6.3 210 50 180 18 88 
12. 71009 6.8 270 52 196 22 110 5.9 240 42 152 20 121 
13. 71838 7.3 168 51 96 21 105 6.9 170 53 92 25 120 
14. 71949 7.3 173 48 103 24 170 6.4 181 52 96 26 120 
15. 74507 8.2 176 58 194 35 167 6.8 189 59 102 33 173 
16. 75203 6.8 265 38 198 25 172 5.5 240 35 135 24 151 
17. 76426 6.7 226 39 136 52 260 5.9 210 68 120 22 110 
18. 76581 6.4 186 60 107 21 105 5 200 61 93 28 98 
19. 82948 7.2 251 39 174 39 198 5.6 205 67 109 21 105 
20. 85387 6.6 196 39 127 23 118 5 192 50 122 20 102 
 
TC-Total Cholesterol, HDL-High Density Lipoprotein, LDL-Low Density Lipoprotein, TGL-Triglyceride 
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INVESTIGATION CHART FOR IN-PATIENT: LIPID PROFILE  
Sl. 
No. IP No. 
BEFORE TREATMENT AFTER TREATMENT 
HbA1C LIPID PROFILE HbA1C LIPID PROFILE  TC HDL LDL VLDL TGL TC HDL LDL VLDL TGL 
1. 1135 7.4 244 34 161 49 246 6.2 167 66 46 55 273 
2. 1737 7 196 39 127 23 118 6.6 192 50 122 20 102 
3. 1779 9.6 201 53 126 22 112 8.2 210 58 102 25 138 
4. 1871 6.5 278 38 119 21 105 5 192 46 102 28 120 
5. 1957 7.7 255 72 150 33 151 6.9 240 80 130 30 148 
6. 2234 7.3 230 54 152 24 178 6.2 230 54 132 34 118 
7. 2441 7.8 190 39 117 23 392 6.3 192 50 122 20 102 
8. 2612 6.8 182 48 98 30 176 5.6 175 58 93 25 113 
9. 2959 7.2 226 30 117 78 392 6.8 154 40 84 30 115 
10. 3167 7.7 240 58 236 46 232 6.6 223 36 140 47 236 
11. 3174 6.9 227 39 136 52 260 5.8 215 46 146 23 75 
12. 106 7.3 191 37 129 24 118 7 180 30 137 13 67 
13. 115 6.8 175 48 103 24 170 5.8 181 52 96 26 120 
14. 112 9.5 270 50 150 20 180 8.2 208 48 106 17 186 
15. 122 7.2 275 35 123 17 87.1 6.2 163 72 66 25 127 
16. 130 6.7 230 54 152 24 178 5 168 46 88 34 171 
17. 271 6.5 227 61 142 23 118 4.7 200 44 128 27 157 
18. 308 6.5 205 57 119 29 145 5 201 54 97 17 98 
19. 426 7.1 218 41 118 58 293 5.7 181 50 150 31 186 
20. 1157 7.6 181 50 150 31 186 6.6 154 40 84 30 150 
TC-Total Cholesterol, HDL-High Density Lipoprotein, LDL-Low Density Lipoprotein, TGL-Triglyceride 
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BMI CHART FOR OUT-PATIENTS (OP) 
Sl. 
No. 
OP 
No. 
Name 
Age 
/ Sex 
BMI 
Before 
Treatment 
After Treatment 
WT HT BMI WT HT BMI 
1. 32101 Shangar 65/M 80 165 29.4 76 165 27.9 
2. 37549 Muththu 63/M 54 153 23.1 48 153 20.5 
3. 40810 Ramapandiyan  65/M 72 151 31.5 65 151 28.5 
4. 40847 Balasunthari 55/F 83 161 32 76 161 29.3 
5. 52651 Kanthavel 48/M 86 171 29.4 84 171 28.7 
6. 58024 Perumal 73/M 70 165 25.7 68 165 24.9 
7. 59223 Ganthimathy 61/F 84 165 30.9 76 165 27.9 
8. 59746 Suriyakala 48/F 66 154 27.8 60 154 25.3 
9. 61703 Suppammal 61/F 86 160 33.6 85 160 33.2 
10. 63884 Thagira 40/F 65 149 29.3 58 149 26.1 
11. 66783 Muththulaxmi 48/F 65 165 23.9 53 165 19.5 
12. 71009 Rajinidevi 56/F 60 147 27.8 54 147 24.9 
13. 71838 Pazanisamy  64/M 72 164 26.8 70 164 26.0 
14. 71949 Peshimuththu 60/M 85 179 26.5 82 179 25.6 
15. 74507 Mani 61/F 54 152 23.4 54 152 23.4 
16. 75203 Vasantha 55/F 58 152 25.1 52 152 22.5 
17. 76426 Seenivashan 51/M 72 162 27.4 63 162 24.0 
18. 76581 Manommani 60/F 58 152 25.1 54 152 23.4 
19. 82948 Chanthanakumar 52/M 74 160 28.9 66 160 25.8 
20. 85387 Sangarammal  56/F 79 149 35.6 74 149 33.3 
                                           WT-Weight, HT-Height, BMI-Body Mass Index 
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BMI CHART FOR IN-PATIENTS (IP) 
Sl. 
No. 
OP 
No. 
Name 
Age / 
Sex 
BMI 
Before Treatment After Treatment 
WT HT BMI WT HT BMI 
1. 1135 Rajam 60/F 79 149 35.6 72 149 32.4 
2. 1737 Sangaran 70/M 80 162 30.4 75 162 28.5 
3. 1779 Thangaraj 65/M 65 165 23.9 64 165 23.5 
4. 1871 Pisshumani  59/M 65 153 27.7 59 153 25.2 
5. 1957 Thaivakambar 71/M 50 150 22.2 49 150 21.8 
6. 2234 Shangar 70/M 80 165 29.0 72 165 26.4 
7. 2441 Thurairaj  65/M 80 165 29.4 75 165 27.5 
8. 2612 Akpar 70/M 78 168 27.6 70 168 24.8 
9. 2959 Suppiramaniyan 69/M 73 158 29.2 68 151 27.2 
10. 3167 Eswaran 65/M 65 154 27.4 62 154 26.1 
11. 3174 Thangasamy  60/M 88 172 29.7 80 172 27.0 
12. 106 Thiruneelakandar   70/M 80 168 28.3 78 168 26.9 
13. 115 Rajakopal 70/M 64 154 26.9 56 154 23.6 
14. 112 Vellammal 66/F 77 150 34.2 76 150 33.7 
15. 122 Serthu  67/M 72 151 31.5 66 151 28.0 
16. 130 Muththaiya 70/M 65 154 27.4 60 154 25.2 
17. 271 Ranjitham 47/F 68 154 28.7 60 154 25.3 
18. 308 Vellaiyammal 63/F 76 158 30.4 68 158 27.2 
19. 426 Saraswathy 60/F 85 160 33.2 75 160 28.0 
20. 1157 Rathasubbulaxmi 54/F 65 154 27.4 61 154 25.7 
                                               
WT-Weight, HT-Height, BMI-Body Mass Index 
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PULMONERY FUNCTION TEST FOR OUT-PATIENTS (OP) & IN-PATIENTS (IP) 
S.No Patients Name Before Treatment After Treatment Parameters Pred M.PRE % Pred  PFT Report Parameters Pred M.PRE % Pred  PFT Report 
1. 
Mr.Perumal 73/M 
Wt:70 
Ht:165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.74 
1.94 
70.80 
2.36 
7.34 
1.53 
1.33 
86.93 
1.31 
4.94 
56 
69 
123 
56 
67 
Early Small 
Airway 
Obstruction 
Moderate 
Restriction 
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.55 
2.00 
78.43 
2.36 
6.63 
2.76 
2.24 
81.16 
2.31 
3.48 
108 
112 
103 
86 
52 
Early Small 
Airway 
Obstruction 
Spirometry 
within Normal 
Limits 
2. 
Mrs.Rajinidev 
56/F 
Wt: 60 
Ht: 147 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
1.87 
1.42 
75.94 
1.79 
5.00 
1.57 
1.00 
63.69 
00.79 
1.16 
84 
70 
84 
44 
23 
Early Small 
Airway 
Obstruction 
Moderate 
Obstruction  
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.35 
1.77 
75.32 
2.81 
7.01 
1.73 
1.73 
100 
4.12 
4.85 
74 
98 
133 
147 
69 
Early Small 
Airway 
Obstruction 
Mild Restriction 
Test within 
Normal Limits 
3 
Mrs.Ganthimathy 
61/F 
Wt:84 
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.50 
1.86 
74.40 
2.06 
5.83 
1.14 
1.14 
100.00 
01.24 
1.56 
46 
61 
134 
60 
27 
Early Small 
Airway 
Obstruction 
Moderate 
Obstruction  
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.69 
1.90 
70.63 
2.34 
7.27 
2.12 
1.55 
73.11 
1.28 
2.30 
79 
82 
104 
55 
32 
Early Small 
Airway 
Obstruction 
Mild Restriction 
Test within 
Normal Limits 
4. 
Mr.Thurairaj 
65/M Wt: 80 
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.28 
1.82 
81.7 
6.58 
2.27 
1.75 
0.88 
50.30 
00.58 
0.27 
77 
48 
65 
29 
22 
Early Small 
Airway 
Obstruction 
Moderate 
Obstruction  
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.25 
1.80 
81.6 
6.55 
2.23 
2.03 
1.04 
51.20 
02.66 
0.51 
90 
58 
63 
41 
23 
Early Small 
Airway 
Obstruction 
Moderate 
Obstruction  
 
5. 
Mr.Serthu 67/M 
Wt: 72 
Ht: 151 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
3.07 
2.26 
73.62 
2.72 
7.79 
00.84 
00.84 
100.00 
00.87 
2.40 
27 
37 
136 
32 
30 
Early Small 
Airway 
Obstruction 
Severe 
Obstruction  
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.22 
1.67 
75.23 
2.31 
6.07 
1.89 
1.44 
76.19 
01.13 
3.79 
85 
86 
101 
49 
262 
 
 
Early Small 
Airway 
Obstruction 
Spirometry 
within Normal 
Limits 
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6. 
Mrs.Muththulaxm
i48/F 
Wt: 65 
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.52 
2.12 
84.4 
5.69 
2.79 
2.19 
1.75 
79.90 
5.48 
1.63 
87 
83 
95 
96 
58 
Early Small 
Airway 
Obstruction 
Severe 
Obstruction  
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.52 
2.12 
84.4 
5.69 
2.79 
2.46 
1.84 
74.80 
5.71 
1.43 
98 
87 
89 
100 
61 
Early Small 
Airway 
Obstruction 
Mild Obstruction 
7. 
Mrs.Suriyakala 
48/F 
Wt: 66 
Ht: 154 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.52 
2.16 
86.7 
5.74 
2.95 
1.32 
0.69 
52.30 
1.14 
043 
52 
32 
60 
20 
15 
Early Small 
Airway 
Obstruction 
Severe 
Obstruction  
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.52 
2.16 
86.7 
5.74 
2.95 
1.73 
1.06 
61.30 
1.79 
074 
69 
49 
71 
31 
25 
Early Small 
Airway 
Obstruction 
Moderate 
Obstruction 
8. 
Mrs.Thagira 40/F 
Wt: 65 
Ht: 149 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
3.82 
3.21 
84.9 
8.62 
4.03 
3.10 
2.80 
88.60 
4.96 
3.33 
83 
87 
104 
58 
83 
Early Small 
Airway 
Obstruction 
Moderate 
Restriction  
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.35 
1.77 
75.32 
2.81 
7.01 
1.73 
1.73 
100.00 
4.12 
4.85 
74 
98 
133 
147 
69 
Early Small 
Airway 
Obstruction 
Mild Restriction 
Test within 
Normal Limits 
9. 
Mr. Shangar 70/M 
Wt: 80 
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.22 
1.60 
72.07 
2.00 
5.96 
2.36 
00.47 
19.92 
00.35 
01.95 
106 
29 
28 
18 
33 
Early Small 
Airway 
Obstruction 
Severe 
Obstruction 
Very Severe 
stage  
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.22 
1.60 
72.07 
2.00 
5.96 
2.36 
00.47 
19.92 
00.35 
01.95 
106 
29 
28 
18 
33 
Early Small 
Airway 
Obstruction 
Severe 
 Obstruction 
Very Severe stage  
10. 
Mr. Thangaraj  
68/M 
Wt: 65 
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.81 
2.04 
72.60 
2.58 
7.52 
1.28 
00.50 
39.06 
00.43 
00.58 
46 
25 
54 
17 
08 
Early Small 
Airway 
Obstruction 
Mixed 
Blockage Very 
Severe stage  
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.81 
2.04 
72.60 
2.58 
7.52 
1.28 
00.50 
39.06 
00.43 
00.58 
46 
25 
54 
17 
08 
Early Small 
Airway 
Obstruction 
Mixed Blockage 
Very Severe stage  
 
 
 
 131 
 
 
PULMONERY FUNCTION TEST REPORT BEFORE TREATMENT, AFTER 
TREATMENT 
S.No Patients Name Parameters Predected BT AT 
1. 
Mr.Perumal 73/M 
Wt:70  
Ht:165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.74 
1.94 
70.80 
2.36 
7.34 
56% 
69% 
123% 
56% 
67% 
108% 
112% 
103% 
86% 
52% 
2. 
Mrs.Rajinidev 56/F 
Wt: 60  
Ht: 147 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
1.87 
1.42 
75.94 
1.79 
5.00 
84% 
70% 
84% 
44% 
23% 
74% 
98% 
133% 
147% 
69% 
3 
Mrs.Ganthimathy 61/F
  
Wt:84  
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.50 
1.86 
74.40 
2.06 
5.83 
46% 
61% 
134% 
60% 
27% 
79% 
82% 
104% 
55% 
32% 
4. 
Mr.Thurairaj 65/M 
Wt: 80  
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.28 
1.82 
81.7 
6.58 
2.27 
77% 
48% 
65% 
29% 
22% 
90% 
58% 
63% 
41% 
23% 
5. 
Mr.Serthu 67/M 
Wt: 72  
Ht: 151 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
3.07 
2.26 
73.62 
2.72 
7.79 
27% 
37% 
136% 
32% 
30% 
85% 
86% 
101% 
49% 
262% 
6. 
Mrs.Muththulaxmi 
48/F  
Wt: 65  
Ht: 165 
 
 
 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.52 
2.12 
84.4 
5.69 
2.79 
87% 
83% 
95% 
96%  
58% 
98% 
87% 
89% 
100% 
61% 
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7. 
Mrs.Suriyakala 48/F
  
Wt: 66  
Ht: 154 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.52 
2.16 
86.7 
5.74 
2.95 
52% 
32% 
60% 
20% 
15% 
69% 
49% 
71% 
31% 
25% 
8. 
Mrs.Thagira 40/F Wt: 
65  
Ht: 149 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
3.82 
3.21 
84.9 
8.62 
4.03 
83% 
87% 
104% 
58% 
83% 
74% 
98% 
133% 
147% 
69% 
9. 
Mr. Shangar 70/M Wt: 
80  
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.22 
1.60 
72.07 
2.00 
5.96 
106% 
29% 
28% 
18% 
33% 
106% 
29% 
28% 
18% 
33% 
10. 
Mr. Thangaraj  68/M  
Wt: 65 
Ht: 165 
FVC L 
FEV 1 L 
FEV1/FVC % 
FEF 25-75 L/s 
PEFR L/s 
2.81 
2.04 
72.60 
2.58 
7.52 
46% 
25% 
54% 
17% 
08% 
46% 
25% 
54% 
17% 
08% 
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Patient Name : GANTHIMANTHI (69Y/F) 
OP No : 59223 
BEFORE TREATMENT 
Patient Name : GANTHIMANTHI (69Y/F) 
OP No : 59223 
AFTER TREATMENT 
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Patient Name : PERUMAL (73Y/M) 
OP No : 58024 
BEFORE TREATMENT 
Patient Name : PERUMAL (73Y/M) 
OP No : 58024 
AFTER TREATMENT 
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Patient Name : RANJINIDEVI (56Y/F) 
OP No : 71009 
BEFORE TREATMENT 
Patient Name : RANJINIDEVI (56Y/F) 
OP No : 71009 
AFTER TREATMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 136 
Patient Name : SERTHU (67Y/M) 
IP  No :  
         BEFORE TREATMENT 
Patient Name : SERTHU (67Y/M) 
IP  No :  
          AFTER TREATMENT 
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CHAPTER-V 
DISCUSSION 
The Iya Neerizhivu refers to Diabetes associated with COPD which leads to 
increases the risks of Respiratory complications. Uncontrolled long standing diabetes is 
the main cause for developing the diabetic complications. This clinical study is designed 
to target the risks of Respiratory complications ensuing diabetes and to improve the 
quality of living of the diabetic individuals, with an efficacious herbal formulation 
mentioned in Siddha literature. In this study, 40 type-II diabetic patients attending the OP 
and IP at the Dept. of Pothu Maruthuvam, Govt. Siddha Medical College and Hospital, 
Palayamkottai were randomly selected for the study. 20 screened and selected patients 
were admitted as in in patients in Department of Pothu Maruthuvam and were treated 
with the trial medicine. After discharge all the twenty patients were followed as the Out 
patients. 20 Out patients in the Out patients Department of Pothu Maruthuvam were also 
treated with the trial drug.The prognosis were closely monitored and recorded under the 
supervision of Professor, Reader and Assistant lecturer. The observations and result are 
discussed below.    
 
1.   Distribution of Gender 
The subjects included males 50% in OP, 70% in IP and females 50% in OP and 
30% in IP were affected proving gender disparity in the onset of the disease.  The male 
population was more than the female counter part. This compares well with a study on 
WHO global data which stated that the prevalence ratio of diabetes between men and 
women varies markedly, with no consistent trend. The ADA stated the relative difference 
in frequency between the sexes is probably related to the presence of underlying factors, 
such as obesity, rather than to a sex-specific genetic tendency.  
 
2.   Distribution of Age 
The highest incidence of Iya Neerizhivu is among the age group of 40-49 years, 
closely followed by 50-59 years. From this study, it was observed that the diabetic 
subjects were averagely older. This shows type-II diabetes begins typically in middle life 
or later, the prevalence rises with age. 
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3.   Distribution of Educational Status 
The assessment of patient’s knowledge showed the majority of patients were 
middle and high school educated. The educational level had no impact on glycemic 
control, but the patients of high educational level had better awareness of the 
complications and a high rate of adherence to diet.  
4.   Distribution of Occupation 
The highest incidence of Iya Neerizhivu is among OP and IP patients were coolie 
workers.it belong. 
5.   Distribution of Religion 
The majority of patients were Hindus among OP 75% and IP 60%. The highest 
incidence is among the Hindu population, which is the major population in India. Diet 
and lifestyle of rituals may influence the control of blood sugar and COPD.  It has been 
suggested that in spite of ethnic and cultural differences diabetics have significantly 
higher prevalence of COPD. 
6.   Distribution of Marital Status 
The highest incidence among the OP and IP patients were married.  
7.   Distribution of Clinical Manifestation 
Diabetes is a chronic illness that requires continuing medical care and patient self-
management education to prevent acute complications and to reduce the risk of long-term 
complications. The data from the observation showed majority of incidence of polyuria, 
polydipsia, nocturia, in both In patients and out-patients. 
COPD itself usually causes symptoms like Coughing, Sputum, Dyspnea, Wheezing, and 
Expectoration of sputum etc., these features also present among OP & IP patients in 
relative percentages who were recruited in the study. 
8.   Distribution of Mode of Onset 
The onset of Iya Neerizhivu ensues a chronic mode of onset with relative 
percentage of 65% in OP and 85% in IP. The percentage of recently found supports the 
fact that in many diabetics the disease is first detected when the patient presents with a 
complication. 
9.    Distribution of Duration of Illness 
Iya Neerizhivu is greatly noticed in 40 patients suffering with about more than 3 
years to 6 years suffering with Neerizhivu. It was observed that duration of type-II 
diabetes had a positive correlation with glycated haemoglobin. This is because the body 
becomes more resistant to insulin with increasing duration of diabetes. Various studies 
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are proved that the amount of carbohydrate attached to the HbA1C increases with 
increasing duration of the disease.  
10.  Distribution of Family History 
Among the Out patients, 60% of the patients had positive family history and 40% 
of the patients had negative family history in in patients 40% had negative family history.  
Family history is high prevalence to get diabetic complications. 
11.  Distribution of Previous Treatment 
Among OP and IP patients of 100% were taken previous therapy. Majority of 
patients despite of previous therapy for Neerizhivu had developed Iya Neerizhivu, 
reflecting the resistance developed to the undertaken therapy. 
12.  Distribution of Personal History 
The observations illustrate that the disease was majority of patients were taken 
mixed diet.  According Yugi Vaidhya Chinthamani, the dietary factors that cause the 
disease are taking excessive consumption of non-vegetarian diet. Here the observations 
coincide with Yugi’s concept. 
Although regulation of blood glucose and PFT to achieve near normal levels is a 
primary goal in the management of diabetes and COPD, and thus, dietary techniques that 
limit hyperglycaemia following a meal are important in limiting the complications of 
diabetes. 
Among the Out patients 20% & 50% of the patients were alcoholics and smokers, Among 
In patients 25% & 70% of the patients also were alcoholics and smokers.  Above the 
patients in OP and IP observed poor control of blood sugar. 
Though smoking has a hand in the incidence of Iya Neerizhivu, it was noted that patients 
with no such habits also reported with the above condition.  
13.  Distribution of Socio economic Status 
Among the Out-patients 25% belonged to the lower middle Socio-Economic 
status and 15% belonged to lower middle and poor group. 
This Observation indicates no class variation in the manifestation of the disease. But the 
low income should influence the awareness of diet, health care and routine medical 
check-up of patients. 
14.  Distribution of Other System Involvement 
Both in patients, Out Patients had central nervous system, cardiovascular system 
and musculo skeletal system affected. Among this majority of cases affected with 
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musculo skeletal system in OP and IP patients. The course may be due to obesity and 
degenerative changes. 
15.  Body Mass Index 
According to WHO 60% of the quality of an individual's health depends on his / 
her diet and regimens.  Early adoptions of healthy habits can problems of future years. 
Present study reflected that there was a higher prevalence of overweight and obesity 
among OP and IP patients (60% & 60%). Subjects with higher HbA1C levels also had 
significantly higher measurements in BMI and waist circumference and hip 
circumference as compared with those of desirable HbA1C levels. 
16.  Distribution of Constitution of Body 
Among, 40 Out patients and In patients 95% were thontha thegi and the present 
study reflected that higher prevalence was kapham combined with other doshas. 
17.  Distribution of Gunam 
100% of all the 40 patients included in the study had Rajogunam. 
18.  Distribution of Kaalam 
The maximum numbers of cases were treated in their pitha kaalam among OP and 
IP patients. But in Siddha text denoted the Iyakaalam is more prevalence to Iya 
Neerizhivu. 
19.  Paruva Kaalam 
There was high incidence of this study reflected Kaar kaalam (75%) among OP 
patients and Munpani kaalam (35%) among IP patients. The text book of Siddha 
maruthuvam stated elavenil and mudhuvenil kaalam. Therefore it could not counterpart of 
the disease origin.  
20.  Thinai 
Among, out patients 90% belonged to Marutham (i.e. Plain & its surroundings) 
and 95% in In patients.The region where the study is conducted is Tirunelveli which 
belongs to the marutham thinai. 
21.  Mukkutram 
a.   Derangement of Vatham 
Pranan, Viyanan, Uthanan , Samanan, Kirukaran and Devathathan were affected in all 
the 100% of the Out patients and In patients. Abanan was affected in 30% of the Out 
patients and 30% of the In patients. Koorman was affected in 10% of the Out patients and 
20% of the in patients. 
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  Pranan maintains the life force in a normal healthy body, this vayu when affected 
causes difficulty in breathing, dyspnoea as presented along with Iya Neerizhivu . 
 Abanan is responsible for excretion of urine and motion. This vayu is affected in 
this disease causing constipation and polyuria. 
 Viyaanan functions to induce normal physiological movements in the body. This 
vayu is affected leading to decreased activity due to tiredness, claudication pain 
and weakness. 
 Uthanan is responsible for upword motion, speech, strength of the mind and the 
body. Since there is a decrease in the expectoration, cough strength of the body 
and mind. 
 Altered Samanan leads polyphagia and indigestion 
 Koorman gives strength to the body and helps in vision; this vayu is affected in 
Iya Neerizhivu causing tiredness and a decreased vision due to aging. 
 Kirukaran is responsible for appetite which is affected in this disease. 
 Devathanthan is responsible for tiredness after sleep and emotion. In Iya 
Neerizhivu tiredness of body and soul occurs due to derangement of devathathan. 
b. Derangement of Pitham 
Analagam, Ranjagam and Sathagam were affected in 100% of both In patients and 
Out patients. Prasagam was affected in 60% of the Out patients and 35% of the In 
patients. Alosagam was affected in 5% of the Out patients and 25% of the In patients. 
Analagam is responsible for appetite. Since there is excess appetite or loss of appetite 
among the patients.  
 Ranjagam contributes to the normal function of the blood components. 
 Sathagam enables the performance of the intended actions if altered causing 
tiredness. 
 Prasagam gives lustre to the skin, which is affected also. 
 Altered Alosagam causing blurring of vision. 
c. Derangement of Kapham 
In types of Kapha dosham, Avalambagam and Kilethagam were affected in all the 
100% of both in patients and Out patients. Santhigam was affected in 65% of out patients 
and 75% of in patients. 
 Avalambagam resides in the lungs and helps the other four types of kapham to 
function in equilibrium. Since the equilibrium is altered due to involvement of 
other forms of kapham also affected. 
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 Deranged Kiethagam excessive appetite or loss of appetite is present. 
 Santhigam resides in the joints and helps in its movement. Since there was joint 
pain, it is affected which may be due to their aging or obesity. 
22.  Involvement of Ezhu Udalthathukkal 
In ezhu udal Kattugal, Saaram and Senneer was affected in all 100% of the Out 
patients and In patients. Oon was affected in 65% of the Out patients and 75% of the In 
patients. Kozhuppu was affected in 80% of the Out patients and 85% of the In patients. 
Enbu was affected in 20% of the out-patients and of the 25% in patients and sukkilam 
was affected in 5% of out patients only. 
 Saaram strengthens the body and mind, since, there is loss of appetite and strength 
less causing body tiredness the first thathu is affected. 
 Senneer is affected which produces decreased haemoglobin. Oon is responsible 
for the structural muscular component of the body; this is affected in the weakness 
caused by stroke. 
 Enbu and Kozhuppu are responsible for the movements of the body and gives 
lubrication to the joint cavities. There was reflected in masculo skeletal disorders 
like Oteo arthritis, back pain, shoulder pain etc…due to obesity, and senility. 
23.   Kanmenthiriyam 
The present study showed kaal and eruvai were affected in majority of cases in OP 
and IP patients (50% & 25%). 
24.  Gnanenthiriyam 
Among Out patients and In patients Mei was affected in 50% and 25% of the 
cases leads to altered sensation and pain in madhumegam due to altered Viyanan and 
Devathathan. The pathology also can be overlap with sign and symptoms of Iya 
Neerizhivu. 
25.  Kosam 
Among 40 patients annamaya kosam (100%) was affected due to altered abanan, 
samana vayu, anaila Pitham and kilethagam, in udalkattukal saaram and senneer. 
 
26.  Envagai Thervugal 
 Sparisam was affected in 50% of out patients and 25% of In patients due to altered 
sensations of pain in claudication and numbness in neuropathy. 
 Niram was affected in 30% of out patients 35% of In patients due to loss of lustre. 
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 Vizhi was affected in 10% of out patients and 20% of in patients, blurring of 
vision due to cataract and aging. 
 Malam was affected in 30% of out patients and in patients due to constipation. 
 Naa and Moothiram were affected in in patients and out patients. There was 
presence of dryness of tongue due to dehydration and polyuria with excretion of 
albumin, glucose, and abnormal neerkuri. 
 Mozhi was affected 10% among In patients only with Iya Neerizhivu in the study. 
 In Naadi examination majority of cases had pitha vatha naadi in OP and IP 
patients (55% & 50%) Kapha vatham were 10% in OP and 30% in IP vatha 
pitham were 25% in OP and 20% in IP. Pitha Kapham and Kapha pitha naadi was 
not seen in Iya Neerizhivu. 
27.  Neerkuri 
In Neerkuri, Niram was affected in 55% of Out-patients and 45% of In patients 
which the colour was replicated crystal clear urine and indicates asathiyam. Manam was 
affected like honey odour in 20% of out patients and 30% of In patients. Nurai was 
affected in 35% of out patients and 25% of In patients. 
28.  Neikuri 
In Neikuri, 60% of out patients and 70% of In patients had Thontha neer. Which 
was reflected some Asathiya Neerkuri such features like conch shape, decoration type, bat 
shape, bow shape etc. 
29.  Laboratory Analysis 
A. HbA1C 
Among the 40 patients recruited for the study most patients in OP & IP (65% & 
70%) had poor control (>8%) of HbA1C. Insulin affects the liver Apo-lipoprotein 
production. It regulates the enzymatic activity of Lipoprotein Lipase (LPL) and 
Cholesterol ester transport protein. All these factors are likely cause of copd in Diabetes 
mellitus. Moreover, insulin deficiency reduces the activity of hepatic lipase and several 
steps in the production of biologically active LPL may be altered in DM. 
B. Pulmonary Function Test  
As expected, those having diabetes were older, were more likely to be male, had a 
greater average BMI, and had a greater report of breathlessness and were more likely to 
have serious pulmonary exacerbations and pulmonary exacerbations more frequently if 
they had COPD. Those with diabetes had greater pack years of smoking 24 in 40 COPD 
subjects. 
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30.  Gradation of results 
Good response was found in 60% of out patients and 55% of in patients. Moderate 
improvement was found in 30% of out patients and in 40% of in patients. Poor result was 
found in 10% of out patients and 5% of the in patients. Bio statistical analysis showed 
significant difference in the action of the trial drug in lowering elevated blood sugar 
levels, HbA1C, total cholesterol, LDL, TGL, and HDL, PFT with a ‘p’ value of p<0.001 
for blood sugar, p< 0.001 for HbA1C, p<0.001 for total cholesterol, p<0.001 for LDL 
p<0.001, for HDL p<0.001, for and TGL p=0.001 and PFT p<0.001, before and after 
treatment with the trial drug. The p value for VLDL cholesterol level was not statistically 
significant, although difference exists in their mean value with SD. It shows that though 
statistically significant clinically the trial drug had an effect in reducing the elevated 
Blood sugar, HbA1C, PFT. Anthropometric measurements also showed significant 
difference in the action of trial drug in lowering body weight, BMI and WHR with p 
value of <0.001 
 
31. Microbiological Examination 
 Microbial test shows is highly sensitivity to both gram positive and gram negative 
bacteria. Escherichia coli 26mm/23mm, Proteus sp. 23mm/20mm, Staphylococcus aureus 
23mm/20mm, Pseudomonas aeruginosa 22mm/21mm, Salmonella typhi 21 mm/19 mm 
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CHAPTER-VI 
SUMMARY 
The reported epidemiological data on the prevalence on diabetes, the expected 
increase in the population of diabetic individuals, the increased risk of respitary 
complications due to diabetes necessitate urgent preventive measures to be undertaken to 
manage the disorder. 
Therefore in these clinical trial 40 patients with Iya Neerizhivu, of both sex and 
varying age groups were screened and selected as 20 in patients and 20 Out patients, to 
evaluate the efficacy of the trial drug in the management of Iya Neerizhivu. 
The patients were subjected to investigations based on Siddha and modern 
parameters. The trial drug Seenthil Sakkarai was administered to all the selected patients, 
at a dose of 30 mg/kg BW three times a day before food, for a study period of 90 days. 
Blood sugar (FBS, PPBS), HbA1C, lipid profile, PFT was recorded before and 
after treatment. Siddha diagnostic parameters of Naadi examination and neerkuri, nei kuri 
were also observed. 
All the cases administered with the trial drug, they were not reported any adverse 
reactions. Few patients adapted to the medicine and recovered spontaneously, for such 
patients the textual dosage of the trial drug was followed. In those who had a persistent 
complaint, the dosage of the trial drug was titrated according to their Body Mass Index. 
Significant improvement was observed in almost all the cases included in the study. 
Symptoms of tiredness, cough, dyspnoea, and expectoration were remarkably reduced. 
Significant decreases in the mean values of blood sugar levels, HbA1C, Lipid levels BMI, 
WHR, PFT were noted before and after treatment. For blood sugar and HbA1C the “p” 
value was p<0.001 and “p” value was p<0.001 and for total cholesterol “p” value was 
p<0.001, for LDL “p” value was p<0.001, for HDL “p” value was p<0.001, for TGL “p” 
value was p<0.001 for BMI  ‘p’ value was <0.001, PFT “p” value was p<0.001 which 
implies that statistically the trial drug has Seenthil sakkarai is potent Anti-Hyperglycemic 
and Bronchodilator activates..  
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   CHAPTER-VII 
CONCLUSION 
In this clinical study 60% of the patients showed good improvement, 30% showed 
moderate improvement and 10% showed poor improvement. 
Clinically there was a significant decrease in the mean values of PFT along with 
blood sugar and HbA1C levels before and after treatment with Seenthil sakkarai. 
 Bio statistically the T2D and COPD, Bronchodilator activity of the trial drug is 
highly significant (‘p’ value of p<0.001 for blood sugar, p<0.001 for HbA1C, p<0.001 for 
PFT. 
It can be concluded that Iya Neerizhivu can be well managed with the trial drug, 
Seenthil sakkarai which reduces blood sugar levels and HbA1C, a biochemical state 
desirable for the prevention of diabetes and its respiratory complications. 
 HbA1C can be used as a potential biomarker for predicting copd in type-II 
diabetic patients in addition to glycaemic control hence early diagnosis and may be 
utilized for screening high-risk diabetic patients for timely intervention with respiratory 
diseases (COPD). 
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ANNEXURE-I  
PREPARATION OF THE TRIAL DRUG 
 
SEENTHIL SARKKARAI 
 
Drugs: 
Seenthil Sarkkarai      
 
Purification and Preparation: 
 
All the ingredients of these herbal formulations will purify according to the 
suitable procedure methods described in Siddha classical literature.   
  Cut and remove the outer covering of aged stem of Tinospora cordifolia will be 
shade dried and make into powder. Add 1400 ml water and knead well, then mix 5600ml 
water and allow precipitating. The flour of Tinospora Cordifolia will be precipitated in 
the latter. After filter the water and again add 5600 ml water into it and allow to 
precipitating. It will be done for 10 times. Then add kaadi neer mixed with lemon juice 
(16:1) allow to precipitating for one day. Like another day buttermilk and lemon juice 
(16:1) allow to precipitating. The ratio should be maintained to flour and solution is 1:4. 
Finally flour will be collected and dried. 
 
Dose: 
30 mg/ Kg/BW/daily three times a day. 
 
Adjuvant: 
Ghee. 
 
Uses: 
Mega Disorders, Diabetes, Diseases Of Urinary Tract, Internal Hemorrhages, 
Intermittent Fevers, Chronic Fevers , Diarrhea, Dysentery, Bilious Disease Due To Hyper 
Acidity, Poisonous Bites, Persistent Cough, Asthma, Jaundice, Indigestion, 
Helminthiasis, Gonorrhea, Inflammations And Allergy,  General Debility 
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PROPERTIES OF INDIVIDUAL DRUGS 
 
rPe;jpy;- Tinospora cordifolia.  
 
Synonym                 :mkpu;jty;yp> Nrhkty;yp> mkpu;ij> mkpu;jf;nfhb> Fz;lyp 
Botanical name       :  Tinospora cordifolia 
Family       :  Menispermaceae 
Parts used       :  leave, Stem, Root  
Part used in trial drug   :  Stem (Seenthil Maa) 
Siddha properties: 
   
 Siddha Name  : Seenthil 
 Suvai   : Kaippu (Bitter)  
 Thanmai : Veppam (Hot) 
 Pirivu  : Karppu (Pungent) 
 
Pharmacological actions: 
  
Anti–Periodic, Bronchodilator, Alternative, Diuretic, Anti Diabetic, Anti- 
microbial actions, Demulcent.    
 
Phytochemical constituents: 
 
Bitter glucoside giloin, Giloinin, Gilo-sterol, Columbin, Chasmanthin, Palmarin, 
Tinosporon, Tinosporic acid, Berberine. 
nghJf;Fzk;: 
 
,q;F ngUe;jhfk; vd;GUf;fp uj;jgpj;jk; 
Xq;Fk; kJNkf Kl;bzk;Nghk;-Xq;fptsu; 
$e;jy; KbkhNj $WQ;rQ; rPtpnaDQ; 
rPe;jy; rUf;fiuapd; rPu;.  
(g.F.tp gf;.vz;-360) 
Fl;lk; gjpndl;Lk; FQ;ruj;jpd; Nwhw;nrhwpAq; 
fl;lk; ngupjhq; faNehAk;-gl;lTld; 
nre;jPKd; gQ;nrdNt rPe;jpYg; Nghlise;j 
je;jh tsePu;f;Fr; rhk;  (Njud; ntz;gh) 
                       (Fzghlk; ghfk; 1- gf;.vz;456) 
Therapeutic Uses in Siddha: 
 
Diabetes, Persistent Cough, Asthma, Inflammations and Allergy, Intermittent 
Fevers, Chronic Fevers. 
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rPe;jpy; rf;fiu 
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ANNEXURE-II  
BIO CHEMICAL ANALYSIS OF “SEENTHIL SARKKARAI” PREPARATION 
OF THE EXTRACT 
The extract is directly prepared from the trial drug Seenthil Sarkkarai. 
 
Preparation of the Extract: 
 5g of the drug was weight accurately and placed in a 20ml of distilled water is 
added and dissolved well. Then it’s boiled well for about 10 minutes. It is coiled and 
filtered in a 100ml volumetric flask and then it is made to 100ml with distilled water. 
This fluid is taken for analysis.  
 
QUALITATIVE ANALYSIS 
 
Sl. 
No. EXPERIMENT OBSERVATION INFERENCE 
1. 
TEST FOR CALCIUM 
2ml of the above prepared extract is taken in 
a clean test tube.  To this add 2ml of 4% 
Ammonium oxalate solution. 
A white 
precipitate is 
formed. 
Indicates the 
presence of 
Calcium. 
2. 
TEST FOR SULPHATE: 
2ml of the extract is added to 5% Barium 
chloride solution. 
A white 
precipitate is 
formed 
Indicates the 
presence of 
Sulphate. 
3. 
TEST FOR CHLORIDE 
The extract is treated with Silver nitrate 
solution. 
No white 
precipitate is 
formed. 
Absence of 
chloride. 
4. 
TEST FOR CARBONATE 
The substance is treated with concentrated 
Hcl. 
No brisk 
effervescence is 
formed. 
Absence of 
Carbonate. 
5. 
TEST FOR STARCH 
The extract is added with weak Iodine 
solution. 
Blue colour is 
formed. 
Indicates the 
presence of 
Starch. 
6 
TEST FOR FERRIC IRON  
The extract is acidified with Glacial acetic 
acid and Potassium ferro cyanide. 
No blue colour is 
formed. 
Absence of 
ferric Iron 
7. 
TEST OF FERROUS IRON 
The extract is treated with concentrated Nitric 
acid and Ammonium thio cynaate solution. 
Blood red colour 
is formed. 
Indicates the 
presence of 
Frrous Iron.  
8. 
TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
molybdate and concentrated Nitric acid. 
No yellow 
precipitate is 
formed. 
Absence of 
phosphate.  
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9. 
TEST FOR ALBUMIN 
The extract is treated with Esbach’s reagent. 
No yellow 
precipitate is 
formed. 
 
Absence of 
albumin. 
10. 
TEST FOR TANNIC ACID 
The extract is treated with Ferric choloride. 
No Blue black 
precipitate is 
formed. 
Absence of 
Tannic acid.  
 
Sl. 
No. EXPERIMENT OBSERVATION INFERENCE 
11. TEST FOR UNSATURATION 
Potassium permanganate solution is added to 
the extract. 
It gets 
decolourised. 
Indicates the 
presence of 
unsaturated 
compound. 
12. TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 2 
mts and added 8-10 drops of the extract and 
again boil it for 2 mts. 
No Colour change 
occurs. 
Absence of 
reducing sugar. 
13. TEST FOR AMINO ACID 
One or two drops of the extract is placed on a 
filter paper and dried it well. After drying, 
1% Ninnydrin is sprayed over the same and 
dried it well. 
Violet colour is 
formed. 
Indicates the 
presence of 
Amino acid. 
14. TEST FOR ZINC: 
The extract is treated with Potassium 
Ferrocyanide. 
No white 
precipitate is 
formed. 
Absence of 
Zinc. 
 
 
INFERENCE: Calcium, Sulphate, Frrous Iron, unsaturated compound, and amino acid 
are present in Seenthil Sarkkarai.  
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ANNEXURE-III (A) 
ANTI-HYPERGLYCEMIC EFFECT OF SEENDHIL SARKKARAI IN 
EXPERIMENTAL DIABETES AND THEIR EFFECTS ON KEY METABOLIC 
ENZYMES INVOLVED IN CARBOHYDRATE METABOLISM 
INTRODUCTION 
            Diabetes mellitus is a metabolic disorder in which the body does not produce or 
properly utilize insulin. It causes disturbance in carbohydrate, protein and lipid 
metabolism and complications such as retinopathy, micro angiopathy and nephropathy. In 
practical terms, diabetes mellitus is a condition in diabetes, a profound alteration in the 
concentration and composition of lipid occurs. The global figure of people with diabetes 
set rise from the current estimate of 150-220 million in 2010 and 300 million in 2025.  
            Despite the immense strides that have been made in the understanding and 
management of diabetes the disease and disease related complications are increasing 
unabated. In spite of the presence of known anti-diabetic medicine in the pharmaceutical 
market, remedies from medicinal plant are used with success to treat this disease. Many 
traditional plants treatments for diabetes are used throughout the world and there is an 
increasing demand by patients to use the natural products with anti-diabetic activity. 
             The present investigation is undertaken to the study the effect of Seendhil 
Sarkkarai on changes in Body weight, Plasma glucose, Hemoglobin and glycosylated 
hemoglobin and lipid profile, metabolic enzymes and antioxidant enzymes levels. 
EXPERIMENTAL MODELS 
                For the study of anti-diabetic an experimental model is selected in such a way 
that it would satisfy the following: 
 The animal should develop hyperglycemia rapidly. 
 Pathological changes in the site of induction should result from pancreatitis or 
damage of   β-cells. 
 The symptoms should be ameliorated or prevented by a drug treatment 
effective in human beings. 
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MATERIALS AND METHODS 
Materials: 
Animals    : Male albino wistar rats (180-220gm) 
Drugs        : Seendhil Sarkkarai 
Chemical  :  Streptozotocin (S. D Fine. Chem. Ltd, Mumbai) 
Selection & acclimatization of animals:        
           Wistar strains of male albino rats weighing between 180-220gm are used for this 
study. The animals were housed in large spacious cages and they were fed with 
commercial pellets and access to water ad libitum. The animals were well acclimatized to 
the standard environmental condition of temperature (220c ± 50c) and humidity (55 ±5%) 
and 12 hr light dark cycles throughout the experimental period. 
INDUCTION OF DIABETES MELLITUS 
            Diabetes mellitus is induced in wistar rats by single intraperitoneal injection of 
freshly prepared solution of Streptozotocin (25mg/kg BW) in physiological saline after 
overnight fasting for 12hrs.[1] 
           Streptozotocin is commonly used to produce diabetes mellitus in experimental 
animals due to its ability to destroy the β-cells of pancreas possibly by generating the 
excess reactive oxygen species such as H202, 02 and H0-. The development of 
hyperglycemias in rats is confirmed by plasma glucose estimation 72 hrs post 
Streptozotocin injection. The rats with fasting plasma glucose level of >180-220mg/dl 
were used for this experiment. 
Experimental procedure: 
 In the experiment a total of 30 rats (24 diabetic surviving rats & 6 normal rats) 
were used. Diabetes was induced in rats 3 days before starting the experiment. The rats 
were divided into 5 groups after the induction of Streptozotocin diabetes. In the 
experiment 6 rats were used in each group. 
TREATMENT PROTOCOL 
 Group-I:  (Normal control) consist of normal rats given with 10ml/Kg of normal 
saline, orally. 
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 Group-II:  (Toxic control) Diabetic control received 25mg/Kg of Streptozotocin 
through I.P. 
 Group-III: Diabetic control received glipizide at a dose of (10mg/Kg orally) for 28 
days. 
 Group-IV: Diabetic control received Seendhil Sarkkarai at a dose of (100mg/Kg 
orally) for 28 days. 
 Group-V: Diabetic control received Seendhil Sarkkarai at a dose of (200mg/Kg 
orally) for 28 days. 
 
METHODOLOGY 
Sample collection:            
           After 28 days of treatment, body weight, blood glucose, haemoglobin, 
glycosylated haemoglobin, plasma insulin, total cholesterol, triglycerides, HDL-
cholesterol and phospholipids and glycogen content and antioxidant enzymes level were 
determined. Blood was collected from the eyes (venous pool) by sino-ocularpuncture. In 
EDTA coating plasma tubes for the estimation of blood parameters. 
BIOCHEMICAL ANALYSIS 
Estimation of blood glucose:   
 Blood glucose was estimated by commercially available glucose kit (One Touch 
Ultra) Johnson Johnson based on glucose oxidase method.  
 
 
Plasma insulin:  
 Plasma insulin was determined by ELISA method using a Boehringer–Mannheim 
kit[4] with an ES300 Boehringer analyzer (Mannheim, Germany). 
Estimation of total haemoglobin and glycosylated haemoglobin: 
 Total haemoglobin was determined by the method of Drabkin and Austin (1932) 
[5] and glycosylated haemoglobin was determined by the method of Sudhakar Nayak and 
Pattabiraman (1981).  
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Estimation of lipid & lipoprotein: 
  Plasma lipids were determined by auto analyzer according to the method 
of Parkeh and Jung (1970) (total cholesterol), Gidez and Webb (1950) (HDL-cholesterol), 
Zilversmith and Davis (1950) (phospholipids) and Rice (1970) (triglycerides).  
Hepatic glucokinase and hexokinase activity 
         The part of liver for each test was perfused with ice cold 0.15M KCl and 1mM 
EDTA solution and homogenized twice its weight of ice cold buffer (0.01 cysteine and 
1mM EDTA in 0.1 ml Tris-HCL, pH 7.4) and centrifuged for 20 min at 40C. Glucose 
phosphorylation was assayed by means of glucose 6 phosphate dependent 
spectrophotometric method (11)(Crane et al., 1955. 
Glucose-6-phosphatase activity 
        The part of the liver for each test was homogenized with 40 times its weight of ice 
cold buffer (0.1 citrate-KOH, pH 6.5) and filtered through cheese cloth. Glucose-6-
phosphatase activity was measured by phosphate release by the method Marjorie. The 
determination of phosphoric acid concentration in assay mixture was done 
calorimetrically (12) (Fiske et al., 1925). 
 
 
Glycogen Content 
          The tissue sample was digested by hot concentrated 30% KOH and treated with 
anthrone reagent. Glycogen content was determined calorimetrically (Morales et al., 
1973). 
Statistical analysis: 
  The data for various biochemical parameters were analyzed using analysis 
of variance (ANOVA), and the group means were compared by Newman-Keul’s multiple 
range test (NKMRT). Values were considered statistically significant at p<0.01. 
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Table No: 1 
 Effect of Seendhil Sarkkarai on initial and final body weight and blood 
glucose in normal and treated animals.   
 
 Values are expressed as mean ± SEM. 
 Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
 ** (a) Values are significantly different from normal control G1 at P<0.001. 
 
        ** (b) Values are significantly different from Diabetic control G2 at P<0.01 
 
 
 
Table No: 2 
 
 Effect of Seendhil Sarkkarai on plasma insulin, Hemoglobin & Glycosylated hemoglobin 
in normal and treated animals. 
 
GROUPS Haemoglobin 
(gm/100ml) 
Glycosylated Haemoglobin 
HbA1C (%) Plasma Insulin (µU/ml) 
G1 13.84 ± 1.62 0.45 ±0.07 37.24 ± 2.78 
G2 6.50 ± 0.50**(a) 0.91 ±0.14**(a) 16.60 ± 1.63**(a) 
G3 14.26 ± 1.47**(b) 0.46 ±0.06**(b) 35.35 ± 2.39**
(b) 
G4 12.41 ± 0.94**(b)  0.52 ±0.09**(b) 33.80 ±2.61**
(b) 
G5 12.60 ± 1.32**(b) 0.49 ±0.05**(b) 32.80 ± 2.63**
(b) 
 
 Values are expressed as mean ± SEM. 
 Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
 ** (a) Values are significantly different from normal control G1 at P<0.001. 
     ** (b) Values are significantly different from Diabetic control G2 at  P<0.01. 
GROUP 
Body weight (g) Blood glucose     
(mg / 100ml) 
Initial 
Blood glucose   
(mg / 100ml) 
Initial Final Final 
G1 243 ± 6.15  245 ± 6.17 86.65 ± 4.40 88.85 ± 3.22 
G2 233 ± 5.61 176 ± 7.33**(a) 85.28 ± 3.72 215.35 ± 5.81**(a) 
G3 237 ± 7.53 241 ± 7.35 87.68 ± 4.33 121.50 ± 4.32*(b) 
G4 233 ± 7.29 245 ± 7.32 86.78 ± 3.68 144.38 ± 7.23**(b) 
G5 239 ± 7.39 243 ± 7.42 90.46 ± 3.85 153.45 ± 4.66**(b) 
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Table No: 3 
 Serum lipids of Normal and experimental groups. 
 
GROUPS Total 
Cholesterol 
(mg/dl) 
Tri 
glyceride 
(mg/dl) 
HDL-C 
(mg/dl) 
Phospholipids 
(mg/dl) 
LDL (mg/dl) 
G1 85.74 ±2.64 94.46 ±2.68 56.46 ±1.84 127.45 ±2.42 19.30 ± 1.40 
G2 225.42±7.46**(a) 158.60±4.55**(a) 36.68±1.34**(a) 219.44±6.32**(a) 44.65±2.52**(a) 
G3 114.86±3.34**(b) 100.90±2.42**(b) 48.18 ±1.44 155.40 ±3.92 28.74±1.76**(b) 
G4 125.54±3.58**(b) 120.70±2.90**(b) 44.43±1.42**(b) 164.60±4.12**(b) 34.25±1.54**(b) 
G5 120.43±3.40**(b) 105.40±2.74**(b) 43.47±1.59**(b) 155.40±3.82**(b) 30.34±1.72**(b) 
 
 Values are expressed as mean ± SEM. 
 Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
 ** (a) Values are significantly different from normal control G1 at P<0.001. 
     ** (b) Values are significantly different from Diabetic control G2 at  P<0.01. 
Table No: 4 
 Effect of Seendhil Sarkkarai on glycogen content (mg/gm tissue) 
 
Groups Liver Tissue Glycogen Content (mg/g tissue) 
Group I 46.30 ± 3.50 
Group II 14.24 ± 0.76*a 
Group III 38.50 ± 1.78*b 
Group IV 30.42 ± 1.30*b 
Group V 32.64 ± 1.50*b 
 
 Values are expressed as mean ± SEM. 
 Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
 ** (a) Values are significantly different from normal control G1 at P<0.001. 
     ** (b) Values are significantly different from Diabetic control G2 at  P<0.01. 
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Table No: 5 
 Effect of Seendhil Sarkkarai on enzymes involved in carbohydrate metabolism in rats 
 
Groups Hexokinase 
(µg/mg) 
Glucose-6-
Phosphate (µg/mg) 
Glucokinase 
(µg/mg) 
Group I  0.216 ± 0.014 0.395 ± 0.010 29.42 ± 1.43 
Group II  0.096 ± 0.004*a 0.132 ± 0.007*a 8.58 ± 0.35*a 
Group III  0.132 ± 0.007*b 0.305 ± 0.010*b 21.22 ± 0.93*b 
Group IV  0.127 ± 0.005*b 0.237 ± 0.007*b 18.15 ± 0.47*b 
Group V  0.147 ± 0.006*b 0.246 ± 0.008*b 18.35 ± 0.96*b 
 
 Values are expressed as mean ± SEM. 
 Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
 ** (a) Values are significantly different from normal control G1 at P<0.001. 
     ** (b) Values are significantly different from Diabetic control G2 at  P<0.01. 
 
Table No: 6 
 Effect of Seendhil Sarkkarai treatment on biochemical parameter I streptozotocin 
induced toxicity. 
 
Groups SOD(U/mg) Protein 
CATALASE 
(U/mg) Protein 
GPX(U/mg) 
Protein 
MOA(U/m
g) 
Protein 
Group I 132.24±2.41 292.42±2.40 1.23±0.07    3.94±0.18 
Group II *a69.23±1.44                 *a191.88±2.73 *a0.47±0.02 *a7.46±0.16 
Group III *b119.10±2.80              *b261.44±1.90 *b0.92±0.02 *b5.54±0.13 
Group IV *b95.52±1.55 *b231.10±1.75 *b0.76±0.02 *b5.67±0.26 
Group V *b106.68±2.62 *b241.60±2.70 *b0.77±0.05 *b4.86±0.08 
 
RESULTS 
 Table No: 1 illustrates the levels of initial and final blood glucose, and change in 
body weight, in normal rat, and treatment control animals in each group. The mean body 
weight of diabetic rats (G2) was significantly decreased as compared to normal control 
rats. The body weight of diabetic control rats treated with Seendhil Sarkkarai at a dose 
of 100mg/kg and 200mg/kg was increased the body weight non-significantly as compared 
to normal control animals. 
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 Fasting blood glucose level was significantly increased 218.45 ± 5.80 in diabetic 
animals as compared to normal animals. However the level of fasting blood glucose, 
returned to near normal range in diabetic rats treated with Seendhil Sarkkarai at a dose 
of 100mg/kg and 200mg/kg. 
 Table No: 2 illustrate the levels of total hemoglobin, glycosylated hemoglobin 
and plasma insulin in normal rat and treatment control animals in each group. 
The levels of total hemoglobin and plasma insulin levels were decreased significantly 
whereas glycosylated hemoglobin levels were increased significantly as compared to 
normal control rats. However the level of total hemoglobin, glycosylated hemoglobin and 
plasma insulin, returned to near normal range in diabetic rats treated with Seendhil 
Sarkkarai at a dose of 100mg/kg and 200mg/kg. 
Table No: 3 shows the level of serum total cholesterol (TC), triglycerides (TG), high 
density lipoprotein (HDL),Low density lipoprotein(LDL) and phospholipids of normal 
and experimental animals in each group.  
  Total cholesterol, triglycerides, high density lipoprotein, Low density lipoprotein 
(LDL) and phospholipids levels were significantly increased, where as HDL-C level was 
decreased in streptozotocin induced diabetic rats as compared to normal rats. Treatment 
of  normal and streptozotocin induced diabetic rats with Seendhil Sarkkarai at a dose of 
100mg/kg and 200mg/kg for 28 days resulted in marked decrease in total cholesterol, 
triglycerides, Low density lipoprotein(LDL) and phospholipids levels and increase in 
HDL-C levels as compared to streptozotocin induced diabetic rats. 
Effect of SEENDHIL SARKKARAI on Glycogen Content 
 Glycogen content of liver tissue was estimated on the 28th day in non-diabetic 
control, diabetic control drug, treated group and positive control group as shown in   
Table No: 4 in diabetic control rat liver glycogen content decreased significantly by 79.89 
% as compared to non-diabetic control. Treatment with Glipizide, Seendhil Sarkkarai at 
a dose of 100mg/kg and 200mg/kg led to 74.47 %, 66.05 % and 68.79% increase in liver 
glycogen content in comparison to diabetic control. 
Effect of SEENDHIL SARKKARAI on Hepatic Enzymes 
 To establish diabetic, plasma glucose was determined 72hr after alloxan 
administration. Only those rats with over 180 mg% were included in the study. On the 
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28th day, hepatic enzymes Hexokinase, Glucokinase and substrate Glucose-6-phosphate 
were estimated in saline control (group I), diabetic control (group II) and treatment 
controls (groups III, IV and V). 
 The result has been compiled in Table No: 5 As compared to non-diabetic control 
values, mean level of enzymes Hexokinase, Glucokinase and substrate Glucose-6-
phosphate values decreased in diabetic control. The respective percentage decrease was 
56.19%, 79.96% and 67.69% in diabetic control. Treatment with  Seendhil Sarkkarai at 
a dose of 100mg/kg and 200mg/kg for 28 days led to rise in percentage of these parameter 
by 22.03%, 56.03%,  and 45.21% , 47.5%, 33.33% and 67.88% respectively (P<0.001) as 
compared to diabetic control. Also, treatment with Glipizide 10mg/kg for 28 days led to 
rise in percentage of these parameters by 27.55%, 65.39% and 58.0% respectively (P< 
0.001) as compared to diabetic control. 
In  liver homogenate, there was significant decrease in SOD, CAT and GPx levels 
and increase in LPO levels were observed in animals treated with streptozocin 25mg/kg 
(group II) as compared to normal control group (Group I).  
 
Pretreatment with Seendhil Sarkkarai at a dose of 100mg/kg and 200mg/kg 
orally for 28 days increase the levels of above indices like SOD,CAT and GPx levels and 
decrease levels of LPO significantly (P<0.01) in group III, IV and V.   
 
DISCUSSION 
Streptozocin causes massive reduction in insulin release, through the destruction of β-
cells of the islets of Langerhans. The mechanism of Streptozocin action was fully 
described elsewhere (Lazarow, 1964; Colca et al., 1983).[14,15] In our study, we have 
observed a significant increase in the plasma insulin level when Streptozocin induced 
diabetic rats were treated with Seendhil Sarkkarai at a dose of 100mg/kg and 200mg/kg 
this could be due to potentiation of the insulin effect of plasma by increasing the 
pancreatic secretion of insulin from existing β- cells of islets of Langerhans or its release 
from bound insulin. 
  In uncontrolled or poorly controlled diabetes there is an increased glycosylation 
of a number of proteins including haemoglobin and α-crystalline of lens (Alberti and 
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Press, 1982). [16] Glycosylated haemoglobin (HbA1C) was found to increase in patients 
with diabetes mellitus to approximately 16% (Koenig et al., 1976) [17] and the amount of 
increase is directly proportional to the fasting blood glucose level (Jackson et al., 1979). 
[18] During diabetes the excess glucose present in blood reacts with haemoglobin. 
Therefore, the total haemoglobin level is decreased in Streptozocin induced diabetic rats 
(Sheela and Augusti, 1992).[19] Administration of Seendhil Sarkkarai at a dose of 
100mg/kg and 200mg/kg for 28 days prevents a significant elevation in glycosylated 
haemoglobin thereby increasing the level of total haemoglobin in diabetic rats. This could 
be due to the result of improved glycemic control produced by Seendhil Sarkkarai at a 
dose of 100mg/kg and 200mg/kg.  
The body weight was decreased in Streptozocin diabetic rats. Seendhil Sarkkarai 
at a dose of 100mg/kg and 200mg/kg increases the body weight in Streptozocin induced 
diabetic rats. The ability of Seendhil Sarkkarai at a dose of 100mg/kg and 200mg/kg to 
protect massive body weight loss seems to be due to its ability to reduce hyperglycemia. 
The level of serum lipids are usually elevated in diabetes mellitus and such an 
elevation represents the risk of coronary heart disease (CHD). Lowering of serum lipids 
concentration through diet or drug therapy seems to be associated with a decrease in the 
risk of vascular disease. The abnormal high concentration of serum lipids in diabetic 
subject is mainly due to increased mobilization of free fatty acids from the peripheral fat 
depots, since insulin inhibits the hormone sensitive lipase. However, glucagon, 
catecholamines and other hormones enhance lipolysis. The marked hyperlipidaemia that 
characterized the diabetic state may therefore be regarded as a consequence of the 
uninhibited actions of lipolytic hormones on the fat depots.  
In the Streptozocin -induced diabetes mellitus, the rise in blood glucose is 
accompanied by an increase in serum cholesterol and triglycerides. The levels of 
cholesterol and triglycerides and Low density lipoprotein (LDL) levels were brought to 
near normal by the treatment with Seendhil Sarkkarai at a dose of 100mg/kg and 
200mg/kg in Streptozocin induced diabetic rats. 
  The effect of Seendhil Sarkkarai at a dose of 100mg/kg and 200mg/kg on 
diabetic hypertriglyceridemia could be through its control of hyperglycaemia. This is in 
agreement with the facts that: 
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1. The level of glycaemic control is the major determinant of total and very low 
density lipoprotein (VLDL), triglyceride, concentrations. Improved glycemic 
control following sulfonylurea therapy decreases the levels of serum VLDL 
and total triglycerides.The main ‘anti-atherogenic’ lipoprotein (HDL) is 
involved in the transport of cholesterol from peripheral tissues into liver and 
thereby it acts as a protective factor against coronary heart disease (CHD). The 
level of HDL-cholesterol was decreased in diabetic rats when compared with 
normal rats. [26] Our results clearly show that the level of HDL-cholesterol was 
increased in Streptozocin induced diabetic rats when treated with Seendhil 
Sarkkarai at a dose of 100mg/kg and 200mg/kg. These results suggest that 
Seendhil Sarkkarai at a dose of 100mg/kg and 200mg/kg has protective 
effect against Streptozocin induced diabetes and its complications. 
As reported earlier (Welihinda et al., 1986) in the current study also the 
liver glycogen content was reduced significantly in diabetic control as 
compared to non-diabetic control. Treatment with Seendhil Sarkkarai at a 
dose of 100mg/kg and 200mg/kg prevented this alteration in glycogen content 
of liver tissue, but could not normalize the content of glycogen of the non-
diabetic control. This prevention or depletion of glycogen in liver is possibly 
due to either stimulation of insulin release from β-cells [28] (Lolitkar et al., 
1966) or due to the insulinomimetic activity of some components of the plants 
resulting in direct peripheral glucose uptake. 
 Decreased enzymatic activity of Hexokinase, Glucokinase and substrate 
glucose-6- phosphate has been reported in diabetic animals resulting in 
depletion of liver and muscle glycogen.  (Hikino et al., 1989) The present 
study also had similar results. Treatment with Seendhil Sarkkarai at a dose of 
100mg/kg and 200mg/kg significantly increased the hexokinase, Glucokinase 
activity and glucose-6-phosphate level in the liver, indicating an overall 
increase in glucose influx thus Seendhil Sarkkarai at a dose of 100mg/kg and 
200mg/kg seems to have an overall effect of increase in glucose utilization. 
Oxidative stress is an imbalance between reactive oxygen species and the 
antioxidant defense mechanisms of a cell or tissue, which leads to lipid 
peroxidation, DNA damage, and the inactivation of many enzymes[30]. The 
enzymatic antioxidant defense system is the natural protector against lipid 
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peroxidation that includes superoxide dismutase, catalase and glutathione 
peroxidase. Reduced activities of these enzymes in the tissue of streptozotocin  
toxic rats were observed in our study. Superoxide dismutase protects against 
the superoxide radical (O2∙−), which damages the membrane and its biological 
structure. Catalase primarily decomposes hydrogen peroxide to H2O at a much 
faster rate, sharing this function with glutathione peroxidase. Glutathione 
peroxidase may play an important role in the removal of lipid hydroperoxides. 
The balance between these enzymes is important for the efficient removal of 
oxygen radicals from tissues[31] Therefore, reduction in the activity of these 
enzymes may result in a number of deleterious effects due to the accumulation 
of superoxide radicals and H2O2. Significant increases in the activities of these 
enzymes were observed on Seendhil Sarkkarai at a dose of 100mg/kg and 
200mg/kg administration.  
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ANNEXURE –III (B) 
ANTIHISTAMINIC AND ANTIANAPHYLACTIC ACTIVITY OF SIDDHA 
FORMULATION OF SEENDHIL SARKKARAI 
 
Introduction 
 
Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent years despite 
an improvement in the general health of the population. Allergic diseases are responsible 
for significant morbidity and have severe economic impact. Various epidemiological 
studies have identified the causes for an increase in the prevalence of upper and lower 
respiratory tract allergic diseases. Some of the postulated reasons are increasing 
environmental pollution and increased predisposition of individuals producing excessive 
IgE through a major change in the gene pool, changing lifestyles, and an increasing 
awareness of the disorders. Intensive research during the last several decades has 
highlighted the role of lymphocytes, immunoglobulins, mast cells, and various autacoids 
in the etiopathogenesis of allergic conditions. Inspite of the voluminous literature on the 
subject, the treatment of allergic diseases continues to be far from satisfactory. The 
available treatment options for upper and lower respiratory tract allergic diseases have 
major limitations owing to low efficacy, associated adverse events, and compliance 
issues.  
 
AYUSH, an Indian system of medicine, has described several drugs from indigenous 
plant sources for use in the treatment of bronchial asthma and allergic disorders. In the 
present study, the effects of Siddha formulation of Seendhil Sarkkarai were studied on the 
active anaphylaxis and mast cell stabilization in rats, and histamine-induced 
bronchospasm in guinea pigs.  
 
Materials and Methods 
 
Animals 
 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either sex housed 
in standard conditions (temperature22 ± 2° C, relative humidity 60 ± 5% and 12 h 
light/dark cycle) were used. They were fed with standard pellet diet and water ad libitum. 
The Institutional Animal Ethics Committee approved the experimental protocol. 
Histamine and horse serum were procured from Sigma Chemicals and toluidine blue from 
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Loba-Chemie, Mumbai. Elisa kit for IgE was supplied by Orion diagnostics, Espoc, 
Finland. All other chemicals and reagents were procured from Hi-Media Laboratories 
limited, Mumbai. 
 
Mast cell stabilizing activity 
 
Treatment protocol 
 
Twenty-four rats were divided into four groups of six animals in each group.  
 
Group I Served as control and received vehicle (water). 
Group II        (Sensitized control group) 
GroupIII       Served as the treatment control, which was treated with Seendhil Sarkkarai 
at a dose of 100mg/kg body weight, in oral route. 
GroupIV        Served as the treatment control, which was treated with Seendhil Sarkkarai 
at a dose of 200 mg/kg body weight, in oral route. 
In group11 to group 1V were sensitized by injecting 0.5 ml of horse serum 
subcutaneously along with 0.5 ml of triple antigen containing 20,000 million Bordetella 
pertussis organisms (Serum Institute of India Ltd.,Pune), Once a day for 14 days.  
On day 14, the rats were sacrificed 2 h after the treatment and the intestinal 
mesentry was taken out for the study on mast cells. Mesentries along with intestinal 
pieces were excised and kept in Ringer Locke solution (NaCl 154, KCl 5.6, CaCl2 2.2, 
NaHCO3 6.0, glucose 5.55 mM/L of distilled water) at 37oC. The mesenteric pieces were 
challenged with 5% horse serum for 10 min after which the mast cells were stained with 
1.0% toluidine blue and examined microscopically for the number of intact and 
degranulated mast cells.[6] 
 
Histamine-induced bronchospasm in guinea pigs 
 
Bronchospasm was induced in guinea pigs by exposing them to 1% histamine 
aerosol under constant pressure (1 kg/cm2) in an aerosol chamber (24 × 14 × 24 cm) 
made of perplex 
Glass,of the three groups of six animals each. 
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Group I          served as control. 
GroupII     served as the treatment control, which was treated with Seendhil Sarkkarai    
at a dose of 100 mg/kg body weight, in oral route. 
Group III    served as the treatment control, which was treated with Seendhil Sarkkarai 
at a dose of 200 mg/kg body weight, in oral route. 
         The animals were exposed to 1% histamine aerosol under constant pressure (1 
kg/cm2) in an aerosol chamber on day 0 without any treatment. The end 
point,preconvulsive dyspnea (PCD) was determined from the time of aerosol exposure to 
the onset of dyspnea leading to the appearance of convulsions.[7] As soon as PCD 
commenced, the animals were removed from the chamber and exposed to fresh air. This 
PCD was taken as day 0 value. On days 1 and 5, 
2 h after the administration of the drug, the time for the onset of PCD was recorded as on 
day 0. 
 
Statistical analysis 
 
The results of various studies were expressed as mean ± SEM and analyzed 
statistically using one-way ANOVA, followed by Newmann keul’s multiple range tests. 
P<0.05 was considered statistically significant.The analysis was performed using 
Graphpad Prism software package (Version 4.0). 
 
RESULTS 
 
Mast cell stabilizing potential of Seendhil SarkkaraiAntigen challenge resulted in 
significant degranulation of the mesentric mast cells. Pretreatment of sensitized animals 
with Seendhil Sarkkaraiat a dose of 100mg/kg and 200mg/kg, p.o., for 2 weeks resulted in 
a significant reduction in the number of disrupted mast cells (P <0.001) when challenged 
with horse serum.  
Effect on Histamine-Induced Bronchospasm 
 
Seendhil Sarkkarai at a dose of 100mg/kg and 200mg/kg p.o., significantly 
prolonged the latent period of PCD (P <0.001) as compared to control, following 
exposure to histamine aerosols on day 5 [Table no. 2]. 
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Discussion 
 
Experimental animal model of asthma is characterized by allergen-induced 
immediate airway constriction and late airway reactivity to a pharmacological 
vasoconstrictor such as histamine and leukotrienes. Histamine is a central mediator in the 
pathogenesis of allergic and inflammatory disorders. In the present study, Seendhil 
Sarkkarai prolonged the latent period of PCD in guinea pigs following histamine aerosol. 
This may be suggestive of an antihistaminic activity following treatment with Seendhil 
Sarkkarai. 
  Antigen challenge, in sensitized animals, results in the degranulation of mast cells, 
which is an important feature of anaphylaxis. In the present study, Seendhil Sarkkarai 
showed marked protection against the mast cell degranulation following antigen 
challenge in sensitized animals. Mast cell stabilizing activity of Seendhil Sarkkarai may 
be attributed to the presence of active constituents which are known for their mast cell 
stabilizing potential against antigen–antibody reaction and/or due to the suppression of 
IgE antibody production, which is responsible for degranulation mast cells.[8]  
This antianaphylactic and antihistaminic effect may be caused by the stabilization 
of the mast cell membrane, suppression of IgE, and inhibition of pathological effects 
induced by the release of inflammatory mediators in Seendhil Sarkkarai treated animals. 
All the above findings lend credence to the beneficial use of Seendhil Sarkkarai in the 
treatment of asthma and related conditions. 
However, further studies with other experimental models, especially to explore the role of 
cytokines are warranted to substantiate the antiasthmatic and antiallergic activity of 
Seendhil Sarkkarai. 
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TABLE NO: 1 
EFFECT OF SEENDHIL SARKKARAI ON MAST CELL STABILIZATION IN 
SENSITIZED RATS 
 
 
 
 
 Values are expressed as Mean±S.E.M 
       *a significantly different from sensitized control at p<0.01 
TABLE NO: 2 
EFFECT OF SEENDHIL SARKKARAI   ON HISTAMINE INDUCED 
BRONCHOSPASM IN GUINEA PIGS. 
 
GROUPS 
PRE-CONVULSION DYSPNEA (PCD)(SEC) 
DAY 0 DAY 1 DAY 5 
GP 1 177.44±7.32 265.17±9.62 217.22±9.62 
GP 2 (Seendhil Sarkkarai 100mg/kg) 184.17±6.42 225.23±6.53 415.23±13.11*a 
GP3  (Seendhil Sarkkarai 200mg/kg) 185.42±6.32 227.30±8.41 410.13±12.32*a 
 
Values are expressed as Mean ±S.E.M 
*a significantly different from control on day 5 at p<0.001 
 
GROUPS 
MAST CELLS 
INTACT DISRUPTED 
Normal Control 85.50±3.48 15.90±0.86 
Sensitized Rats 14.80±0.94 84.34±2.66 
Seendhil Sarkkarai  100mg/kg 67.36±2.88*a 33.30±1.45*a 
Seendhil Sarkkarai  200mg/kg 65.28±2.77*a 33.86±1.54*a 
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ANNEXURE –III (C) 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION OF 
SEENDHIL SARKKARAI 
 
Introduction 
 
Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent years despite 
an improvement in the general health of the population. Allergic diseases are responsible 
for significant morbidity and have severe economic impact. Various epidemiological 
studies have identified the causes for an increase in the prevalence of upper and lower 
respiratory tract allergic diseases. Some of the postulated reasons are increasing 
environmental pollution and increased predisposition of individuals producing excessive 
IgE through a major change in the gene pool, changing lifestyles, and an increasing 
awareness of the disorders. Intensive research during the last several decades has 
highlighted the role of lymphocytes, immunoglobulins, mast cells, and various autacoids 
in the etiopathogenesis of allergic conditions. Inspite of the voluminous literature on the 
subject, the treatment of allergic diseases continues to be far from satisfactory. The 
available treatment options for upper and lower respiratory tract allergic diseases have 
major limitations owing to low efficacy, associated adverse events, and compliance 
issues.  
 
AYUSH, an Indian system of medicine, has described several drugs from indigenous 
plant sources for use in the treatment of bronchial asthma and allergic disorders. In the 
present study, the effects of Siddha formulation of Seendhil Sarkkarai were studied on the 
active anaphylaxis and mast cell stabilization in rats, and histamine-induced 
bronchospasm in guinea pigs.  
 
Materials and Methods 
 
Animals 
 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either sex housed 
in standard conditions (temperature22 ± 2° C, relative humidity 60 ± 5% and 12 h 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION SEENDHIL 
SARKKARAI 
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The anti-inflammatory activities of siddha formulation Seendhil Sarkkarai at a dose of 
100 and 200mg/kg were evaluated using carrageenan-induced paw edema method. The 
inflammation was readily produced in the form of edema with the help of irritant such as 
carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea weed 
(Rhodophyceae) and when injected cause the release of prostaglandins by the way it 
produces inflammation and edema. 
REQUIREMENTS: 
Animal                                : Albino rat (180-200 g) 
Drugs and chemicals          : Carrageenan (1%w/v), Diclofenac sodium (standard), 
                                              Carboxy methyl cellulose (1%w/v), 
                                               Digital plethysmo meter. U G O Basile (Italy) 
Test compounds                :   siddha formulation Seendhil Sarkkarai 
 
METHOD: 
Anti-inflammatory activity was performed by the following procedure of Bhandri et al (1) 
the animals were divided into 4 groups each having six animals. A freshly prepared 
suspension of carrageenan (1% w/v, 0.1 ml) was injected to the planter region of left hind 
paw of each rat. One group was kept as control and the animals of the other groups were 
pretreated with the siddha formulation Seendhil Sarkkarai test Compounds dissolved with 
2 ml sterile water given through orally 30 min before the carrageenan treatment. The paw 
volumes of the test compounds, standard and control groups were measured at 60,240,360 
minutes of carrageenan treatment with the help of Digital plethysmometer (Ugo basile, 
Italy). Mean increase in paw volume was measured and the percentage of inhibition was 
calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc- mean increase in paw volume in control group of rats. 
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TABLE No: 1 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION 
SEENDHIL SARKKARAI 
Treatment Dose (mg/kg) 
Paw volume(ml) as 
measuredby mercury 
displacement at 6 
hour 
Percentage 
inhibition of 
paw edema 
Group I 
Normal saline 10ml/kg orally 5.62±0.96 - 
Group II 
Std 
10mg/kg 
I.P.Diclofenac sodium 1.77±0.43 72.36%*a 
Group III 
Seendhil Sarkkarai 100mg/kg.Orally. 2.12±0.55 67.06%*a 
Group IV 
Seendhil Sarkkarai 200mg/kg.Orally.  1.99±0.47 69.04%*a 
 
* Data are expressed as Mean ± S.E.M. 
* Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple range 
tests, to determine the significance of the difference between the control group and rats 
treated with the test compounds. 
* A Values were significantly different from normal control at P< 0.01. 
 
Results 
Anti- inflammatory activity 
 
Both doses of siddha formulation Seendhil Sarkkarai at 100mg/kg and 200mg/kg 
were tested for their Anti- inflammatory activity by using carrageenan Induced rat paw 
edema method and the results are tabulated in table no 1.  The results reveals that   both 
doses of siddha formulation Seendhil Sarkkarai at 100mg/kg and 200mg/kg doses 
possesses significant Anti- inflammatory activity when compared to control group at 
p<0.01. 
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ANNEXURE –III (D) 
ANALGESIC ACTIVITY OF SIDDHA FORMULATION OF SEENDHIL 
SARKKARAI 
 
Introduction 
 
Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent years despite 
an improvement in the general health of the population. Allergic diseases are responsible 
for significant morbidity and have severe economic impact.Various epidemiological 
studies have identified the causes for an increase in the prevalence of upper and lower 
respiratory tract allergic diseases. Some of the postulated reasons are increasing 
environmental pollution and increased predisposition of individuals producing excessive 
IgE through a major change in the gene pool, changing lifestyles, and an increasing 
awareness of the disorders. Intensive research during the last several decades has 
highlighted the role of lymphocytes, immunoglobulins, mast cells, and various autacoids 
in the etiopathogenesis of allergic conditions. Inspite of the voluminous literature on the 
subject, the treatment of allergic diseases continues to be far from satisfactory. The 
available treatment options for upper and lower respiratory tract allergic diseases have 
major limitations owing to low efficacy, associated adverse events, and compliance 
issues.  
 
AYUSH, an Indian system of medicine, has described several drugs from indigenous 
plant sources for use in the treatment of bronchial asthma and allergic disorders. In the 
present study, the effects of Siddha formulation of Seendhil Sarkkarai were studied on the 
active anaphylaxis and mast cell stabilization in rats, and histamine-induced 
bronchospasm in guinea pigs.  
 
Materials and Methods 
 
Animals 
 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either sex housed 
in standard conditions (temperature22 ± 2° C, relative humidity 60 ± 5% and 12 h  
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ANALGESIC ACTIVITY 
             Analgesic activity of siddha formulation Seendhil Sarkkarai was evaluated by 
acetic acid induced writhing reflux in mice. Painful reaction in animals may be produced 
by the chemicals such as phenylquinone, bradykinin etc.  Like that, acetic acid pain 
reaction which is characterized as a writhing response. Construction of abdomen, turning 
of trunk (twist) and extension of hind legs are taken as reaction to chemically induced 
pain. Analgesics (both narcotic and non-narcotic) inhibit writhing response. 
REQUIREMENTS: 
Animal                                : Swiss albino mice (20-25g) either sex 
Drugs and chemicals          : Diclofenac sodium (standard), 
                                              Acetic acid (1%v/v), Seendhil Sarkkarai 
METHOD: 
TREATMENT PROTOCOL 
Group-1:   Treated as normal control received 10ml/kg of normal saline through orally. 
Group-2:  Treated as Standard control received 10mg/kg of diclofenac sodium through                     
Intraperitonealy. 
Group-3: Treated as treatment control received 100mg/kg of Seendhil Sarkkarai 
administered through orally.                                     
Group-4: Treated as treatment control received 200mg/kg of Seendhil Sarkkarai 
administered through orally.                           
                         Siddha formulation Seendhil Sarkkarai was administered one hour prior 
to the acetic acid administration. Note the onset on writhing. Record the numbers of 
abdominal contractions, trunk twist and extension of hind limbs as well as the number of 
animals showing such response during a period of 10 minutes were noted. 
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STATISTICS: 
          Data are expressed as mean ± SEM; data analyzed by one way ANOVA 
followed by Newman’s keul’s multiple range tests to determine the significance of the 
difference between the control group and rats treated with the extracts. 
  *   Values were considered significant at P< 0.01. 
TABLE No:1 
ANALGESIC ACTIVITY OF SEENDHIL SARKKARAI BY ACETIC ACID 
INDUCED WRITHING REFLUX IN MICE 
Treatment Dose (mg/kg) No. of writhing 
% reduction in 
reaction time 
Group I 
Normal saline 
Inject 1%v/v acetic 
acid 1ml/100g of 
body weight 
48.5±2.83 - 
Group II 
Std 
10mg/kg  
I.P.Diclofenac 
sodium 
        16.5±0.81 92.13%** 
Group III 
Seendhil Sarkkarai 
100mg/kg 
Administered 
through orally. 
23.5±1.51 76.55%** 
Group IV 
Seendhil Sarkkarai 
200mg/kg 
Administered 
through orally  
21.8±1.24 79.37%** 
 
Values are expressed as mean±SEM 
Values were find out by using one-way ANOVA followed by Newman’s keuls multiple 
range tests. 
**   Values were considered significant at P< 0.01. 
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RESULTS 
The table values show that analgesic activity of Seendhil Sarkkarai by acetic acid induced 
writhing reflex. The results reveals that both dose of Seendhil Sarkkarai possess 
significant analgesic activity at p<0.01.  
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ANNEXURE –III (E) 
ANTIHISTAMINIC AND ANTIANAPHYLACTIC ACTIVITY OF SIDDHA 
FORMULATION OF SEENDHIL SARKKARAI 
 
Introduction 
 
Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent years despite 
an improvement in the general health of the population. Allergic diseases are responsible 
for significant morbidity and have severe economic impact. Various epidemiological 
studies have identified the causes for an increase in the prevalence of upper and lower 
respiratory tract allergic diseases. Some of the postulated reasons are increasing 
environmental pollution and increased predisposition of individuals producing excessive 
IgE through a major change in the gene pool, changing lifestyles, and an increasing 
awareness of the disorders. Intensive research during the last several decades has 
highlighted the role of lymphocytes, immunoglobulins, mast cells, and various autacoids 
in the etiopathogenesis of allergic conditions. Inspite of the voluminous literature on the 
subject, the treatment of allergic diseases continues to be far from satisfactory. The 
available treatment options for upper and lower respiratory tract allergic diseases have 
major limitations owing to low efficacy, associated adverse events, and compliance 
issues.  
 
AYUSH, an Indian system of medicine, has described several drugs from indigenous 
plant sources for use in the treatment of bronchial asthma and allergic disorders. In the 
present study, the effects of Siddha formulation of Seendhil Sarkkarai were studied on the 
active anaphylaxis and mast cell stabilization in rats, and histamine-induced 
bronchospasm in guinea pigs.  
 
Materials and Methods 
 
Animals 
 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either sex housed 
in standard conditions (temperature22 ± 2° C, relative humidity 60 ± 5% and 12 h 
ACUTE TOXICITY STUDY OF SEENDHIL SARKKARAI 
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Determination of acute oral toxicity is usually the initial screening step in the assessment 
and evaluation of the toxic characteristics of all compounds. The types of toxicity tests 
which are routinely performed by pharmaceutical manufacturers in the investigation of a 
new drug involve acute, sub-acute and chronic toxicity. Acute toxicity is involved in 
estimation of LD50 (the dose which has proved to be lethal (causing death) to 50% of the 
tested group of animals) (Shetty Akhila, et al., 2007).(1) 
 
Method: Acute oral toxicity of Seendhil Sarkkaraiis carried out as per the guidelines 
Organization of Economic Co-operation and Development (OECD) -423 guidelines after 
the animal ethical clearance from Institutional Animal Ethics Committee.  
The albino mice are fasted overnight and provided only water, after which the 
Seendhil Sarkkaraiis administered by gastric intubations to the relevant group of 
animals orally at the dose of 50 mg.kg-1 body weight in Tween-80. The animals are then 
observed for 14 days and maintained with normal food. A mortality rate of 2 or 3 animals 
in 14 days is recorded and the dose is said to be toxic dose. But when mortality of one 
animal is observed, then the same dose is repeated again for confirmation. However, if 
mortality is not observed, the procedure is repeated for further higher doses such as 300 
and 2,000 mg.kg-1 body weight. Toxic symptoms are observed for 72 hrs including 
behavioral changes, locomotion, convulsions and mortality (Shah Ayub, 1997, Bürger, 
2005). (2,3). 
Cage Side Observations 
 Observations include changes in skin and fur, eyes and mucous membranes, and 
also respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Special attention is directed for the observation of tremors, 
convulsions, salivation, diarrhea, lethargy, sleep and coma. 
Body Weight, Food and Water Intake 
 Body weight, food and water intake are recorded at two day intervals.  
Pathology 
 Surviving animals are fasted overnight, weighed and humanely killed on the 15th 
day using anesthetic ether. All test animals are subjected to gross necropsy. 
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SUBCHRONIC TEST FOR SEENTHIL SARKKARAI 
This experiment evaluates the toxicity potential of Seenthil Sarkkarai. 
Method: Male and female Wistar rats weighing 180 ± 10 g are used for the present study. 
The animals are divided into five groups of six animals each. The dose of the preparation 
is calculated based on the body weight of the animal.   The animals in Group I are 
administered with a single daily dose of 0.5 ml of Tween 80 orally for 20 days. The 
animals in Group II are administered with 50 mg.kg-1b.w. of the Seenthil Sarkkaraiorally 
once daily for 20 days. The animals in Group III are administered with 100 mg.kg-1b.w. 
of the Seendhil Sarkkaraiorally once daily for 20 days. The animals in Group IV and V 
are administered once daily with 200 and 400 mg.kg-1b.w. of the Seendhil 
Sarkkarairespectively for 20 days orally (Pieme,et al 2006, Joshi, et al 2007, 
Mythilypriya, et al., 2007).(4,5,6)The animals are then weighed every five days, from the 
start of the treatment, to record the weight variation. At the end of the treatment, blood 
samples are collected by puncturing retro orbital plexus after mild anesthesia for 
biochemical analysis. The collected blood sample is centrifuged within 5 min of 
collection at 4000 g for 10 min to obtain plasma, which is analyzed for total cholesterol, 
total triglyceride, HDL-cholesterol levels,LDL-cholesterol,plasma glucose, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and urea. 
RESULTS 
ACUTE TOXICITY STUDY WITH SEENTHIL SARKKARAI 
 The acute toxicity of Seenthil Sarkkarai was evaluated using OECD-423 
guidelines. There was no mortality or morbidity observed in animals through the 15 days 
period following single oral administration at all selected dose levels of the Seenthil 
Sarkkarai (Table-1).   The animals did not show any changes in the general appearance 
during the observation period. Morphological characteristics such as fur, skin, eyes and 
nose appeared normal. No tremors, convulsion, salivation, diarrhea, lethargy or unusual 
behaviors such as self mutilation, walking backward and so forth were observed.   Gait 
and posture, reactivity to handling or sensory stimuli, grip strength was also normal. 
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 Dose (mg.kg-1) Sign of Toxicity (ST. NB-1) Mortality (D.S
-1) 
Group I 0 0/3 0/3 
Group II 300 0/3 0/3 
Group III 2000 0/3 3/3 
 
Table 1.  
Acute toxicity study of Seendhil Sarkkarai on experimental mice. The acute toxicity of 
Seendhil Sarkkarai on experimental mice was tested using OECD-423 guidelines, where 
ST- sign of toxicity; NB- normal behavior; D- died; S- survive.  Values are expressed as 
number of animals (n=3). 
Effect of Seendhil Sarkkarai in Subchronic Toxicity  
Seenthil Sarkkarai was evaluated for subchronic toxicity. 
Effect of Seendhil Sarkkarai on body weight changes in rats 
The effect of Seenthil Sarkkarai was observed for their effect on the body weight changes 
from the study it was observed that, there was significant increase (p<0.05) in body 
weight in all the animals observed.   The results are shown in Table.2. 
Treatment Day 1 Day 5 Day 10 Day 20 
Control 179.19±5.4 180.40  ±6.12 189.10 ±6.30 189.6±6.30 
Seenthil Sarkkarai 
50 mg.kg-1 
186.34 ±6.2 189.30  ±6.44 190.48 ±6.75 190.30±6.84* 
Seenthil Sarkkarai 
100 mg.kg-1 
179.36 ±6.0 186.43  ±6.42 188.30  ±6.54 190.84±6.70* 
Seenthil Sarkkarai 
200 mg.kg-1 
188.25  ±7.0 190.20±6.34 190.48  ±6.58** 198.35±6.72** 
Seenthil Sarkkarai 
400 mg.kg-1 
179.54  ±6.34 186.35  ±6.65 188.15  ±6.65** 196.52±6.74** 
 
Table.2  
The effects of Seendhil Sarkkarai on body weight changes in rats. A study on the effects 
of Seendhil Sarkkarai on body weight changes in rats was carried out... where, group I 
animals (GPI) were treated with normal saline (5ml.kg-1), group II animals (GPII)with 50 
mg.kg-1 of Seenthil Sarkkarai,group III animals (GPIII) with 100 mg.kg-1 of Seenthil 
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Sarkkarai, group IV animals (GPIV) with 200 mg.kg-1 of Seenthil Sarkkarai, group V 
animals (GPV) with 400 mg.kg-1 Seenthil Sarkkarai. The values are expressed as mean 
± S.E.M. n=6. The results of group I were compared with other groups such as II, III, IV, 
and V.   The statistical analysis was carried out using one way ANOVA method, where 
**P<0.01 *P<0.05. 
Effect of Seendhil Sarkkarai on kidney,heart, liver and brain in rats. 
The effects of Seendhil Sarkkarai on kidney, heart, liver and brain of the rats were 
observed. From the study it was clear that, significant (p<0.01) changes in the weights of 
various organs of the animals occurred with higher doses of the extract (400 mg.kg-1bwt), 
but macroscopic examinations did not show any changes in colour of the organs of the 
treated animals compared with the control.   The results are shown in Table.3. 
Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms)   
Control 0.34 ± 0.04 0.72± 0.03 3.32± 0.14 0.72± 0.05 
Seendhil Sarkkarai@ 
50 mg.kg-1 
0.36± 0.05 0.82± 0.05 3.42± 0.19 0.70± 0.03 
Seendhil Sarkkarai@ 
100 mg.kg-1 
0.39± 0.06 0.82± 0.04 3.44±0.21 0.68± 0.08 
Seendhil Sarkkarai@ 
200 mg.kg-1 
0.34± 0.03 0.75± 0.02 3.36± 0.22 0.76± 0.09 
SeendhilSarkkarai@ 
400 mg.kg-1 
0.37± 0.05 0.74± 0.02 3.38± 0.15 0.75± 0.12 
 
Table.3  
The effects of Seenthil Sarkkarai on kidney, heart, liver and brain of the rats. A study on 
the effects of Seenthil Sarkkarai on kidney, heart, liver and brain of the rats was tested. 
where, group I animals (GPI) treated with normal saline (5 ml.kg-1), group II animals 
(GPII)  with 50 mg.kg-1 of Seenthil Sarkkarai,  group III animals (GPIII)   with 100 
mg.kg-1 of Seenthil Sarkkarai, group IV animals (GPIV)   with 200 mg.kg-1 of Seenthil 
Sarkkarai, group V animals (GPV)  with 400 mg.kg-1 Seenthil Sarkkarai.  The values 
are expressed as mean ± S.E.M. n=6.   The results of group I were compared with other 
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groups such as II, III, IV, and V.  The statistical analysis was carried out using one way 
ANOVA method, where **P<0.01. 
Effect of Seendhil Sarkkarai on biochemical profiles of rats 
 
The effect of Seendhil Sarkkarai on various biochemical parameters of the experimental 
animal ‘rats’ were tested. From the study it was evident that, there was significant 
decrease (p<0.05) in the plasma glucose level in treated rats especially at higher dose 
(400 mg.kg-1) compared with control rats.   The control rats were administered only with 
5 ml of normal saline. Significant decrease (p<0.05) in the plasma total cholesterol (TC), 
triglyceride (TG) and LDL-cholesterol levels were observed.   But a significant increase 
(p<0.05) in HDL-cholesterol levels were observed in all the treated animals compared 
with the control animals. AST, ALT and ALP levels were also normal in the Seendhil 
Sarkkarai treated animals. From the results of biochemical study there was no evidence 
of severe toxicity associated with the administration of higher concentration of Seenthil 
Sarkkarai. The results are shown in Table.4. 
 
 
 
Treatment Glucose (mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 99.42±1.74 34.05± 0.62 33.25±1.43 143.45±3.15 90.30±1.85 
Seendhil Sarkkarai@ 
50 mg.kg-1 
97.50±1.62 30.30± 0.36* 16.36± 0.85* 181.40±3.65* 75.75±1.38 
Seenthil Sarkkarai@ 
100 mg.kg-1 
95.44±1.52 28.65± 0.30* 18.32± 0.90* 170.30±3.40* 74.54±1.30 
Seendhil Sarkkarai@ 
200 mg.kg-1 
94.30±1.35** 29.20± 0.38 20.40± 0.92* 189.34±3.70* 51.52±1.18 
Seendhil Sarkkarai@ 
400 mg.kg-1 
97.28±1.43** 35.45± 0.48 23.30±1.15* 187.24±3.66* 50.30±1.05 
 
 
Table.4 
The effect of Seendhil Sarkkarai on biochemical parameters such as glucose, 
cholesterol, triglyceride, HDL and LDL. A study on the  effect of Seenthil Sarkkarai on 
biochemical parameters such as glucose, cholesterol, triglyceride, HDL and LDL in rats 
was tested. Where, group I animals (GPI) treated with normal saline (5 ml.kg-1), group II 
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animals (GPII)  with 50 mg.kg-1 of Seenthil Sarkkarai,  group III animals (GPIII)  with 
100 mg.kg-1 of Seenthil Sarkkarai, group IV animals (GPIV)  with 200 mg.kg-1 of, 
group V animals (GPV)   with 400 mg.kg-1 Seenthil Sarkkarai. The values are expressed 
as mean ±S.E.M. n=6.   The results of group I were compared with other groups such as 
II, III, IV, and V.  The statistical analysis was carried out using one way ANOVA 
method, where **P<0.01 *P<0.05 
 
Treatment 
AST 
(IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMIN 
(g.l-1) 
Control 330.3±11.60 75.4± 3.42 255.35± 8.60 73.36± 3.31 43.30±2.45 
Seenthil Sarkkarai@ 
50 mg.kg-1 
320.4±10.52** 73.3±2.90** 267.15±8.75** 73.30±3.20 40.24±2.30 
Seenthil Sarkkarai@ 
100 mg.kg-1 
319.5±10.60** 70.3±2.92** 268.38±8.30** 83.12±3.80 41.30±2.45 
Seendhil Sarkkarai@ 
200 mg.kg-1 
318.5±9.90 67.3± 2.38 268.20±8.36 74.35± 3.65 42.28±2.46 
Seendhil Sarkkarai@ 
400 mg.kg-1 
320.4±9.94 67.6±2.45 268.42±8.44 75.30± 3.75 42.64±2.50 
 
Table.5 
The effects of Seendhil Sarkkarai on biochemical parameters such as AST, ALT, ALP, 
TP and Albumin in rats. A study on the effects of Seendhil Sarkkarai on biochemical 
parameters such as AST, ALT, ALP, TP and Albumin rats was tested. where, group I 
animals (GPI)  were treated with normal saline (5ml.kg-1),  group II animals (GPII) with 
50 mg.kg-1 of HAEBD group III animals (GPIII)  with 100 mg.kg-1 of Seenthil 
Sarkkarai, group IV animals (GPIV)  with 200 mg.kg-1 of Seenthil Sarkkarai,  and 
group V animals (GPV)  with 400 mg.kg-1 Seendhil Sarkkarai The values are expressed 
as mean ± S.E.M. n=6.   The results of group I were compared with other groups such as 
II, III, IV, and V.   The statistical analysis was carried out using one way ANOVA 
method, where **P<0.01 *P<0.05. 
Effect of Seendhil Sarkkaraion haematological parameters in rats   
The effects of Seenthil Sarkkarai were observed for its effect on haematological 
parameters on the experimental rats. From the study it was evident that, a significant 
increase (p<0.01) were observed in the haemoglobin contents and  RBC count  in the 
group treated with 200 mg.kg-1 body weight of Seenthil Sarkkarai and a significant 
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decrease of the parameters occurred in the group treated with 400 mg.kg-1 b.w.t compared 
with the control.   There was no significant change in the calcium level in all the treated 
animals compared to the control. 
Treatment Haemoglobin (mg.dl-1) 
RBC 
(106 /mm3) 
WBC 
(106 /mm3) 
Calcium 
(mg.dl-1) 
Control 13.53±1.28 9.27± 0.93 11.54± 0.90 9.43 ±0.60 
Seendhil Sarkkarai@  
50 mg.kg-1 
14.37±1.35* 9.35±1.05* 9.33± 0.82* 9.25 ±0.38 
Seendhil Sarkkarai@ 
100 mg.kg-1 
14.22±1.84* 9.48±1.20* 8.32± 0.28* 9.27 ±0.45 
Seenthil Sarkkarai@ 
200 mg.kg-1 
13.25±1.25* 8.37± 0.85* 11.56± 0.83* 9.55 ±0.56 
Seenthil Sarkkarai@  
400 mg.kg-1 
13.21±1.23* 8.46± 0.92* 10.83±0.75* 9.64 ±0.64 
 
 
Table.6 
The effect of Seendhil Sarkkarai on haematological parameters such as HB, Calcium, 
RBC and WBC in rats. A study on the effect of Seendhil Sarkkarai on haematological 
parameters such as Hb, RBC, WBC, and Calcium in rats was tested. where, group I 
animals (GPI) treated with normal saline (5 ml.kg1), group II animals (GPII)  with 50 
mg.kg-1 of Seenthil Sarkkarai,  group III animals (GPIII)   with 100 mg.kg-1 of Seenthil 
Sarkkarai,   group IV animals (GPIV)   with 200 mg.kg-1 of Seenthil Sarkkarai, and  
group V animals (GPV)  with 400 mg.kg-1 Seenthil Sarkkarai. The values are expressed 
as mean ± S.E.M. n=6. The results of group I were compared with other groups such as II, 
III, IV and V.   The statistical analysis was carried out using one way ANOVA method, 
where *P<0.05. 
Discussion 
The evaluation of sub-chronic and chronic dosing in experimental animals may be 
more relevant in determining the overall toxicity of the plant preparation.  The highest 
overall concordance of toxicity in animals in comparison with humans is with 
hematological, gastrointestinal, and cardiovascular adverse effects whiles certain adverse 
effects in humans, especially hypersensitivity and idiosyncratic reactions, are poorly 
correlated with toxicity observed in animals (Olson, et al., 2000).(7) 
In the present study, where the acute toxicity study of Seendhil Sarkkarai was 
carried out as per OECD-423 guidelines,no mortality was observed in both the animals of 
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control group as well as animals treated with a maximum dose of 2000 mg.kg-1.   Hence, 
1/10th of 2000 mg.kg-1 i.e. 200 mg.kg-1 of dose was selected as a minimum dose for sub-
acutetoxicity study (Abu TahaNael, et al., 2008).(8) 
The results of sub-acute toxicity study shows that there was no significant change 
in animal behaviour due to the absence of toxicity.   The animals treated with Seendhil 
Sarkkarai showed normal growth pattern and body weight compared with control rats 
treated with normal saline. So the changes in body weight can be used as an indicator of 
adverse effects of drugs and chemicals (Tofovic and Jackson, 1999; Raza, et al., 2002; 
Teo, 2002).(9,10,11)  
The changes in enzymes like ALP, AST and ALT levels show liver impairment, 
due to toxicity (Hayes, 1989).(12)   Serum cholesterol and proteins mainly regulated via 
synthesis in the liver and increase or decrease in serum concentrations of constituents 
suggest liver toxicity.   The results of the present study were assessed after 28 days of 
administration of Seenthil Sarkkarai, and it was found that Seendhil Sarkkarai at all 
concentrations do not produce liver damage. 
There was a slight decrease in plasma glucose level, when higher doses of 
Seendhil Sarkkarai (400 mg.kg-1) were administered in the treated rats.. 
Analysis of blood parameters is likely to risk evaluation as the change in 
hematological system has a higher predictive value for human toxicity, when data are 
translated from animal studies (Olson, et al., 2000).(7)   After 28 days of treatment, there 
were no significant changes in the haematological parameters between control and treated 
groups.   No significant changes in the levels of WBC, RBC were observed between 
control and test groups following repeated administration of Seenthil Sarkkarai. 
Interestingly, significant increase in the levels of hemoglobin was found in treatment with 
Seendhil Sarkkarai with a higher dose of 400 mg.kg-1. The possible reason could be that 
one of the constituents Seendhil Sarkkarai may increase absorption of iron.  
The overall results suggest that Seendhil Sarkkaraiare nontoxic to the 
haaematopoietic and leucopoietic system.   The haematopoietic and leucopoietic systems 
are the most sensitive targets for toxic compounds and an important index of 
physiological and pathological status in man and animal (Adeneye, et al., 2006).(13)   
Therefore, it is possible to assume that the Seenthil Sarkkarai is non haematotoxic. 
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ANNEXURE- IV (A) 
MICROBIOLOGICAL EXAMINATION OF SEENTHIL SAKKARAI 
Evaluation of Total Aerobic Bacterial Count 
1.1.Preparation of  Sample for Experimental Work 
  Weighed 10 gm of the homogenized drug sample aseptically and dissolved 
in 10 ml of sterile water and made up to 100 ml with the sterile water. The 
insoluble drug product was suspended in 100 ml of buffered sodium chloride-
peptone solution (pH 7.0).   
1.2.Serial dilution of Sample 
 A serial dilution is the dilution of a sample, in 10-fold dilutions. From the sample, 1 
ml of the sample was added to 9 ml of sterile distilled water and mixed it well. This 
dilution was denoted as 10-1 dilution. From this dilution, one ml was taken from that 
mixture is added to 9 ml, and designated as 10-2 dilution. The same procedure was 
repeated up to 10-4. 
1.3. Isolation of Total Viable Aerobic Microbial Count 
1.3.1. Isolation of Bacteria by Plate Count Method 
 In this test, the bacteria in sample were made to grow as colonies, by 
inoculating a known volume of sample into a solidifiable nutrient medium (Casein 
Soybean Digest agar or Nutrient agar medium) in petridish. The agar plate was 
prepared by mixing growth medium with agar and then sterilized by autoclaving. 
Once the agar was cooled to 45oC, approximately 15 to 20 ml of medium was 
poured into a sterile Petri dish under aseptic condition and left to solidify for 15 
minutes. After solidification, each plate was smear with 0.1 ml of sample from the 
dilution of 10-1 and 10-2. After inoculations, all the plates were incubated at 37oC 
for 24 hours. After incubation, the bacterial colonies were developed as visible to 
the naked eye and the number of colonies on a plate was counted using Quebec 
Colony Counter. Plates with an average of from 30 to 300 colonies of the target 
bacterium were selected for colony count. Because of the statistical problems, 
plates with lower than 30 colonies greater than 300 colonies were rejected     
1.3.1.1. Composition of Nutrient Agar Media 
Peptone   : 5.0 gm  
Sodium chloride  : 5.0 gm  
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Beef extract   : 1.5 gm 
 Yeast extract   : 1.5 gm 
Agar    : 15.0 gm 
Distilled water   : 1000 ml  
 pH ( at 25°C)    : 7.4±0.2 
 
1.3.2. Isolation of Fungi 
From each of the above prepared samples, 0.1 ml of sample was 
transferred to Sabouraud Dextrose agar (SDA) prepared with Chloramphenicol. 
The plates were then incubated for 5 days at room temperature (20 to 25°C). After 
incubation, the fungal colonies were observed and calculated.   
1.3.2.1. Composition of SDA 
Dextrose   ; 40 gm 
Peptone   : 10 gm 
Agar   : 15 gm 
Distilled water  : 1000 ml 
1.4. Evaluation of Antimicrobial Activity of Drug 
  Antimicrobial activity was performed by agar well diffusion method on 
agar. 
1.4.1 Preparation of drug extracts solutions for the experiment  
The dried drugs were weighed and dissolved in sterile distilled water to prepare 
appropriate dilution to get required concentrations of about 10, 20 and 30µg/ml. They 
were kept under refrigerated condition unless they were used for the experiment. 
 1.4.2. Procedure for the Agar Well Diffusion Test 
 The antibacterial screening of the drugs were carried out by determining the zone 
of inhibition using agar well diffusion method. All the drug extracts were tested against 
four pathogenic bacterial strains of gram positive and gram negative organism by agar 
well diffusion method. 
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1.4.3. Bacterial Inoculums Preparation 
 Inoculums of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, 
Proteus vulgaris, and Bacillus substilis were prepared in nutrient broth medium and kept 
for incubation at 37°C for 8 hrs. 
1.4.4. Agar well-diffusion method  
This method was followed to determine the antimicrobial activity. Muller-Hinton 
Agar media plates were swabbed (sterile cotton swabs) with 8 hour old - broth culture of 
respective bacteria. After inoculation, wells with the size of 10 mm diameter and about 2 
cm a part were made in each of these plates using sterile cork borer. Stock solution of 
each drug extract was prepared at a concentration of 1 mg/ml in water. About 100 µl of 
different concentrations of drug solvent extracts were added into the wells and allowed to 
diffuse at room temperature for 2 hrs. The plates were incubated at 37°C for 24 hrs. After 
incubation, the diameter of the inhibition zone (mm) was measured and the activity index 
was also calculated.  
 1.4.4.1. Composition of Muller Hinton Agar Media 
 Beef Extract     : 02.00 gm 
 Acid Hydrolysate of Casein   : 17.50 gm 
 Starch      : 01.50 gm 
 Agar     : 17.00 gm 
 
1.5. Evaluation of Specified Microorganisms  
        1.5.1. Isolation & Identification of Escherichia coli 
One ml of the prepared sample was added in a sterile screw-capped container 
containing 50 ml of nutrient broth and mixed well. Then, it was allowed to stand for 1 
hour and mixed well again. After one hour, the screw caps of the bottle was loosened and 
incubated at 37º for 18 to 24 hours. 
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  1.5.2. Primary Test 
From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into a tube containing 5 ml of Mac- Conkey broth. Inoculated tubes were 
incubated in a water-bath at 36º to 38º for 48 hours.  
 1.5.3. Secondary Test 
From the primary test, 1.0 ml of the enrichment culture was taken and transferred 
aseptically in to 5 ml of peptone water. It was then incubated in a water-bath at 43.5º to 
44.5º C for 24 hours and observed the tubes for acid and gas. Then, the culture was 
subjected to biochemical tests of imvic and the results were observed and correlated.       
1.5.4. Alternative test  
It was done by a loop full of enriched culture in the primary test was streaked on a 
sterile Mac-Conkey agar medium. Then, the plates were inverted and incubated at 37 º C 
for 24 hours. After incubation, the pink or brick red color colonies were examined and 
transfer them individually into the surface of Eosin Methylene Blue agar medium (EMB), 
on Petri dishes. Inoculated plates were inverted and incubated at 37 º C for 24 hours. 
After incubation, the colonies on medium were checked for their color appearance like 
green metallic sheen under reflected light. The colonies were subjected to confirmation 
by further suitable cultural and biochemical tests. 
1.5.5. Components of Eosin Methylene Blue Agar Media 
Pancreatic digest of gelatin   : 10.0 g 
Dibasic potassium phosphate    : 2.0 g 
Lactose      : 10.0 g 
Eosin Y      : 400 mg 
Methylene blue    : 65 mg 
Agar       : 15.0 g 
Distilled water      : 1000 ml 
 
 193 
 
1.5.2. Isolation & Identification of Salmonella sp.  
One ml of the prepared sample was added in a sterile screw-capped container 
containing 100 ml of nutrient broth and mixed well. Then, it was allowed to stand for 1 
hour and mixed well again. After one hour, the screw caps of the bottle was loosened and 
incubated at 37º for 18 to 24 hours. 
1.5.2.1. Primary Test  
From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into a tube containing 10 ml of Selenite F broth. Inoculated tubes were 
incubated in a water-bath at 36º to 38º for 48 hours. After incubation, the culture was 
subcultured on two of the agar media namely Bismuth sulphate agar and Deoxy cholate 
citrate agar and incubated the plates at 36º to 38º for 18 to 24 hours. After incubation, 
colonies were observed on the medium and confirmed the genus Salmonella based on 
guidelines. 
1.5.2.2. Secondary test 
The suspected colonies of the primary test were subcultured on the slant of triple 
sugar-iron agar in test tube and in urea broth. Both media were incubated at 37ºC for 24 
hours. After incubation, the results were observed according to the development of color 
change and acid / gas in media.  The presence of Salmonella was confirmed by 
agglutination tests. 
1.5.2.3. Composition of Salmonella Shigella Agar Media 
Beef Extract     : 5.0 gm 
Enzymatic Digest of Casein   : 2.5 g 
Enzymatic Digest of Animal Tissue  : 2.5 gm 
Lactose     : 10 gm 
Bile salts     : 8.5 gm 
Sodium Citrate     : 8.5 gm 
Ferric Citrate     : 1.0 gm 
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Brilliant Green    : 0.00033 gm 
Neutral Red     : 0.025 
Agar      : 13.5 gm 
Distilled water     : 1000 ml 
  
1.5.3. Isolation and Identification of Pseudomonas aeruginosa  
From the above prepared enrichment culture, 1.0 ml was taken and transferred 
aseptically into 100 ml of fluid soyabean-casein digest medium and mixed well.  The 
inoculated tubes were incubated at 37º C for 24 hours. After incubation, the growth of 
bacteria was checked. From this, a loop full of culture was streaked on the surface of 
Cetrimide agar medium and Pseudomonas Isolation Agar medium and incubated at 
incubated at 37º C for 24 hours. After incubation, the colonies from the agar surface of 
these two media were checked for detection of fluorescein and pyocyanin. 
 
1.5.3.1. Composition of Cetrimide Agar Media 
Pancreatic digest of gelatin   : 20.0 g 
Magnesium chloride    : 1.4 g 
Potassium sulphate    : 10.0 g 
Cetrimide     : 0.3 g 
Agar      : 13.6 g 
Glycerin     : 10.0 g 
Distilled Water t    : 1000 ml 
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1.5.4. Isolation and Identification of Staphylococcus aureus 
From the above prepared enrichment culture, a loop full of culture was taken and 
transferred aseptically on Mannitol salt agar and incubated at 37º C for 24 hours.. After 
incubation, the colonies were subjected to confirmation by hem agglutination test. 
 
 
1.5.4.1. Composition of Mannitol Salt Agar Media 
Pancreatic digest of gelatin   : 5.0 g 
Peptic digest of animal tissue  : 5.0 g 
Beef extract     : 1.0 g 
D-Mannitol     : 10.0 g 
Sodium chloride    : 75.0 g 
Agar      : 15.0 g 
Phenol red     : 25 mg 
Distilled Water    : 1000 ml 
 
Microbial Limit Tests 
Table 1: Results of Microbial Contamination Test 
S.No. Test Particulars 
Colony Counts 
(CFU/ g) 
Limits Value 
(CFU/g) 
1. Total  Viable Aerobic Bacterial Count 13 x 102 1 x 105 
2. Total  Viable Fungal Count No growth 1 x 103 
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Table 2: Results of Specific Pathogens Test  
S.No. Test for Specified Pathogens 
Colony Counts 
(CFU/ g) 
Limits Value 
(CFU/g) 
1. Salmonella sp.  No growth - 
2. Staphylococcus aureus No growth - 
3. Escherichia coli No growth - 
4. Pseudomonas aeruginosa No growth - 
 
 
 
Table 3: Antimicrobial Activities of Drug by Agar Well Diffusion Method 
S.No. Test Pathogens Result 
Zone of Inhibition (mm) at 30µl 
Positive Control 
(Gentamycin) 
Size of Inhibition 
1. Escherichia coli Sensitive  26 mm 23 mm 
2 Proteus sp. Sensitive 23 mm 20 mm 
3 Staphylococcus aureus Sensitive  23 mm 20 mm 
4 Pseudomonas aeruginosa Sensitive 22 mm 21 mm 
5. Salmonella typhi Sensitive 21 mm 19 mm 
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RESULTS AND DISCUSSION 
The Results of the microbiological analysis for microbial contamination of the 
drug Seenthil Sakkarai was given in Table 1. The total viable aerobic bacterial counts on 
Nutrient agar plate was 13 x 102 CFU / g and the fungal count on SDA agar plates was 
NIL growth CFU/ g. This results were found to comply with the specification limit for 
total bacterial count i.e. NMT 1× 105 CFU/ml and total fungal count i.e. NMT 1× 103 
CFU/ml (Protocol for testing Ayurveda, Siddha and Unani medicines). 
The analytical screening of sample showed in Table 2 that the product is free from 
specific pathogen like Escherichia coli, Proteus sp., Salmonella, Pseudomonas 
aeruginosa and Staphylococcus aureus. Microbial contamination usually occurs because 
of improper drying or storage of the plant material which eventually results in 
degradation of the plant constituents. Microbial contamination can also render plant 
material toxic, either by transforming the chemicals in the plant material or through the 
production of toxic compounds by the microbes. Therefore, microbial quality tests should 
be applied to starting plant materials, intermediate and finished products where necessary. 
During the quality analysis, precautions must be taken to ensure that conditions do not 
adversely affect any microorganisms that are to be measured.  
Thus, the present study proves that Seenthil Sakkarai is free from microbial 
contamination and also highlighted the safety of the same. The information obtained from 
microbial screening tests will be use full in finding out the quality of the drug. The good 
antibacterial activity of herbal medicines implies that the antimicrobial compounds 
present in herbal medicines are possibly controlling the microbial activity. Herbal 
medicines showed varying degrees of in vitro antibacterial activity against test bacteria.  
Both Gram positive and Gram negative bacteria E.coli, Klebsiella pneumoniae and 
Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella typhi were found to be 
sensitive  when compared to the standard drug Gentamycin (Broad spectrum) (Table 3). 
The herbal drug Seenthil Sakkarai exhibited broad spectrum activity against bacterial 
pathogens at 100mg / ml concentration of the drug.  
From these results, it is accomplished that this study would lead to the 
establishment of several important compounds that have to be used to formulate new, 
different and more potent antimicrobial drugs of natural origin. However, further studies 
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are required to screen the biologically active compounds and to evaluate the efficiency of 
this compound against pathogenic microorganisms associated with various human 
diseases. 
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ANNEXURE- IV (B) 
PHYTO-CHEMICAL STUDY OF SEENTHIL SAKKARAI 
  This experimental study was taken up to qualitative analysis of Phyto-
chemicals in the drug of Seenthil Sakkarai using various test and the results are exhibited 
in Table No. 4. 
Table No 4: Incidence of various phyto-chemicals in Seenthil Sakkarai 
S.No. Name of Tests Conducted Result Observed 
Observation of Alkaloids 
1. Mayer’s Test Positive 
2. Dragendroff’s Test Negative 
3. Hager’s Test  Positive 
Observation of Carbohydrates and Glycosides 
4. Molisch Test  Positive 
5. Legal’s Test Negative 
6. Borntrager’s Test for anthraquinones Negative 
Observation of Phytosterols 
7. Liebermann – Burchard Test Negative 
8. Salkowski Test Negative 
Observation of Flavanoids 
9. 
Shinoda Test 
(Magnesium turnings & Hydrochloric acid) 
Negative 
10. Fluorescence Test Negative 
Observation of Tannins 
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11. Ferric chloride test Negative 
12. Potassium dichromate test Positive 
13. Lead acetate test Positive 
14. Millon’s test Positive 
15. Biuret test Negative 
16. Ninhydrin test Negative 
 
 
S.No. Name of Tests Conducted Result Observed 
Observation of fixed oils and fats  
17. Spot test Negative 
18. Saponification test Positive 
Observation of Lignin 
19. Phloroglucinol test Negative 
Observation of Saponins 
20. Frothing test Negative 
  
Note: Positive indicates the presence of Phytochemical; Negative indicates the    
absence of Phytochemical 
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ANNEXURE-V 
BIOSTATISTICAL ANALYSIS OF AN A PROSPECTIVE OPEN 
LABELED RANDOMIZED CLINICAL Trial of “SEENTHIL 
SARKKARAI” for IYA NEERIZHIVU (CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE IN TYPE II DIABETES MELLITUS) 
Correlations 
 B.FBS B.PPBS B.SU A.FBS A.PPBS A.SU 
B.FBS 
Pearson Correlation 1 .853** .541* .821** .662** -.079 
Sig. (2-tailed)  .000 .014 .000 .001 .740 
N 20 20 20 20 20 20 
B.PPBS 
Pearson Correlation .853** 1 .362 .834** .758** -.182 
Sig. (2-tailed) .000  .117 .000 .000 .442 
N 20 20 20 20 20 20 
B.SU 
Pearson Correlation .541* .362 1 .423 .334 .282 
Sig. (2-tailed) .014 .117  .063 .150 .028 
N 20 20 20 20 20 20 
A.FBS 
Pearson Correlation .821** .834** .423 1 .904** -.181 
Sig. (2-tailed) .000 .000 .063  .000 .445 
N 20 20 20 20 20 20 
A.PPBS 
Pearson Correlation .662** .758** .334 .904** 1 -.233 
Sig. (2-tailed) .001 .000 .150 .000  .323 
N 20 20 20 20 20 20 
A.SU 
Pearson Correlation -.079 -.182 .282 -.181 -.233 1 
Sig. (2-tailed) .740 .442 .028 .445 .323  
N 20 20 20 20 20 20 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Correlations 
 B.FBS B.PPBS B.SU A.FBS A.PPBS A.SU 
B.FBS 
Pearson Correlation 1 .822** -.184 .843** .777** .230 
Sig. (2-tailed)  .000 .438 .000 .000 .330 
N 20 20 20 20 20 20 
B.PPBS 
Pearson Correlation .822** 1 -.430 .753** .822** -.007 
Sig. (2-tailed) .000  .058 .000 .000 .976 
N 20 20 20 20 20 20 
B.SU 
Pearson Correlation -.184 -.430 1 -.301 -.393 .714** 
Sig. (2-tailed) .438 .058  .198 .087 .000 
N 20 20 20 20 20 20 
A.FBS 
Pearson Correlation .843** .753** -.301 1 .937** -.037 
Sig. (2-tailed) .000 .000 .198  .000 .878 
N 20 20 20 20 20 20 
A.PPBS 
Pearson Correlation .777** .822** -.393 .937** 1 -.089 
Sig. (2-tailed) .000 .000 .087 .000  .708 
N 20 20 20 20 20 20 
A.SU 
Pearson Correlation .230 -.007 .714** -.037 -.089 1 
Sig. (2-tailed) .330 .976 .000 .878 .708  
N 20 20 20 20 20 20 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Correlations 
 B.Hb B.TC B.DC.P B.DC.L B.DC.E A.Hb A.TC A.DC.P A.DC.L A.DC.E 
B.Hb 
Pearson Correlation 1 -.122 -.403 .263 -.146 .751** -.347 -.113 .328 -.481* 
Sig. (2-tailed)  .608 .078 .262 .538 .000 .134 .637 .159 .032 
N 20 20 20 20 20 20 20 20 20 20 
B.TC 
Pearson Correlation -.122 1 .356 -.418 .166 -.216 .624** .624** -.541* .158 
Sig. (2-tailed) .608  .123 .067 .484 .360 .003 .003 .014 .505 
N 20 20 20 20 20 20 20 20 20 20 
B.DC.P 
Pearson Correlation -.403 .356 1 -.820** .225 -.139 .131 .778** -.720** .285 
Sig. (2-tailed) .078 .123  .000 .340 .558 .581 .000 .000 .223 
N 20 20 20 20 20 20 20 20 20 20 
B.DC.L 
Pearson Correlation .263 -.418 -.820** 1 -.666** .094 -.013 -.666** .636** -.284 
Sig. (2-tailed) .262 .067 .000  .001 .692 .957 .001 .003 .226 
N 20 20 20 20 20 20 20 20 20 20 
B.DC.E 
Pearson Correlation -.146 .166 .225 -.666** 1 -.065 -.043 .155 -.282 .331 
Sig. (2-tailed) .538 .484 .340 .001  .784 .858 .515 .228 .154 
N 20 20 20 20 20 20 20 20 20 20 
A.Hb 
Pearson Correlation .751** -.216 -.139 .094 -.065 1 -.108 -.075 .116 -.120 
Sig. (2-tailed) .000 .360 .558 .692 .784  .649 .753 .626 .616 
N 20 20 20 20 20 20 20 20 20 20 
A.TC 
Pearson Correlation -.347 .624** .131 -.013 -.043 -.108 1 .243 -.320 .277 
Sig. (2-tailed) .134 .003 .581 .957 .858 .649  .302 .168 .236 
N 20 20 20 20 20 20 20 20 20 20 
A.DC.P 
Pearson Correlation -.113 .624** .778** -.666** .155 -.075 .243 1 -.871** .262 
Sig. (2-tailed) .637 .003 .000 .001 .515 .753 .302  .000 .265 
N 20 20 20 20 20 20 20 20 20 20 
A.DC.L 
Pearson Correlation .328 -.541* -.720** .636** -.282 .116 -.320 -.871** 1 -.702** 
Sig. (2-tailed) .159 .014 .000 .003 .228 .626 .168 .000  .001 
N 20 20 20 20 20 20 20 20 20 20 
A.DC.E 
Pearson Correlation -.481* .158 .285 -.284 .331 -.120 .277 .262 -.702** 1 
Sig. (2-tailed) .032 .505 .223 .226 .154 .616 .236 .265 .001  
N 20 20 20 20 20 20 20 20 20 20 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Correlations 
 B.Hb B.TC B.DC.P B.DC.L B.DC.E A.Hb A.TC A.DC.P A.DC.L A.DC.E 
B.Hb 
Pearson Correlation 1 .338 .573** -.473* -.286 .727** .031 .095 -.065 -.059 
Sig. (2-tailed)  .145 .008 .035 .221 .000 .896 .692 .784 .804 
N 20 20 20 20 20 20 20 20 20 20 
B.TC 
Pearson Correlation .338 1 .313 -.456* .394 -.035 .828** .094 -.034 .270 
Sig. (2-tailed) .145  .180 .043 .086 .884 .000 .694 .886 .249 
N 20 20 20 20 20 20 20 20 20 20 
B.DC.P 
Pearson Correlation .573** .313 1 -.928** -.185 .400 .004 -.171 .197 -.181 
Sig. (2-tailed) .008 .180  .000 .435 .081 .988 .041 .405 .444 
N 20 20 20 20 20 20 20 20 20 20 
B.DC.L 
Pearson Correlation -.473* -.456* -.928** 1 -.189 -.282 -.141 .198 -.166 .023 
Sig. (2-tailed) .035 .043 .000  .426 .229 .553 .403 .045 .923 
N 20 20 20 20 20 20 20 20 20 20 
B.DC.E 
Pearson Correlation -.286 .394 -.185 -.189 1 -.310 .396 -.022 -.127 .446* 
Sig. (2-tailed) .221 .086 .435 .426  .184 .084 .927 .594 .009 
N 20 20 20 20 20 20 20 20 20 20 
A.Hb 
Pearson Correlation .727** -.035 .400 -.282 -.310 1 -.162 -.035 -.192 -.083 
Sig. (2-tailed) .000 .884 .081 .229 .184  .496 .884 .417 .727 
N 20 20 20 20 20 20 20 20 20 20 
A.TC 
Pearson Correlation .031 .828** .004 -.141 .396 -.162 1 .128 -.218 .429 
Sig. (2-tailed) .896 .000 .988 .553 .084 .496  .591 .356 .059 
N 20 20 20 20 20 20 20 20 20 20 
A.DC.P 
Pearson Correlation .095 .094 -.171 .198 -.022 -.035 .128 1 -.432 -.155 
Sig. (2-tailed) .692 .694 .041 .403 .927 .884 .591  .057 .515 
N 20 20 20 20 20 20 20 20 20 20 
A.DC.L 
Pearson Correlation -.065 -.034 .197 -.166 -.127 -.192 -.218 -.432 1 -.386 
Sig. (2-tailed) .784 .886 .405 .045 .594 .417 .356 .057  .093 
N 20 20 20 20 20 20 20 20 20 20 
A.DC.E 
Pearson Correlation -.059 .270 -.181 .023 .446* -.083 .429 -.155 -.386 1 
Sig. (2-tailed) .804 .249 .444 .923 .009 .727 .059 .515 .093  
N 20 20 20 20 20 20 20 20 20 20 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Correlations 
 B.FVCL.M.
PRE 
B.FEV1L.M.P
RE 
B.FEV1.FVC
.M.PRE 
B.FEF25.M.
PRE 
B.PEFRL.M.
PRE 
A.FVCL.M.P
RE 
A.FEV1L.
M.PRE 
A.FEV1.F
VC.M.PR
E 
A.FEF25.M.PR
E 
A.PEFRL.M
.PRE 
B.FVCL.M.PRE 
Pearson Correlation 1 .675* -.169 .627 .261 .162 .072 .082 .491 .226 
Sig. (2-tailed)  .032 .640 .052 .466 .001 .844 .821 .149 .531 
N 10 10 10 10 10 10 10 10 10 10 
B.FEV1L.M.PRE 
Pearson Correlation .675* 1 .573 .849** .510 .140 .645* .663* .703* .527 
Sig. (2-tailed) .032  .083 .002 .132 .700 .004 .037 .023 .117 
N 10 10 10 10 10 10 10 10 10 10 
B.FEV1.FVC.M.PRE 
Pearson Correlation -.169 .573 1 .427 .507 .217 .806** .787** .344 .538 
Sig. (2-tailed) .640 .083  .218 .135 .548 .005 .007 .330 .109 
N 10 10 10 10 10 10 10 10 10 10 
B.FEF25.M.PRE 
Pearson Correlation .627 .849** .427 1 .280 .211 .514 .470 .790** .204 
Sig. (2-tailed) .052 .002 .218  .433 .558 .129 .171 .006 .571 
N 10 10 10 10 10 10 10 10 10 10 
B.PEFRL.M.PRE 
Pearson Correlation .261 .510 .507 .280 1 .574 .639* .390 .118 .631 
Sig. (2-tailed) .466 .132 .135 .433  .083 .047 .265 .745 .011 
N 10 10 10 10 10 10 10 10 10 10 
A.FVCL.M.PRE 
Pearson Correlation .162 .140 .217 .211 .574 1 .474 .156 .201 .064 
Sig. (2-tailed) .001 .700 .548 .558 .083  .166 .666 .578 .861 
N 10 10 10 10 10 10 10 10 10 10 
A.FEV1L.M.PRE 
Pearson Correlation .072 .645* .806** .514 .639* .474 1 .888** .656* .615 
Sig. (2-tailed) .844 .004 .005 .129 .047 .166  .001 .039 .058 
N 10 10 10 10 10 10 10 10 10 10 
A.FEV1.FVC.M.PRE 
Pearson Correlation .082 .663* .787** .470 .390 .156 .888** 1 .679* .688* 
Sig. (2-tailed) .821 .037 .007 .171 .265 .666 .001  .031 .028 
N 10 10 10 10 10 10 10 10 10 10 
A.FEF25.M.PRE 
Pearson Correlation .491 .703* .344 .790** .118 .201 .656* .679* 1 .314 
Sig. (2-tailed) .149 .023 .330 .006 .745 .578 .039 .031  .376 
N 10 10 10 10 10 10 10 10 10 10 
A.PEFRL.M.PRE 
Pearson Correlation .226 .527 .538 .204 .631 .064 .615 .688* .314 1 
Sig. (2-tailed) .531 .117 .109 .571 .011 .861 .058 .028 .376  
N 10 10 10 10 10 10 10 10 10 10 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Correlations 
 B.HbA1C B.LIP.TC B.LIP.HD
L 
B.LIP.LDL B.LIP.VLDL B.LIP.TGL A.HbA1C A.LIP.TC A.LIP.HDL A.LIP.LD
L 
A.LIP.
VLDL 
A.LIP.TGL 
B.HbA1C 
Pearson Correlation 1 .260 -.138 .102 .356 .395 .732** .172 .033 .186 .306 .402 
Sig. (2-tailed)  .268 .562 .667 .124 .085 .000 .468 .889 .432 .189 .079 
N 20 20 20 20 20 20 20 20 20 20 20 20 
B.LIP.TC 
Pearson Correlation .260 1 -.062 .718** .159 .148 .252 .870** -.225 .765** .056 .154 
Sig. (2-tailed) .268  .795 .000 .504 .534 .284 .000 .341 .000 .813 .518 
N 20 20 20 20 20 20 20 20 20 20 20 20 
B.LIP.HDL 
Pearson Correlation -.138 -.062 1 -.004 -.307 -.480* -.204 .054 .378 -.041 -.234 -.245 
Sig. (2-tailed) .562 .795  .987 .187 .032 .388 .822 .100 .863 .321 .298 
N 20 20 20 20 20 20 20 20 20 20 20 20 
B.LIP.LDL 
Pearson Correlation .102 .718** -.004 1 -.277 -.216 .137 .548* -.410 .744** -.297 -.198 
Sig. (2-tailed) .667 .000 .987  .238 .361 .565 .012 .073 .000 .204 .403 
N 20 20 20 20 20 20 20 20 20 20 20 20 
B.LIP.VLDL 
Pearson Correlation .356 .159 -.307 -.277 1 .931** .534* .299 .283 -.183 .862** .866** 
Sig. (2-tailed) .124 .504 .187 .238  .000 .015 .200 .227 .440 .000 .000 
N 20 20 20 20 20 20 20 20 20 20 20 20 
B.LIP.TGL 
Pearson Correlation .395 .148 -.480* -.216 .931** 1 .579** .273 .111 -.159 .807** .816** 
Sig. (2-tailed) .085 .534 .032 .361 .000 
 
.007 .243 .640 .503 .000 .000 
N 20 20 20 20 20 20 20 20 20 20 20 20 
A.HbA1C 
Pearson Correlation .732** .252 -.204 .137 .534* .579** 1 .295 .114 .038 .467* .532* 
Sig. (2-tailed) .000 .284 .388 .565 .015 .007 
 
.207 .631 .874 .038 .016 
N 20 20 20 20 20 20 20 20 20 20 20 20 
A.LIP.TC 
Pearson Correlation .172 .870** .054 .548* .299 .273 .295 1 -.148 .554* .207 .292 
Sig. (2-tailed) .468 .000 .822 .012 .200 .243 .207  .532 .011 .381 .212 
N 20 20 20 20 20 20 20 20 20 20 20 20 
A.LIP.HDL 
Pearson Correlation .033 -.225 .378 -.410 .283 .111 .114 -.148 1 -.537* .037 .008 
Sig. (2-tailed) .889 .341 .100 .073 .227 .640 .631 .532  .015 .878 .974 
N 20 20 20 20 20 20 20 20 20 20 20 20 
A.LIP.LDL 
Pearson Correlation .186 .765** -.041 .744** -.183 -.159 .038 .554* -.537* 1 -.201 -.135 
Sig. (2-tailed) .432 .000 .863 .000 .440 .503 .874 .011 .015  .396 .571 
N 20 20 20 20 20 20 20 20 20 20 20 20 
A.LIP.VLDL 
Pearson Correlation .306 .056 -.234 -.297 .862** .807** .467* .207 .037 -.201 1 .982** 
Sig. (2-tailed) .189 .813 .321 .204 .000 .000 .038 .381 .878 .396  .000 
N 20 20 20 20 20 20 20 20 20 20 20 20 
A.LIP.TGL 
Pearson Correlation .402 .154 -.245 -.198 .866** .816** .532* .292 .008 -.135 .982** 1 
Sig. (2-tailed) .079 .518 .298 .403 .000 .000 .016 .212 .974 .571 .000  
N 20 20 20 20 20 20 20 20 20 20 20 20 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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                       Profoma 
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“A PROSPECTIVE OPEN LABELED RANDOMIZED CLINICAL TRIAL OF 
“SEENTHIL SARKKARAI” FOR IYA NEERIZHIVU  
(CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TYPE II DIABETES MELLITUS)” 
CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
      I certify that I have disclosed all details about the study in the terms easily understood 
by the patient. 
Date: ………….             Signature of the Investigator: ………………………………….... 
 
                                         Name of Investigator: ………………………………………….. 
 
CONSENT BY SUBJECT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
I, exercising my free power of choice, hereby give my consent to be included        
 As a subject in A Prospective Open Labeled Randomized Clinical Trial of “SEENTHIL 
SARKKARAI” for IYA NEERIZHIVU (CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE IN TYPE II DIABETES MELLITUS) 
 
Date: ……………                 Name of the Subject: ……………………………………….. 
                                               Signature or Thumb impression: …………………………… 
 
Date: ……………                Name of witness: ……………………………………………. 
                                             Signature or Thumb impression: …………………………….. 
                                             Relationship: ……………………………………………….... 
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IaePupopTNeha;f;FkUe;jhfrPe;jpy; rf;fiughpfhpg;Gj; jpwidf; fz;lwpAk; 
kUj;JtMa;Txg;Gjy; gbtk; 
Ma;thshpd; rhd;wpjo; 
 
ehd; ,e;jMa;TFwpj;jmidj;Jtpguq;fisAk; Nehahspf;Fg; GhpAk; 
tifapy; vLj;Jiuj;Njd; vdcWjpaspf;fpNwd;. 
ifnahg;gk; : 
ngaH : 
Njjp : 
,lk; : 
Nehahspapd; xg;Gjy; 
vd;dplk; ,e;jkUj;JtMa;tpd; fhuzj;ijAk;>kUe;jpd; jd;ikkw;Wk; 
kUj;JttopKiwiag; gw;wpAk; njhlHe;JvdJcly; 
,af;fj;ijfz;fhzpf;fTk;>mjidg; ghJfhf;fTk; gad;gLk; kUj;JtMa;Tf; $l 
ghpNrhjidfs; gw;wpjpUg;jpmspf;Fk; tifapy; Ma;TkUj;Jtuhy; tpsf;fpf; 
$wg;gl;lJ. 
ehd; ,e;jkUj;JtMa;tpd;NghJfhuzk; vJTk; $whky; 
vg;nghOJNtz;LkhdhYk; ,e;jMa;tpypUe;Jvd;idtpLtpj;Jf; nfhs;Sk; 
chpikianjhpe;jpUf;fpNwd;. 
ehd; vd;DilaRje;jpukhfNjHTnra;Ak; chpikiaf; 
nfhz;LIaePupopT(COPD IN Type II Diabetes Mellitus)Neha;f;FkUe;jhfrPe;jpy; 
rf;fiughpfhpg;Gj; jpwidf; fz;lwpAk; kUj;JtMa;tpw;Fvd;idcl;gLj;jxg;Gjy; 
mspf;fpNwd;. 
ifnahg;gk; :                          rhl;rpapd; ifnahg;gk; : 
ngaH :ngaH : 
Njjp :                              cwTKiw : 
,lk; :                               Njjp : 
,lk; : 
Nkw;ghu;itahsu; ifnahg;gk; : 
Njjp :                   
,lk; : 
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 “A PROSPECTIVE OPEN LABELED RANDOMIZED CLINICAL TRIAL OF 
“SEENTHIL SARKKARAI” FOR IYA NEERIZHIVU  
(CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TYPE II DIABETES MELLITUS)” 
PATENT INFORMATION SHEET 
• It is a chronic obstructive pulmonary disease  
• This disease is not contagious. 
• It is a clinical syndrome occurs due to pulmonary function disorder by exposure of 
tobacco    smoking, exposure of dust and fume etc., in type II diabetes mellitus.  
• Many herbal and mineral siddha medicines are currently practiced by the siddha 
practioners for   managing the complications of Diabetes mellitus. 
• The trial drug is prescribed only with evidence of siddha literature. 
• The trial drug is prepared at the Gunapadam lab of government siddha medical college 
&   hospital, palayamkottai, under the   direct supervision of teaching faculties of   
Maruthuvam and Gunapadam Dept. 
Details of the trial drug      
Trial Medicine     : SeenthilSarkkarai  
Dosage           :  30 mg/ Kg/BW/daily two times a day 
Adjuvant      :  Ghee  
Duration      :  90 days   
 Patients are advised to take green vegetables, protein foods, fibre foods, wheat. 
 Patients must walk 30-45 minutes per day 
 Patients are advised to avoid tamarind, betel chewing, tobacco, alcohol and 
smoking.    
 
 
 
 
 
 
 211 
 
 “A PROSPECTIVE OPEN LABELED RANDOMIZED CLINICAL TRIAL OF 
“SEENTHIL SARKKARAI” FOR IYA NEERIZHIVU  
(CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TYPE II DIABETES MELLITUS)” 
CASE REPORT FORM- SCREENING. 
 
1. Centre: GSMC,Palayamkottai,Tirunelveli. 
2. Name of the subject:…………………………………………………………………….. 
3. Sr. No. of the Subject: …………………………………………………………………... 
4. OP/ IP No:……………………………………………………………………………….. 
5. Date of Admisión: ………………………………………………………………………. 
6. Date of Terminition: ……………………………………………………………………. 
4. Address: ………………………………………………………………………………… 
5. Date of Birth: ………………………………              Age (in yrs): ……………………. 
6. Gender 
  
CRITERA OF INCLUSON   
1 Age between 40 and 75 years    
2 Type 2 diabetes mellitus  
3 
If yes in any of three  
a. FBS      > 126 mg/dl and ≤250mg/dl or  
b. PPBS    > 200mg/dl and ≤350mg /dl or  
c. HbA1c  > 6.4 and<12  
4 Persistent cases of COPD (as per the standard key indicators for assessment)  
5 FEV1 between > 50% and <80% of the predicted value   
6 Willing to give blood sample for the investigations  
7 Patients who are mono therapy alone  
 
 
Male  Female  
Yes 1 No 2 
 212 
 
 
 
CRTERIA FOR EXCLUSION   
 
8 Age below 40 and above 75  
9 
If yes in any of three  
a. FBS     < 125 mg/dl and ≥251mg/dl or  
b. PPBS   <199mg/dl and ≥351mg /dl or   
c. HbA1c < 6.4 and >12  
10 Type 1 diabetes mellitus  
11 FEV1 <50% and >80% of the predicted value  
12 Malignant and accelerated hypertension   
13 Pregnant woman and plan to pregnant six months   
14 Lactating mother   
15 Chronic kidney disease / Renal failure  
16 Corticosteroid therapy  
17 Chronic active hepatitis/cirrhosis/ascites  
18 Multisystem involvement  
 
A patient is eligible for admission 
If 'Yes' to S.No.1 - 3 & 'No' to 4 - 12 
…………….                                                                            ……...……………………… 
Date                                                                                          Signature of the Investigator 
………………………………..        …………….................................. 
SIGNATURE OF GUIDE                                               SIGNATURE OF SUPERVISOR  
  
…………………………….. 
SIGNATURE OF HOD 
 
Yes 1 No 2 
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 “A PROSPECTIVE OPEN LABELED RANDOMIZED CLINICAL TRIAL OF 
“SEENTHIL SARKKARAI” FOR IYA NEERIZHIVU  
(CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TYPE II DIABETES MELLITUS)” 
Case report form II – History  
1. Centre: GSMC,Palayamkottai,Tirunelveli. 
 2. Sr. No. of the subject: ………………………………………………………………… 
3. Name of the subject: …………………………………………………………………… 
4. Address: ………………………………………………………………………………… 
5. Gender:     
 
6. Date of Birth: ……………………..                             Age (in yrs): …………………… 
8. Educational status: 
Illiterate 1 High school 5 
Read and write 2 College 6 
Primary 3 Others (specify) 7 
Middle school 4 INA 8 
 
9. Occupation  
Desk work  1 Housewife 3 
Field work  2 Others   4 
 
    Indicate nature of work: ………………………………………………………………… 
10. Religion  
Hindu 1 Christian 2 Muslim 3 
 
 
Male  Female  
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11. Marital status  
Married 1 Separated 4 
Widowed 2 Single 5 
Divorced 3 
11. Total Family members: ……………………………………………………………… 
12. Income per capita per month (in Rs): ………………………………………………… 
 
Chief complaint with duration (if any) in 
 
No Chief complaint 0/1 Duration  
13 Polyuria (Excessive Urine)   
14 Polyphagia (Excessive Hunger)   
15 Polydipsia (Excessive Thirst)   
16 Nocturia   
17 Dyspnoea    
18 Wheezing    
19 Chest pain   
20 Tightness of chest    
21 Cough    
22 
Expectoration of sputum  (thick and scanty/ mucoid/ 
mucopurulent/streaks with blood) 
  
23 Othres   
 
If Yes specify:  …………………………………………………………………………… 
 
 
 
Absent  0 Present  1 
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History of Present illness   
 
No History of COPD symptoms 
24 
Dyspnoea  
A. Progressive (worsens over time)  
B. Usually worse with exercise  
C. Persistent (present every day)  
D. Described by the patient as an “Increased effort to breathe, “heaviness,” 
“air hunger,” or “gasping.” 
 
25 
Chronic Cough  
A. Intermittent   
B. Unproductive  
26 
Chronic sputum production 
A. Any pattern of chronic sputum production  
27 Anorexia   
28 Weight loss  
29 Weight gain    
 
Treatment history    
30 Ayurveda / Unani/ Homeopathic   
31 Modern medicine  
 
History of Past illness   
No Past illness 0/1 Duration 
32 History of diabetes Mellitus    
33 Repeated colds     
34 COPD   
Absent  0 Present  1 
Yes 1 No 2 
Absent  0 Present  1 
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Family history 
If present then specify:  
No Family history 0/1 1/2/3 
35 Diabetes Mellitus    
36 COPD   
 
Personal history  
 
36 
Diet 
Veg  
Non-veg  
37 Constipation  
38 
Sleep 
satisfactory  
unsatisfactory  
 
History of Environmental  
     39. Tobacco Smoking exposure   
            If yes specify: (a) Quantity packs: ………………………………………… 
                                    (b) Total Duration in year's: ………………………………. 
     40. Tobacco chewing  
            If yes specify: (a) Quantity: ………………………………………………. 
                                    (b) Total Duration in years: ……………………………….. 
     41. Betel chewing         
            If yes specify: (a) Quantity: ………………………………………………. 
Absent  0 Present  1 
Parents  1 Sibling 2 Both 3 
Yes 1 No 2 
Yes 1 No 2 
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                                    (b) Total Duration in years: ……………………………….. 
 
   42. Alcohol  
  
 
   43. Exposure of risk factors   
 
Risk Factors of COPD 0/1 Duration 
Occupational dusts and chemicals   
Smoke from home cooking   
Heating fuels   
 
Any other (specify): 
………………………………………………………………………….. 
     44. Thegi 
Vata 1 Kapha 3 Vata-kapha 5 Sannipata 7 
Pitta 2 Vata-pitta              4 Pitta-Kapha 6 
 
Physical Examination 
45. Built    
     
46. Gait  
   
     47. Height (cm): ……………………………………. 
     48. Weight (kg): ……………………………………. 
     49. BMI {weight (kg)/Height (m)2}………………………. 
     50. Pulse (per min): ………………………………… 
     51. Blood Pressure (in sitting position) 
Occasional 1 Regular 2 Never 3 
Absent  0 Present  1 
Lean  1 Medium  2 Heavy 3 
Normal 1 Abnormal  2 
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      Systolic (mm Hg)  : ………………………... 
      Diastolic (mm Hg): ………………………… 
     52. Body temperature (o F): ……………………….. 
     53. Respiration rate (per min): …………………….. 
 
 
54 Cyanosis  
55 Jaundice  
56 Heating fuels  
57 Clubbing nails  
58 Oedema  
59 Pallor  
60 Jugular venous pulsation  
61 
Lymphadenopathy  
If present 
specify , 
General  
Local  
Area    ……………………………………………………………………… 
 
 
SYSTEMC EXAMINATION     
62. Respiratory system  
      Shape of the chest ………………………………………. 
Auscultation  
 
Expiratory / inspiratory wheezes  
Inspiratory crackles  
Present 1 Absent    2 
Normal 1 Abnormal 2 
Present  1 Absent 2 
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Reduced breath sounds  
 
      2. Cardio Vascular System  
    If abnormal, details: ………………………………………………………………… 
3.Central Nervous System 
    If abnormal, details: ………………………………………………………………… 
4. Uro-Genital system 
    If abnormal, details: ………………………………………………………………… 
5. Digestive system 
    If abnormal, details: ………………………………………………………………… 
6. Locomotor System 
   If abnormal, details: …………………………………………………………………. 
7. Endocrine System 
   If abnormal, details: …………………………………………………………………. 
8. Integumentary System 
   If abnormal, details: …………………………………………………………………. 
…………….                                                                           
……………………………… 
Date                                                                                Signature of the Investigator 
 
………………………………..                                               ……………………… 
Signature of Guide                                                Signature of Supervisor  
                                                      …………………………….. 
                                                          Signature of HOD 
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SIDDHA SYSTEM OF EXAMINATION 
A. ENVAGAI THERVU: (EIGHT-FOLD EXAMINATION) 
1. NAADI  (PULSE PERCEPTION) 
Naadi 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Vali         
Azhal         
Iyyam         
ValiAzhal         
ValiIyyam         
AzhalVali         
AzhalIyyam         
IyyaVali         
IyyaAzhal         
 
2. NAA (TONGUE) 
Naa 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Colour         
Taste         
Coating         
Fissure         
Saliva         
Dryness         
Glossitis         
Baldness         
 
 
 
3. NIRAM (COMPLEXION) 
Niram 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Dark         
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Yellow         
Tinted         
Pale         
 
4. MOZHI (VOICE) 
Mozhi 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Medium         
High         
Low         
Pitched          
 
5. VIZHI  (EYES) (Lower palpebral conjunctiva) 
Niram 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Dark         
Yellow         
Red         
Pale         
 
6. MALAM  (BOWEL HABITS / STOOLS) 
Malam 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Colour         
Consistency         
Stool bulk         
Constipation         
Diarrhea         
 
7. URINE EXAMINATION 
NEER KURI 0st 
Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Niram(Colour)         
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Manam(Odour)         
Nurai(Froth)         
Edai(Sp.gravity)         
Enjal(Deposits)         
 
 
NEI KURI 0st 
Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Serpentine 
fashion  
        
Annular/Ringed 
fashion 
        
Pearl beaded 
fashion 
        
Mixed fashion         
Other fashion         
 
8. SPARISAM (PALPATORY PERCEPTION) 
Sparisam 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Warmth         
Cold         
Sweat         
 
B. THEGI (TYPE OF BODY CONSTITUTION)  
Vatham predominant 1 
Kabam predominant 2 
Pitham predominant 3 
Thondhaudal 4 
  
C. NILAM (LAND WHERE PATIENT LIVED MOST) 
Kurinji (Hilly terrain) 1 
Mullai (Forest range) 2 
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Marutham (Plains) 3 
Neithal (Coastal belt) 4 
Palai (Arid regions) 5 
 
D. KAALAM 
Kaarkalam 1 Pinpanikalam 4 
Koothirkalam 2 Ilavenil 5 
Munpanikalam 3 Muthuvenil 6 
 
 
 
E. GUNAM 
Sathuvam 1 
Rasatham   2 
Thamasam 3 
 
 
 
 
 
 
 
F. IMPORIGAL (SENSORY ORGANS) 
 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Mei (Skin)         
Vai (Buccal 
Cavity) 
        
Kann (Eye)         
Sevi (Ear)         
Mooku (Nose)         
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G. KANMENDRIYAM (MOTOR FUNCTIONS) 
 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Kai 
(Upperlimb) 
        
Kaal 
(lowerlimbs) 
        
Vai 
(buccalcavity) 
        
Eruvaai 
(excretory 
organs) 
        
Karuvaai  
(reproductive 
organs)  
        
 
 
 
 
H. KOSANGAL(Sheath)   
 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Annamaya 
Kosam 
        
Pranamaya 
Kosam 
        
Manomaya 
Kosam 
        
Vignanamaya 
Kosam 
        
Ananthamaya 
Kosam 
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I. MUKKUTRAM (AFFECTION OF THREE HUMORS) 
A) VATHAM 
 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Praanan         
Abaanan         
Viyaanan         
Udhaanan         
Samanan         
Naagan         
Koorman         
Kirukaran         
Devathathan         
Dhananjeyan         
 
 
B) PITHAM 
 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Analapitham         
Ranjagam         
Saathagam         
Praasagam         
Aalosagam         
 
C) KAPHAM 
 
0st Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam         
Santhigam         
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J. SEVEN DHATHUS (7 SOMATIC COMPONENTS) 
 0st 
Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Saaram(Chyme)         
Senneer(Blood)         
Oon(Muscle)         
Kozhuppu(Fat)         
Enbu(Bones)         
Moolai (Bone 
Marrow) 
        
Sukkilam/Suronitham 
(Genital discharges) 
        
 
 
COLOUR  TASTE          
Dark 1 Sweet 1 Present 1 Normal 1 Solid 1 Normal 1 
Yellow 2 Bitter 2 Absent 2 Increased 2 Watery 2 Increased 2 
Red 3 Sour 3   Decreased 3 Semisolid 3 Reduced 3 
Pale 4  None 4 
Tinted 5 Pungent 5 
…………….                                                                           ……………………………… 
Date                                                                                         Signature of the Investigator 
 
………………………………..                                               ……………………… 
Signature of Guide                                                Signature of Supervisor  
 
                                                      …………………………….. 
                                                          Signature of HOD 
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“A PROSPECTIVE OPEN LABELED NON RANDOMIZED CLINICAL TRIAL 
OF “SEENTHIL SARKKARAI” FOR IYA NEERIZHIVU  
(CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TYPE II DIABETES MELLITUS)” 
1. SYSTEMIC EXAMINATION 
Absent 1 Present 2      
 
 0st 
Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
RS          
CVS          
GIT         
CNS          
LOCOMOTOR 
SYSTEM  
        
UROGENITAL 
SYSTEM 
        
ENDOCRINE 
SYSTEM 
        
 
2. CLINICAL SYMPTOMS 
Yes 1 No 2 
 
 0st 
Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Polyuria         
Polydipsia         
Polyphagia         
Nocturia         
Pain in the limbs         
Pain &burning 
sensation in the both 
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sole 
Parasthesia in the feet         
Vulvo- vaginitis          
Balanitis         
Asymptomatic         
3. GENERAL EXAMINATION  
 0st 
Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Height (cms)         
Weight (kg)         
BMI         
Waist circumference          
Hip circumference          
Temperature (F0)         
Pulse rate (per min)         
Heart rate (per min)         
Respiratory rate(per 
min) 
        
Blood pressure 
(mm/Hg) 
        
Anaemia         
Jaundice         
Cyanosis         
Lymphade-nopathy         
Pedal edema         
Clubbing         
Jugular vein 
pulsation 
        
Grade of Dyspnoea  
Dyspnea scale  
Score  
0st 
Day 
14th 
Day 
28th 
Day 
42nd 
Day 
56th 
Day 
70th 
Day 
84th 
Day 
90th 
Day 
Grade  0         
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Grade  1         
Grade 2         
Grade 3         
Grade 4         
 
MMRC (Modified Medical Research Council) Dyspnea Scale Score  
Equivalent to point value for highest level question to which a respondent answers “Yes.” 
Dyspnea Query Score 
Are you troubled by shortness of breath when hurrying on level ground or walking up a slight 
hill?                     
0 
Do you have to walk slower than people of your age on level ground because of shortness of 
breath?                  
1 
Do you ever have to stop for breath when walking at your own pace on level ground?                                         2
Do you ever have to stop for breath when walking about 100 yards (or after a few minutes) on 
level ground?    
3 
Are you too short of breath to leave the house or short of breath on dressing or undressing?                                4
…………….                                                                           ……………………………… 
Date                                                                                         Signature of the Investigator 
………………………………..                                               ……………………… 
Signature of Guide                                                Signature of Supervisor  
 
                                                      …………………………….. 
                                                          Signature of  HOD 
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“A PROSPECTIVE OPEN LABELED NON RANDOMIZED CLINICAL TRIAL 
OF “SEENTHIL SARKKARAI” FOR IYA NEERIZHIVU  
(CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TYPE II DIABETES MELLITUS)” 
DRUG COMPLIANCE FORM. 
 
1. Centre: ………………………………………………………………………………… 
2. Name of the subject: …………………………………………………………………… 
3. Sr. No. of the Subject: ………………………………………………………………… 
4. Address: ………………………………………………………………………………… 
5. Date of Birth: ………………………………              Age (in yrs): …………………… 
6. Code No. (of clinical trial): …………………………………………………………… 
7. Bed No: ………………………………………………………………………………… 
8. Gender 
Male 1 
Female 2 
 
9. Name of the Drug: 
   Drugs issued date:  
   Drugs returned date:  
S.No Date 
Drug Taken Time 
Morning/Time Night/Time 
Day 01    
Day 02    
Day 03    
Day 04    
Day 05    
Day 06    
Day 07    
Day 08    
Day 09    
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Day 10    
Day 11    
Day12    
Day13    
Day14    
Day15    
Day16    
Day17    
Day18    
Day19    
Day20    
Day21    
Day22    
Day23    
Day24    
Day25    
Day26    
Day27    
Day28    
Day29    
Day30    
Day31    
Day32    
Day33    
Day34    
Day35    
Day36    
Day37    
Day38    
Day39    
Day40    
Day41    
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Day42    
Day43    
Day44    
Day45    
Day46    
Day47    
Day48    
Day49    
Day50    
Day51    
Day52    
Day53    
Day54    
Day55    
Day56    
Day57    
Day58    
Day59    
Day60    
Day61    
Day62    
Day63    
Day64    
Day65    
Day66    
Day67    
Day68    
Day69    
Day70    
Day71    
Day72    
Day73    
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Day74    
Day75    
Day76    
Day77    
Day78    
Day79    
Day80    
Day81    
Day82    
Day83    
Day84    
Day85    
Day86    
Day87    
Day88    
Day 89    
Day 90    
 
…………….                                                                           ……………………………… 
Date                                                                                         Signature of the Investigator 
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Signature of Guide                                                Signature of Supervisor  
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                                                          Signature of HOD 
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LABORATORY PARAMETERS-CHART 
 
1. Centre: ………………………………………………………………………………… 
2. Name of the subject: …………………………………………………………………… 
3. Sr. No. of the Subject: ………………………………………………………………… 
4. Address: ……………………………………………………………………………… 
5. Date of Birth: ………………………………              Age (in yrs): …………………… 
6. Code No. (of clinical trial): …………………………………………………………… 
7. Bed No: …………………………………………………………………………………. 
8. Gender 
Male 1 
Female 2 
 
LAB INVESTIGATION CHART 
Blood Investigation Normal Values 
BeforeTMT 
(WithDate) 
In Between 
(WithDate) 
After TMT 
(WithDate) 
Hb(gms%)  
M:12-15 
W:11.5-14 
    
T.RBC(milli/cu.mm) 
M:4.0-5.5 
W:3.5-4.5 
    
 ESR  
(mm /hr) 
1/2 hr ------     
1 hr 
M:6-12 
W:7-18 
    
T.WBC (cells  /cu.mm) 4000-10000      
Differen
tial 
Polymorphs 40-75     
Lymphocytes 20-40     
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Count 
(%) 
Monocytes 2-10     
Eosinophil 1-6     
Basophil 0-1     
Platelets ;(lak/ cubic mm) 1,50000-500000      
HbA1C 
LESS THAN 
6%  
    
Blood 
glucose 
(mg/dl)  
Fasting < 100     
PP <  140     
Random <  120     
Lipid  
profile 
(mg/dl) 
Serum 
cholesterol 
150-200 
    
HDL 30-63     
LDL < 100     
VLDL 40     
TGL < 160     
RFT  
(mg/dl) 
Blood urea 20-40     
Serum 
creatinine 
<1.5 
    
Serum Uric 
acid 
M:2.5-6 
W: 1.5-6 
    
LFT  
(mg/dl) 
Total bilirubin 0.3-1.0      
Direct 
bilirubin 
0.1-0.3  
    
Indirect 
bilirubin  
0.2-0.7  
    
 
 
Urine 
investigation 
Before Treatment 
(with Date) 
InBetween 
(WithDate) 
After Treatment  
(With Date) 
Albumin     
Sugar(F)      
Sugar(PP)     
Sugar( R)     
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Deposits     
Bile salts     
Bile pigments     
Urobilinogen     
 
Pulmonary Function Test  
PFT Before Treatment 
(with Date) 
InBetween 
(WithDate) 
After Treatment  
(With Date) 
FEV1/FVC <0.70    
FEV1  <80%    
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………………………………..                                               ……………………… 
Signature of Guide                                                Signature of Supervisor  
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                                                          Signature of HOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 237 
 
 “A PROSPECTIVE OPEN LABELED NON RANDOMIZED CLINICAL TRIAL 
OF “SEENTHIL SARKKARAI” FOR IYA NEERIZHIVU  
(CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TYPE II DIABETES MELLITUS)” 
 
WITHDRAWAL FORM  
1. Centre: ………………………………………………………………………………… 
2. Name of the subject: ………………………………………………………………….. 
3. Sr. No. of the Subject: ………………………………………………………………… 
4. Address: ………………………………………………………………………………. 
5. Date of Birth: ………………………………              Age (in yrs): …………………… 
6. Code No. (of clinical trial): …………………………………………………………….. 
7. Gender 
Male 1 
Female 2 
 
8. Date of trial commencement: ………………………………………………………… 
9. Date of withdrawal from trial: ………………………………………………………… 
Reasons for withdrawal 
Yes 1 No 2 
 
Long absence at reporting  
Irregular treatment  
Shift of locality  
Increase in severity of symptoms  
Development of severe adverse drug reactions  
 
…………….                                                                           ……………………………… 
Date                                                                                         Signature of the Investigator 
………………………………..                                               ……………………… 
Signature of Guide                                                Signature of Supervisor  
                                                      …………………………….. 
                                                          Signature of HOD 
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ADVERSE DRUG REACTION FORM   
1. Centre: ………………………………………………………………………………… 
2. Name of the subject: …………………………………………………………………… 
3. Sr. No. of the Subject: ………………………………………………………………… 
4. Address: ………………………………………………………………………………… 
5. Date of Birth: ………………………………              Age (in yrs): ……………………. 
6. Code No. (of clinical trial): …………………………………………………………… 
7. Gender 
Male 1 
Female 2 
 
8.Date of trial commencement: …………………………………………………………. 
9. Date of withdrawal from trial: ………………………………………………………… 
10. Description of adverse reaction: ……………………………………………………… 
…………….                                                                           ……………………………… 
Date                                                                                         Signature of the Investigator 
………………………………..                                               ……………………… 
Signature of Guide                                                Signature of Supervisor  
 
                                                      …………………………….. 
                                                          Signature of HOD 
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